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ABSTRACT  
Long noncoding RNAs are critical regulators of pancreatic islet development and function 
Ruth A. Singer 
 
Diabetes is a complex group of metabolic disorders with genetic, immunological, and 
environmental etiologies. Decades of diabetes research have elucidated many genetic drivers of 
normal islet function and dysfunction. Furthermore, genome wide associated studies (GWAS) 
have discovered that most diabetes susceptibility loci fall outside of coding regions, which 
suggests a role for noncoding elements in the development of disease. This highlights our 
incomplete understanding of the islet regulome and suggests the need for detailed functional 
analyses of noncoding genes to precisely determine their contribution to diabetes susceptibility 
and disease progression. Transcriptome analyses have revealed that the eukaryotic genome is 
pervasively transcribed. Strikingly, only a small proportion of the transcriptome is subsequently 
translated into protein; the majority is made up non-protein coding RNAs (ncRNAs). The most 
abundant class of these ncRNAs are called long noncoding RNAs (lncRNAs), defined as 
transcripts longer than 200 nucleotides that lack protein-coding potential. The establishment of 
lncRNAs, once dismissed as genomic dark matter, as essential gene regulators in many 
biological processes has redefined the central role for RNA in cells. While evidence suggests a 
role for lncRNAs in islets and diabetes, in vivo functional characterization of islet lncRNAs is 
lacking.  
 
For my thesis project, I sought to understand the lncRNA regulatory mechanisms that promote 
pancreas development and function. We conducted comparative transcriptome analyses between 
  
embryonic mouse pancreas and adult mouse islets and identified several pancreatic lncRNAs that 
lie in close proximity to essential pancreatic transcription factors. One of the candidate lncRNAs, 
Pax6 Upstream Antisense RNA (Paupar), mapped near Pax6, a gene encoding an essential 
pancreatic regulatory protein. We demonstrate Paupar is enriched in glucagon-producing alpha 
cells where it promotes the alternative splicing of Pax6 to an isoform required for activation of 
essential alpha cell genes. Consistently, deletion of Paupar in mice resulted in dysregulation of 
Pax6 alpha cell target genes and corresponding alpha cell dysfunction. These findings illustrate a 
distinct mechanism by which lncRNAs can contribute to cell-specific regulation of broadly 
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CHAPTER 1: INTRODUCTION 
 
I. Pancreatic islet development 
Pancreas anatomy 
The pancreas is a dual functioning organ that plays a critical role in the regulation of 
macronutrient digestion and blood glucose levels. The majority of the pancreas is made up of 
exocrine, or acinar, cells that secrete digestive enzymes, such as amylase, lipase, trypsin, and 
chymotrypsin, into the duodenum via the pancreatic ducts (Figure 1-1). In contrast, pancreatic 
hormones are released in an endocrine manner via direct secretion into the blood stream (Figure 
1-1). The endocrine cells, which account for only 1–2% of the entire organ, are clustered 
together in island-like structures, aptly named islets of Langerhans, within the exocrine 
pancreatic tissue (Figure 1-1). There are four different cell types releasing various hormones 
from the pancreatic endocrine compartment: glucagon-producing alpha cells (15-20% of mouse 
islets; ~40% of human islets), insulin-producing beta cells (60-80% of mouse islets, ~50% of 
humans islets), somatostatin-producing delta cells (<10% of both mouse and human islets), and 
pancreatic polypeptide-producing PP-cells (<2% of both mouse and human islets) (Steiner et al., 
2011; Brissova et al., 2005; Cabrera et al., 2006) (Figure 1-2). Two additional endocrine cell 
types, gastrin-producing G cells (Suissa et al., 2013) and ghrelin producing epsilon cells (Prado 
et al., 2004; Sussel et al., 1998), are found transiently in the embryonic pancreas. Interestingly, in 
most mammalian species, the different islet endocrine cells are organized in a non-random 
pattern, with a core of beta cells surrounded by a discontinuous mantle of delta, alpha, and 
pancreatic polypeptide cells (Erlandsen et al. 1976; Orci and Unger 1975; Shih et al., 2013) 
(Figure 1-2). In contrast, several aspects of human islet morphology have remained
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controversial, including islet composition and islet architecture. Recently, studies using confocal 
microscopy concluded that human islets lack the typical core-mantle structure and non-beta cells 
were dispersed throughout the islet (Brissova et al., 2005; Cabrera et al. 2006). However, a 
comprehensive study by Bonner-Weir and colleagues using non-diabetic adult human pancreas 
and enhanced microscopy technologies showed that there was far more variability in islet 
composition in human pancreas than rodent pancreas (Bonner-Weir et al., 2015). They 
concluded that while a subset of human islets had interspersed alpha and beta cells within the 
islet core, the fundamental architectural arrangement is similar between mice and men (Bonner-





Figure 1-1. Anatomical organization of the pancreas. The exocrine function of the pancreas is 
mediated by acinar cells that secrete digestive enzymes into the upper small intestine via the 
pancreatic duct. Its endocrine function involves the secretion of various hormones from different 
cell types within the pancreatic islets of Langerhans. The micrograph shows the pancreatic islets. 






Figure 1-2. The localization and number of alpha cells differ between mouse and human 
pancreatic islets. Mouse islets have a beta cell-rich core (insulin stain in green), which is 
surrounded by a low number of alpha cells (glucagon stain in red). Human islets are composed of 
substructures, each with an arrangement similar to that of mouse islets. Cell nuclei are stained in 
blue. The pie charts show the proportions of the major endocrine cell types in mouse and human 
islets. DAPI, 4′,6-diamidino-2-phenylindole; PP, pancreatic polypeptide. Adapted from Gromada 
et al 2018. 
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Specification of pancreatic progenitor cells 
The development of the pancreas is a complex process in which two morphologically distinct 
tissue types, exocrine and endocrine cells, must derive from one simple epithelium (Gu et al., 
2002). In order to form the mature architecture of the pancreas, there is a carefully orchestrated 
series of events mediated by extrinsic signals from adjacent mesodermal derivatives, as well as 
by intrinsic programs controlled by factors expressed within the endodermal cells themselves 
(reviewed in Gittes, 2009; Jørgensen et al., 2007; Larsen and Grapin-Botton, 2017; Shih et al., 
2013; Pan and Wright, 2011). Mouse pancreas development begins at embryonic day 9.0 (E9.0) 
when the dorsal foregut endoderm thickens and evaginates into the surrounding mesenchyme 
(Munger, 1958; Wessells and Cohen, 1967; Kallman and Grobstein, 1964; Pictet et al., 1972) 
(Figure 1-3). Approximately 12 hours later, the ventral pancreas and common bile duct emerge 
from the ventral foregut endoderm. At E11.5, the gut tube begins to undergo rotation and 
elongation that allows the ventral and dorsal buds to come into contact with one another. 
Subsequent fusing of the dorsal and ventral buds into a single anlage occurs at ~E12 (Figure 1-
3). This process is not well understood, but when it is disrupted as in hedgehog mutants, 
malformations such as annular pancreas (a ring of pancreatic tissue that completely encircles the 
duodenum) can develop (Ramalho-Santos et al., 2000; Hebrok et al., 2000). Interestingly, at this 
early stage, isolated pancreatic endoderm can grow and differentiate in vitro to form pancreatic 
structures in organ culture experiments (Wessells and Cohen, 1967). However, growth and 
differentiation at this stage is dependent on signaling factors from the pancreatic mesenchyme, 
which was demonstrated by elegant co-culture experiments where pancreas development could 
proceed although the epithelium was separated from the mesenchyme by a porous membrane 
(Golosow and Grobstein, 1962).  
6 
Differentiation of pancreatic progenitor cells  
During this early phase of pancreatic development, which has been referred to as the primary 
transition (Pictet et al., 1972), a complex network of transcriptional regulators mediates 
expansion of pancreatic progenitor cells and maintains pancreatic identity over other lineages 
(Figure 1-3). The pancreatic and duodenal homeobox 1 (Pdx1) transcription factor is the earliest 
detectable marker of the pancreatic anlage and is one of the most central nodes in the pancreatic 
transcriptional network (Ahlgren et al., 1996; Guz et al., 1995) (Figure 1-4). Genetic lineage 
tracing experiments showed that Pdx1+ cells represent progenitors of all the mature pancreatic 
cell types, including duct, islet, and acinar cells (Gu et al., 2002). Mice deleted for Pdx1 exhibit 
complete pancreatic agenesis at birth despite initial formation of epithelial buds (Offield et al., 
1996; Marty-Santos and Cleaver, 2016; Ahlgren et al., 1996). Furthermore, maintenance of the 
pancreatic lineage requires higher levels of Pdx1 (Offield et al., 1996; Fujitani et al., 2006), 
which appears to be partly achieved by binding of pancreatic transcription factor 1 subunit alpha 
(Ptf1a) to enhancer elements upstream of Pdx1 (Wiebe et al., 2007). Ptf1a expression is initiated 
after Pdx1 in the posterior foregut endoderm (Burlison et al., 2008) and has a critical function in 
pancreas development (Obata et al., 2001; Kawaguchi et al., 2002; Krapp et al., 1998; Sellick et 
al., 2004; Weedon et al., 2014). In addition to Pdx1 and Ptf1a, several other transcription factors 
have been shown to be important for the primary transition, including Sox9, Gata4/6, Foxa1/2, 
Hnf6a (Onecut1), Hnf1b (Tcf2, Onecut2), Prox1, and Mnx1 (Ahlgren et al. 1996, Guz et al. 
1995, Kawaguchi et al. 2002, Krapp et al. 1998, Seymour et al. 2007) (Figure 1-4). Importantly, 
mice lacking any one of these factors display varying degrees of pancreas hypoplasia or agenesis 
(reviewed in Gittes, 2009, Pan and Wright, 2011, Seymour and Sander, 2011). 
 
7 
Specification of pancreatic endocrine progenitor cells  
Shortly after the primary transition, the nascent pancreatic buds are almost entirely composed of 
multipotent progenitor cells (MPCs). During the secondary transition (E13.5-E15.5), non-
committed multipotent progenitor cells (MPCs) differentiate into an organ with different cellular 
compartments; the pancreatic epithelium undergoes dynamic structural changes, resulting in 
multiple protrusions that bud from the edges (Figure 1-3). These structures consist of a tip 
domain, marked by expression of Ptf1a and Cpa, and a trunk domain, identified by Nkx6.1/6.2, 
Sox9, Hnf6b, Hnf6a, Prox1, and Hes1 (Schaffer et al. 2010; Klinck et al., 2011; Kopinke et al. 
2011, Jacquemin et al. 2003, Vanhorenbeeck et al. 2007, Wang et al. 2005, Zhou et al. 2007) 
(Figure 1-4). Lineage-tracing experiments revealed that the trunk predominantly gives rise to the 
endocrine and ductal cell lineages, whereas the tips are quickly restricted to an acinar fate 
(Kopinke et al. 2011, Kopp et al. 2011, Pan et al. 2013, Solar et al. 2009, Zhou et al. 2007) 
(Figure 1-3). The transcription factors Nkx6.1 and Ptf1a act as master regulators during this 
process. These factors are initially co-expressed in MPCs, but their expression domains entirely 
segregate during tip and trunk compartmentalization: Nkx6.1/6.2 promote trunk identity and 
segregate to trunk cells, and Ptf1a has an equivalent role in the tip compartment (Schaffer et al. 
2010). Mechanistically, this process is initiated by transcriptional cross-repression between 
Nkx6.1/6.2 and Ptf1a (Schaffer et al. 2010) (Figure 1-4).  
 
Downstream of Nkx6.1-mediated specification of trunk cells, several factors play a role in the 
ductal versus endocrine fate decision. The central intrinsic regulator of endocrine specification is 
the bHLH transcription factor Ngn3, the expression of which is necessary and sufficient for 
endocrine development in the pancreatic endoderm (Gu et al., 2002; Apelqvist et al., 1999; 
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Gradwohl et al., 2000; Grapin-Botton et al., 2001; Schwitzgebel et al., 2000) (Figure 1-4). Mice 
lacking Ngn3 function fail to develop endocrine cells (Gradwohl et al., 2000), whereas ectopic 
Ngn3 expression under the Pdx1 promoter induces premature differentiation of the entire 
pancreatic bud progenitor pool into endocrine cells (Apelqvist et al., 1999; Schwitzgebel et al., 
2000). Surprisingly, Ngn3 is expressed in only a subset of cells within the trunk domain, which 
raises the question of how its expression is repressed in the majority of embryonic ductal cells. 
Biochemical and genetic evidence suggests that the transcription factor Hes1 plays an important 
role in repressing Ngn3 transcription and preventing widespread Ngn3 activation (Ahnfelt-Ronne 
et al. 2012, Apelqvist et al. 1999, Jensen et al. 2000, Lee et al. 2001). Recently, Hes1 was found 
to accelerate NGN3 protein degradation (Qu et al. 2013), which suggests that Ngn3 is regulated 
posttranslationally. Supporting this idea, a separate study reported that Ngn3 mRNA is detected 
in a much broader domain than NGN3 protein (Villasenor et al., 2008).  
 
Differentiation pancreatic endocrine progenitor cells 
Once Ngn3 is expressed, progenitors exit the cell cycle, delaminate, and migrate away from the 
progenitor cords to form endocrine clusters (Gouzi et al. 2011, Miyatsuka et al. 2011). During 
this process, endocrine precursors go through progressive differentiation towards mature 
endocrine cells by initiating temporal waves of transcription factors ensuring unidirectional 
differentiation. It is important to note that some transcription factors promote cellular lineage 
decisions by activating downstream genetic targets, while others act as repressors of alternative 
cellular programs. Ngn3 activates the expression of a number of endocrine transcription factors 
including: NeuroD1, Pax4, Arx, Insm1, Rfx6, Nkx2.2, and Myt1 (Pan and Wright, 2011; Huang 
et al., 2000; Smith et al., 2003; Smith et al., 2004; Watada et al., 2003; Mellitzer et al., 2006; 
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Wang et al., 2007; Rukstalis and Habener, 2007; Soyer et al., 2010; Larsen and Grapin-Botton 
2017) (Figure 1-4). Isl1 is also thought to be downstream of Ngn3 (Du et al., 2009), but whether 
Ngn3 directly activates Isl1 expression remains to be determined. Eventually, the combinatorial 
expression of multiple downstream factors will define the identity of specific islet cell types 
(reviewed in Spence and Wells, 2007). Over the next several days (E14-E18) the maturing 
endocrine cells begin to accumulate along the ducts and blood vessels in a cord-like linear 
pattern. In the neonatal pancreas, these linear endocrine collections begin to coalesce into 
aggregates that represent the first islets of Langerhans (Figure 1-3). Although conventional 
lineage diagrams depict single Ngn3+ cells giving rise to multiple islet cell types, it is equally 
plausible that four (or more) independent classes of Ngn3+ cells exist, one for each mature cell 
type in the islet (Murtaugh, 2007). Distinguishing these models, however, will require lineage-





Figure 1-3. Illustrated overview of pancreatic organogenesis. (A) The dorsal and ventral 
pancreatic epithelium evaginates into the surrounding mesenchyme between e9.0-e11.5 in mice. 
11 
At this stage, the pancreatic epithelium is comprised of a multilayered core of unpolarized cells 
engulfed by a basement membrane. Scattered microlumens (light yellow) arise between 
epithelial cells. Blood vessels surround but have not yet penetrated the epithelial buds. (B) At 
e12.5, the outer tip cell layer (green) of the pancreatic epithelium forms recognizable branch 
protrusions. In the trunk portion of the pancreatic epithelium, microlumens fuse to form a 
primitive plexus, and groups of newly polarized cells (purple) organize into rosettes around a 
lumen. At the same time, blood vessels begin to intercalate into the epithelium and contact trunk 
cells. (C) At e15.5, the luminal plexus progressively remodels into a single-layered epithelium 
consisting of highly branched primitive ducts (also known as progenitor cords) and newly 
differentiated acinar cells. Ngn3-expressing endocrine precursors (orange) delaminate and 
migrate away from the progenitor cords to form endocrine clusters. Blood vessels are 
intercalated between nascent branches of the pancreatic ductal tree. (D) In the mature pancreas, 
acinar cells cap the endings of small terminal ducts and form functional exocrine secretory units. 
Endocrine cells are clustered in so-called islets of Langerhans, which are penetrated by a dense 







Figure 1-4. Lineage hierarchy during pancreas organogenesis. Following specification, the 
multipotent pancreatic progenitors co-express a range of pancreas-associated transcription 
factors facilitating establishment of the gene regulatory network mediating multipotency at the 
early stages of pancreas development. Priming towards the endocrine lineage occurs in scattered 
multipotent progenitors via transient expression of Ngn3, subsequently leading to the emergence 
of primary transition-derived alpha cells. Notch signaling and reconfiguration of the 
transcriptional connectivity between Ptf1a and Nkx6.1 next initiate tip-trunk segregation, leading 
to the segregation of the acinar and ducto-endocrine lineages. In the ductal-endocrine bipotent 
population, scattered progenitors are primed towards the endocrine lineage via NGN3 expression 
facilitated by low levels of Notch signaling. The population of secondary transition-derived 
endocrine precursors primarily gives rise to beta cells but also to the other four endocrine 
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subtypes. Remaining ductal progenitors eventually mature into ductal cells displaying primary 
cilia and hydrogen bicarbonate production. Adapted from Larsen and Grapin-Botton, 2017. 
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Alpha and Beta cell specification and maturation 
Endocrine lineage specification towards mono-hormonal endocrine cells is controlled by the 
expression of lineage-specific transcription factors (Figure 1-4). For example, the transcription 
factors Pax4, Nkx2-2, Pdx1, and Nkx6.1 are all critical beta cell determinants (Sussel et al., 
1998; Collombat et al. 2003, Gannon et al. 2008, Henseleit et al. 2005, Holland et al. 2002, Sosa-
Pineda et al. 1997) (Figure 1-5). Similarly, several essential alpha cell transcription factors have 
been identified, including Pax6, Arx, and Foxa2, and mice lacking any of these factors do not 
produce functional alpha cells (Gromada et al., 2007; Sander et al., 1997; Masson et al., 2014; 
Jin, 2008) (Figure 1-5). Following the initial instigation of endocrine subtype lineages, 
subsequent functional maturation is orchestrated by another set of transcription factors. The 
transcription factors MafA and MafB play pivotal roles in the functional maturation of beta and 
alpha cells, respectively. MafB is expressed in nascent embryonic alpha and beta cells and 
becomes restricted to mature alpha cells where it directly regulates the expression of glucagon by 
binding to upstream promoter elements (Artner et al., 2006). While immature beta cells express 
MafB, fully mature beta cells are characterized by the expression of MafA and absence of MafB 
(Artner et al., 2007; Artner et al., 2010; Nishimura et al., 2006), although this switch is not 
conserved in humans (Riedel et al., 2012). Expression of MafA is controlled by direct 
transcriptional activation of beta cell factors such as Pdx1, Nkx2.2, Foxa2 and Pax6 (Raum et al., 
2006; Zhang et al., 2005).  
 
Cell specific function of pancreatic transcription factors 
Studies in mice have shown that several pancreatic transcription factors have dual regulatory 
roles: a single transcription factor can be required during development for cell lineage decisions 
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and for the maintenance of mature islet cell identity and function. There are several examples of 
these dual regulators in the literature. Nkx6-1 has been shown to be necessary and sufficient to 
promote differentiation of endocrine progenitor cells into mature beta cells (Schaffer et al., 
2013). Once the beta cells have matured, Nkx6-1 expression must be maintained or the cells will 
acquire molecular characteristics of delta cells, initiating the rapid onset of diabetes (Taylor et 
al., 2013) (Figure 1-5). This archetype is not unique to Nkx6-1; multiple transcription factors 
have been shown to be required during both pancreas development and in mature beta cells, 
including Nkx2-2 (Sussel et al., 1998; Gutierrez et al., 2016; Churchill et al., 2016), NeuroD1 
(Anderson et al., 2009; Naya et al., 1997), Glis3 (Kang et al., 2016), Pdx1 (Offield et al., 1996; 
Gao et al., 2014) (Figure 1-5). This archetype of transcription factors is also not unique to beta 
cells. The transcription factor, Arx, has been shown to be required for alpha cell development 
(Collombat et al., 2003) and the maintenance of mature alpha cell identity and function 
(Courtney et al., 2013) (Figure 1-5).  
 
To make matters even more complicated, some transcription factors have triple duty: they are 
required during development and in several different mature islet cell types. One of the more 
characterized pancreatic transcription factors, Pax6, exhibits these regulatory properties. Pax6 is 
required downstream of Ngn3 for proper development of all endocrine lineages, hormone 
production and islet organization (Sander et al., 1997; St-Onge, 1997). Conditional deletion of 
Pax6 in mature alpha or beta cells showed that Pax6 is also required to maintain the identity and 
function of both endocrine cell types (Ahmad et al., 2015; Gosmain et al., 2012; Mitchell et al., 
2017; Swisa et al., 2017). Some cell specific regulatory function of Pax6 has been explained; in 
alpha cells, Pax6 heterodimerizes with MafB and stimulates Gcg expression by binding to the G1 
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element (Gauthier et al., 2002; Gosmain et al., 2007) (Figure 1-6); in beta cells, Pdx1, Pax4, and 
Nkx6.1 bind to G1 and inhibit Gcg expression by blocking the binding of the Pax6/Maf 
heterodimer to the G1 element (Gauthier et al., 2007, Gosmain et al., 2007; Ritz-Laser et al., 
2002) (Figure 1-6). Although these studies shed light on how the Glucagon gene is activated in 
alpha cells and repressed in beta cells, many other cell-specific, or gene-specific, transcription 
factor regulatory mechanisms remain poorly understood. For example, recent work has shown 
that within mouse beta cells, Pax6 directly activates critical beta cell genes and represses genes 
that specify the alternative islet endocrine cell lineages (Swisa et al., 2017). Similar findings 
were reported for the transcription factor, Pdx1, which acts as an activator of mature beta cell 
genes (Gao et al., 2014). Interestingly, conditional deletion of Pdx1 in mature beta cells induced 
upregulation the alpha cell transcription factor, MafB (Gao et al., 2014). This study further 
demonstrated that Pdx1 normally binds and represses MafB beta cells, showing that Pdx1 has 
both activating and repressive functions, depending on the cellular context (Gao et al., 2014). I 
will describe the regulatory role of Pax6 in islets in greater detail in Chapter 2, but collectively, 
these findings highlight that the molecular mechanism mediating cell specific regulatory 





Figure 1-5. Comparison of mouse beta and alpha cell transcriptomes based on functional 
annotation. Establishment and maintenance of alpha and beta cell identity is regulated by a 
complex interplay of transcription factors (A), whose expression pattern is accurately reflected 
by our mouse alpha and beta cell transcriptomes. A dot plot represents actual transcription factor 
expression in beta and alpha cells where each dot represents an individual gene (B). Genes that 
are significantly enriched in beta or alpha cells are highlighted in red and green, respectively. 






Figure 1-6. Schematic on the transcriptional regulation of preproglucagon in the pancreatic 
alpha and beta cells. The expression of preproglucagon is regulated through interaction of 
homeodomain proteins that bind to the preproglucagon promoter region, which comprises a 
minimal promoter region and an enhancer region. Adapted from Muller et al., 2017.  
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II. Pancreatic islet function 
Bihormonal regulation of glucose homeostasis 
Each islet hormone has a distinct function: insulin decreases blood glucose levels (Goke 2008); 
glucagon increases blood glucose levels; somatostatin inhibits glucagon and insulin release 
(Hauge-Evans et al., 2009); PP regulates the exocrine and endocrine secretion activity of the 
pancreas (Katsuura et al., 2002). Together, these hormones maintain blood glucose levels within 
a very narrow physiological range (4-6 mM), referred to as glucose homeostasis (Figure 1-7). 
Briefly, during sleep or between meals, when blood glucose levels are low, glucagon is released 
from alpha cells to promote hepatic glycogenolysis and gluconeogenesis thereby increasing 
endogenous blood glucose (Freychet et al., 1988). In contrast, postprandial hyperglycemia 
stimulates insulin secretion from beta cells (Komatsu et al., 2013). Insulin acts on its receptors in 
muscle and adipose tissue to promote the uptake of glucose and thereby lowers blood glucose 
levels by removing the exogenous glucose from the blood stream (Khan and Pessin, 2002, Kohn 
et al., 1996, Zisman et al., 2000). In these next two sections, I will explore the pivotal findings 
that have led to our understanding of the role of insulin and glucagon in regulating glucose 
homeostasis (Figure 1-8).  
 
Beta cells and insulin 
The discovery of insulin was one of the key achievements of the twentieth century and arguably 
the first instance in which science provided a new lifesaving medicine for the morbidly ill. Prior 
to the discovery of insulin, a diagnosis of diabetes, particularly in children, was equivalent to a 
death sentence (Bliss, 1982). The only existing treatment was a starvation diet advocated by 
Frederick Madison Allen, a physician and diabetes expert working at the Rockefeller Institute for 
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Medical Research (now Rockefeller University) (Allen, 1913). In 1889, Oskar Minkowski and 
Josef von Mering observed that removal of a dog’s pancreas, but not ligation of the pancreatic 
duct, resulted in polyuria, polydipsia, and diabetes, suggesting that the pancreas is of crucial 
importance for maintaining euglycemia (von Mering and Minkowski, 1890). Another study 
noted that the islets of Langerhans in the pancreas were often destroyed in humans with diabetes, 
but how this pancreatic component controlled sugar metabolism was unknown (Opie, 1900). One 
possibility was that the islets of Langerhans produced a hormone, referred to then as an “internal 
secretion,” that regulated glucose concentrations in the blood. In the years that followed, work 
from several scientists, including Israel Kleiner (Kleiner, 1919), Georg Ludwig Zuelzer (Zuelzer, 
1908), and Nicolae Paulescu (Paulescu, 1920), successfully used pancreatic extracts to lower 
blood glucose in diabetic dogs. These studies collectively paved the way for the work of 
Frederick Grant Banting (Friedman, 2010). In 1921, Banting approached John James Rickard 
Macleod, a physiology professor at the University of Toronto, and proposed a study to eliminate 
the exocrine part of the pancreas and enrich for pancreatic islets (Ceranowicz et al., 2015). 
Macleod accepted Banting's proposal and, before leaving on summer break, gave him lab space, 
ten dogs, and the help of two medical students, Charles Herbert Best and E. Clark Noble 
(Wright, 2002). Banting felt he only needed one extra pair of hands, and Best and Noble decided 
to toss a coin. Best won the coin toss and Banting and Best began a series of experiments that led 
to the discovery of insulin (Banting and Best, 1922). They initially sourced insulin from dog 
pancreases, then from pancreases harvested from cattle embryos, and finally from ox pancreases. 
After Macleod returned from vacation he assumed oversight over the investigations. The alcohol 
extract that Banting obtained from pancreases lowered glucose levels in dogs that had induced 
diabetes, but because the extracted insulin was relatively impure, it was unsuitable for clinical 
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studies, which is why an experienced biochemist, James Betram Collip, joined the team in 
December 1921. Collip developed a successful method that enabled the extraction of large 
amounts of highly purified insulin from ox pancreases, and this made it possible for a clinical 
study to commence in January 1922. The study was a great success and confirmed insulin's 
effectiveness in treating diabetes. In 1922, Banting, Best, and Collip were granted patent rights 
for producing insulin, but they sold them to the University of Toronto for a dollar (Friedman, 
2010). In 1923, Frederick Grant Banting and John James Rickard Macleod were awarded the 
Nobel Prize in recognition of their discovery. The first study to suggest diversity among 
pancreatic islet cells identified two populations of cells, the A cells and B cells (Lane 1907). In B 
cells, which are now known as beta cells, researchers found basophilic granules that were not 
present in A cells (Stanger and Samols, 1991). In 1957, a study used immunohistochemistry to 
show that insulin was the hormone produced by beta cells (Lacy and Davies, 1957). Later, 
researchers used electron microscopy on human beta cells to determine the ultrastructure of beta 
cells (Like, 1967).  
 
The primary functional feature of the beta cell is its ability to secrete insulin in a tightly regulated 
manner in response to metabolic demands. There are different molecules that can promote 
insulin secretion, such as the glucagon-like- peptide 1 (GLP-1), gastric inhibitory polypeptide 
(GIP), cholecystokinin (CCK), and peptide YY (PYY). However, the main stimulus for insulin 
release is elevated blood glucose levels following a meal (Poitout et al., 2006). In beta cells, 
glucose is taken up by the facilitative glucose transporter, Glut2 (Thorens et al., 1988). Once 
inside the cell, glucose undergoes glycolysis resulting in increased cellular ratios of free 
adenosine triphosphate (ATP) to adenosine diphosphate (ADP) (Kennedy et al., 1999). This 
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altered ratio then leads to the closure of ATP-sensitive K+-channels (KATP) (Ashcroft et al., 
1984; Cook and Hales, 1984). Under non-stimulated conditions, these channels are open to 
ensure the maintenance of the resting potential by transporting positively charged K+-ions down 
their concentration gradient out of the cell. Upon closure, the subsequent decrease in the 
magnitude of the outwardly directed K+-current elicits the depolarization of the membrane, 
followed by the opening of voltage-dependent Ca+-channels (VDCCs) (Roder 2016). The 
increase in intracellular calcium concentrations eventually triggers the fusion of insulin-
containing granules with the membrane and the subsequent release of their content (Jonkers and 
Henquin 2001; Yang and Berggren, 2006). The insulin secretory process is biphasic with the first 
phase peaking around 5 minutes after the glucose stimulus with the majority of insulin being 
released during this first phase. In the second, somewhat slower, phase, the remaining insulin is 
secreted (Ceraso and Luft, 1967; Porte and Pupo, 1969; Curry et al, 1968).  
 
Alpha cells and glucagon 
The monumental discovery of insulin overshadowed the simultaneous observation that 
pancreatic extracts imposed a brief hyperglycemic response prior to the decrease in blood 
glucose (Banting and Best, 1922; Rosenfeld, 2002). These hyperglycemic properties of 
pancreatic extracts were first misjudged as an unimportant byproduct of the extraction method. 
However, in 1922, C.P. Kimball and John R. Murlin identified a pancreatic fraction that potently 
increased blood glucose when injected in rabbits and dogs (Kimball and Murlin, 1923). Their 
study concluded that the pancreas produces a specific factor that opposes the hypoglycemic 
effect of insulin and therefore named the substance “the glucose agonist,” or glucagon (Kimball 
and Murlin, 1923). Prior to the purification of glucagon, research demonstrated that the 
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hyperglycemic effect of this unidentified substance was partly mediated through a direct 
glycogenolytic effect on the liver (Burger and Brandt, 1935; Burger and Kramer, 1929). By the 
mid 1950s, scientists at Eli Lilly successfully crystallized and determined the amino acid 
sequence of glucagon (Staub et al., 1953; Bromer et al., 1957). These breakthroughs enabled the 
development of the first radioimmunoassay used subsequently to detect glucagon (Unger et al., 
1959) and the medicinal use of glucagon in the treatment severe hypoglycemia (Arieff et al., 
1960; Esquibel et al., 1956; MacCuish et al., 1970). The exact place where glucagon was 
produced in the islets was unknown until 1962, when the previously identified A cells (Lane, 
1907), renamed alpha cells, were shown to be the site of glucagon production (Baum 1962; 
Mikami and Ono, 1962).  
 
Glucagon is the primary secretory product of alpha cells and is the principle measure of alpha 
cell function. The major physiological stimuli for glucagon release from alpha cells are mixed 
nutrient or protein ingestion, activation of the autonomic nervous system (ANS), and 
hypoglycemia (Dunning and Gerich, 2007; Gromada et al., 2007). As suggested by the diversity 
of these regulatory factors, control of secretion at the level of the islet is complex and 
multilayered. Interestingly, much of the secretory machinery found in beta cells is also found in 
alpha cells, including membrane surface receptors, KATP ion channels, and exocytotic proteins 
(Cheng-Xue et al., 2013; Gromada 2004). Given that alpha and beta cells have opposite secretory 
responses, these findings were initially difficult to explain (Figure 1-8). However, studies have 
shown that differences in resting electrical characteristics and ion channel function downstream 
of KATP channel closure can explain much of the reciprocal pattern of these two hormones and 
different glycemic conditions (MacDonald et al., 2002; Ramracheya et al., 2010; Rorsman and 
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Braun, 2012). For example, the glucose transporter Glut2 (encoded by Slc2a2), which has an 
affinity for glucose in the physiological range, is largely absent from alpha cells, whereas the 
higher-affinity glucose transporter Glut1 (encoded by Slc2a1) is present in both mouse 
(Heimberg et al., 1995; Benner et al., 2014) and human (Blodgett et al., 2015) alpha cells. Thus, 
the differential expression of GLUT1 and GLUT2 in alpha versus beta cells might affect the 
range of glucose detection and, conceivably, downstream cellular responses (Gromada, 2018).  
 
In addition to glucose, several paracrine, hormonal, and neuronal signals fine-tune glucagon 
secretion under different physiological conditions (Gromada et al., 2007). It has long been 
appreciated that amino acids are important regulators of alpha cells (Holst et al., 2017; Longuet 
et al., 2013; Solloway et al., 2015; Dean et al., 2017); protein meals or infusions of amino acids 
stimulate glucagon release, and arginine is potent glucagon secretagogues used in research 
studies. Furthermore, several studies have provided evidence that insulin suppresses glucagon 
secretion (Taborsky et al., 2002; Maruyama et al., 1985; Kawamori and Kulkarni, 2009). This 
effect could be mediated directly via insulin receptors on the alpha cells or indirectly via 
increased somatostatin secretion from neighboring delta cells (Briant et al., 2018). Lastly, 
Ishihara and colleagues showed that in the perfused rat pancreas, glucose-stimulated release of 
zinc ions from beta cells contributed to the inhibition of glucagon secretion (Ishihara et al., 
2003). However, examination of mouse islets found that zinc ions did not have an effect on 




Figure 1-7. Maintenance of blood glucose levels by glucagon and insulin. When blood 
glucose levels are low, the pancreas secretes glucagon, which increases endogenous blood 
glucose levels through glycogenolysis. After a meal, when exogenous blood glucose levels are 
high, insulin is released to trigger glucose uptake into insulin-dependent muscle and adipose 




Figure 1-8. Schematic on the glucose-dependent regulation of glucagon and insulin 
secretion. The cellular machinery controlling the secretion of glucagon in alpha cells is 
remarkably similar to that regulating the secretion of insulin in beta cells, yet their secretion is 
reciprocally regulated by blood glucose concentration. In contrast to the secretion of insulin, the 
release of glucagon is stimulated under conditions of hypoglycemia and subsequently decreases 
when blood glucose increases. In line with glucose being a major determinant of glucagon (and 
insulin) secretion, the islets of Langerhans are well vascularized to ensure rapid glucose sensing. 




III. Islet dysfunction and diabetes  
Health burden  
Diabetes represents a complex set of diseases with genetic, immunological, and environmental 
etiologies. Of the three major types of diabetes, type 2 diabetes mellitus (T2DM) is far more 
common (accounting for more than 90% of all cases) than either type 1 diabetes mellitus 
(T1DM) or gestational diabetes; however, T1DM is the most common form of diabetes in 
children under 15 and over 500,000 children are currently living with this condition worldwide 
(Katsarou et al., 2014). According to the International Diabetes Federation, 8.8% of the adult 
population worldwide has diabetes (IDF Diabetes Atlas, 2017). In recent years, there has been an 
unprecedented increase in diabetes prevalence in the U.S. and worldwide. Sixty years ago, the 
National Center for Health Statistics (NCHS) began conducting the National Health Interview 
Survey (NHIS) to gather information on the health of the U.S. population. In 1958, 1.58 million 
Americans had diabetes, corresponding to the 0.93% of the total population. As of 2015, 30.3 
million Americans, or 9.4% of the population, have diabetes (CDC, National Diabetes Statistics 
Report, 2017). Strikingly, another 84.1 million Americans exhibit impaired glucose tolerance, or 
prediabetes, a condition that if not treated often leads to diabetes within five years (CDC, 
National Diabetes Statistics Report, 2017). This rapidly increasing prevalence of diabetes is 
thought to be due to environmental factors, such as increased availability of food and decreased 
physical activity, acting on genetically susceptible individuals (Sladek et al., 2007). Diabetes is 
also currently the seventh leading cause of death in the U.S., corresponding to 76,488 deaths 
annually (CDC, National Diabetes Statistics Report, 2017). This alarming trend, coupled with 
limited treatment options and severe comorbidities, highlights the urgent need to address gaps in 
our understanding diabetes etiology.  
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Pathophysiology of islet dysfunction 
Although the exact pathophysiology differs for each diabetes subtype, the disease generally 
results from the failure of pancreatic beta cells to meet the insulin demands required for glucose 
homeostasis. T2DM is a multifactorial disease involving genetic and environmental factors. The 
disease is characterized by dysregulation of macronutrient metabolism, and results from 
progressively impaired insulin secretion by pancreatic beta cells, resulting from impaired 
function, increased cell death, or loss of cell identity (reviewed in DeFronzo, 2015). This beta 
cell impairment is often in the background of pre‐existing insulin resistance in skeletal muscle, 
liver and adipose tissue. Specifically, beta cell resistance GLP-1 contributes to progressive beta 
cell dysfunction, while increased glucagon levels and enhanced hepatic sensitivity to glucagon 
contribute to excessive glucose production by the liver (Magnusson et al., 1992; DeFronzo et al., 
2009; DeFronzo et al., 2010). Insulin resistance in adipocytes results in accelerated lipolysis and 
increased plasma free fatty acid (FFA) levels, both of which aggravate the insulin resistance in 
muscle and the liver and contribute to beta cell failure (Groop et al., 1989; Guilherme et al., 
2008). Increased renal glucose reabsorption by the sodium/glucose co‐transporter 2 (SGLT2) and 
the increased threshold for glucose spillage in the urine contribute to the maintenance of 
hyperglycemia (Gerich et al., 2001; DeFronzo et al., 2013). Resistance to the appetite‐
suppressive effects of insulin, leptin, GLP-1, amylin, and PYY, as well as low brain dopamine 
and increased brain serotonin levels contribute to weight gain, which exacerbates the underlying 
resistance (Blazquez et al., 2014; Kleinridders et al., 2014; Samuel and Shulman, 2012).  
 
T1DM is a chronic autoimmune disease characterized by persistent hyperglycemia due to insulin 
deficiency that occurs following destruction of islet beta cells (The SEARCH Study group, 2004; 
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Gepts, 1965; Eisenbarth, 1986; Atkinson et al., 2014). For the vast majority of patients (70–
90%), the loss of beta cells is the consequence T1DM-related autoimmunity, concomitant with 
the formation of T1DM-associated autoantibodies (American Diabetes Association, 2015). 
Similar to T2DM, the incidence of T1DM is increasing worldwide and it is estimated that nearly 
90,000 children are diagnosed each year (Diaz‐Valencia et al., 2015).  
 
The long-standing view of T1DM pathogenesis was that autoimmune beta cell destruction 
resulted in complete loss of pancreatic insulin secretion. The improved sensitivity of C-peptide 
detection as well as studies using pancreatic specimens have recently led to the realization that 
many individuals with T1DM have insulin-secreting cells, even 50 years after diagnosis (Keenan 
et al., 2010; Oram et al., 2015). Recent work by Brissova and colleagues defined the functional 
and molecular properties of T1DM islets (Brissova et al., 2018). Surprisingly, they found that 
remaining islet beta cells maintained several features of regulated insulin secretion. In contrast, 
islet alpha cells showed severely impaired glucagon secretion, corresponding to decreased levels 
of essential alpha cell transcription factors (Brissova et al., 2018). These findings highlight the 
complexity of T1DM pathogenesis and suggest alpha cells play an important role in diabetic 
hyperglycemia (Brissova et al., 2018).  
 
Current Treatments  
The ultimate goal of diabetes care is to minimize fluctuations in blood glucose levels, which will 
prevent or minimize acute and long‐term microvascular complications, such as retinopathy, 
nephropathy and neuropathy, and macrovascular complications, such as a heart attack and stroke 
(Pozzilli et al., 2010; Stratton et al., 2000; Holman et al., 2008). The major treatment option for 
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T1DM is exogenous insulin replacement. More recently, insulin pumps and continuous glucose 
monitors have made substantial improvements in T1DM care. For T2DM, tight blood glucose 
control can involve lifestyle interventions (diet and exercise) and/or different kinds of 
pharmacological agents (Jeon et al., 2007; Sigal et al., 2006). The most common 
pharmacological agents for T2DM include: suppressors of hepatic glucose production 
(Metformin), enhancers of insulin sensitivity (thiazolidinediones (TZDs)), and enhancers of 
insulin secretion (sulfonylureas). Although these agents are the conventional line of treatment, 
success of these medications varies between patients, and their effectiveness in some cases is 
only temporary. Furthermore, many of these drugs have several associated risks, including fluid 
retention, increased cardiovascular risk, lactic acidosis, and dangerous hypoglycemia (Inzucchi 
et al., 2015).  
 
An alternative treatment for patients with diabetes is the transplantation of human cadaveric 
islets. This procedure, termed the Edmonton protocol, typically results in better glycemic control, 
can render patients insulin independent for prolonged periods of time, and improves overall 
quality of life (Lacy and Scharp, 1986; Mullen et al., 1977; Bellin et al., 2012; Shapiro et al., 
2000; Posselt et al, 2010; Barton et al, 2012). However, the severe shortage of cadaveric organ 
donors and requirement for lifelong immunosuppression impedes the use of islet transplantation 
as a readily available treatment for people with diabetes (Russ et al., 2015). Consequently, 
numerous research efforts have focused on identifying alternative sources of surrogate glucose-
responsive insulin-producing cells (Zhou and Melton, 2018; Kieffer, 2016; Efrat and Russ, 2012; 
Hebrok, 2012; Nostro and Keller, 2012; Bouwens et al, 2013; Pagliuca and Melton, 2013). In 
this next section, I will highlight what is known about the three major strategies for generating 
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new beta cells: pluripotent stem cell differentiation, reprogramming from other cell types, and 
induction of replication in existing beta cells (Figure 1-9).  
 
Beta cell replacement therapy 
A major advance for the field of beta cell replacement therapy was the identification of 
pluripotent human ESCs (hESCs) that are capable of generating tissues from all three 
developmental germ layers (Thomson et al., 1998). In the decade following this discovery, the 
Yamanaka factors were identified and shown to induce reprogramming of murine fibroblasts into 
pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Wernig et al., 2007; Yu et al., 
2007) and soon thereafter, iPSCs were also engineered from human cells (Lowry and Plath, 
2008; Nakagawa et al., 2008; Takahashi et al., 2007; Yu et al., 2007). These studies opened the 
door for research aiming to create fully functional beta cells from pluripotent cells. Two groups 
were among the first to report differentiation of hESCs towards pancreatic progenitor cells and 
immature islet cells (D’Amour et al., 2006; Kroon et al., 2008). Importantly, these differentiation 
protocols were informed by decades of research on pancreas development that mapped out the 
key steps and critical signaling events required for the formation of mature islets. More recently, 
several groups have devised enhanced differentiation protocols, which yield cellular clusters with 
remarkable morphological and functional resemblance to pancreatic islets (Pagliuca et al., 2014; 
Rezania et al., 2014; Szot et al., 2015; Zhu et al., 2016) (Figure 1-9). Furthermore, 
transplantation of these clusters into mice led to further functional maturation in vivo and robust 
rescue of experimental diabetes in mouse models (Pagliuca et al., 2014; Rezania et al., 2014; 
Szot et al., 2015; Zhu et al., 2016). While these protocols represent a positive step forward in 
terms of therapeutic development, there are several risks that still need to be assessed, including 
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1) inadequate control of post- prandial glucose excursions; (2) formation of teratoma, pancreatic 
adenocarcinoma, or hormone-secreting tumor; (3) hyper-functioning or constitutive functioning 
of the graft of insulin or other hormones resulting in hypoglycemia; (4) provocation of systemic 
autoimmunity; and (5) HLA sensitization (Kushner et al., 2014).  
 
Given the complexity of hESC to beta cell differentiation protocols, there is a great interest in 
converting cell types more closely related to beta cells, such as other islet cell types (Figure 1-9). 
In the pancreas of adult mice, following near-total beta cell ablation, 1–2% of alpha cells and 
delta cells spontaneously expressed insulin, leading to correction of diabetic hyperglycemia 
(Chera et al., 2014; Thorel et al., 2010). A separate study showed that inhibition of the 
transcription factor Arx, the dimethyltransferase Dnmt1, or forced expression of Pax4, 
specifically in alpha cells caused transdifferentiation into insulin positive cells, irrespective of 
beta cell loss (Courtney et al., 2013; Chakravarthy et al., 2017). Additionally, a study from 
Matsuoka and colleagues showed that forced expression of MafA in pancreatic alpha cells 
enabled Pdx1-dependent transdifferentiation into beta cells (Matsuoka et al., 2017). Interesting, a 
recent study showed that a unique population of insulin-producing cells at the periphery of the 
islets could be an intermediary in the transition from alpha cells to beta cells (van der Meulen et 
al., 2017). In addition to non-beta islet cells, several studies have explored non-islet cell types as 
well as extra pancreatic tissues as sources for new beta cells. A combinatorial screening strategy 
showed that three developmental regulators of beta cells, Ngn3, Pdx1, and MafA, could 
efficiently convert pancreatic acinar cells into beta-like cells after delivery into the adult mouse 
pancreas using adenoviral vectors (Zhou et al., 2008). More recently, the same group reassessed 
the long-term stability of induced insulin+ cells from acinar cells in vivo (Li et al., 2014). This 
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study showed that by using a newly optimized induction protocol using a polycistronic construct 
containing Pdx1, Ngn3, and MafA, large numbers of beta-like cells aggregated to islet-like 
clusters and persisted throughout the observation period up to 13 months (Li et al., 2014). 
Another group showed that gastrointestinal epithelial cells could also be converted into beta-like 
cells (Chen et al., 2014). Furthermore, conditional deletion of Foxo1 from Ngn3+ intestinal 
endocrine progenitors also led to the formation of insulin-producing cells in the gut (Talchai et 
al., 2012). Other examples of reprogramming mouse cells include: cytokine-mediated conversion 
of acinar cells to insulin-expressing cells (Baeyens et al., 2014), conversion of duct cells to 
insulin-expressing cells by FBW7 deletion (Sancho et al., 2014), conversion of Sox9+ ductal 
cells during development (Kopp et al., 2011), and conversion of hepatocytes to insulin-producing 
cells by TGIF2 (Cerda-Esteban et al., 2017). Despite numerous proof-of-concept demonstrations 
of beta cell reprogramming in animal models, efforts to reprogram human cells have been less 
successful. While several studies have suggested that human alpha cells can be reprogrammed to 
become beta cells (Ben-Othman et al., 2017; Xiao et al., 2018), in the absence of lineage tracing 
tools, direct evidence is still lacking. At this point, the main challenge in translating the 
reprograming approach into the clinic is to define reliable methods for efficient production of 
human beta-like cells that can develop stable and functional transplants.  
 
Stimulating beta cell proliferation is a simple and intuitive solution to replenishing beta cell mass 
(Dor et al., 2004; Nir et al., 2007; Zhou and Melton, 2018) (Figure 1-9). In fact, a large number 
of growth factors and mitogenic agents have been shown to promote beta cell proliferation in 
animal models, including parathyroid hormone-related protein, hepatocyte growth factor, GLP-1, 
insulin-like growth factors, gastrin, epidermal growth factors, platelet-derived growth factor, and 
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adenosine kinase inhibitors (Mezza and Kulkarni, 2014; Wang et al., 2017; Saunders and 
Powers, 2016; Wang et al., 2015; Andersson et al., 2012; Schulz et al., 2016; Annes et al., 2012). 
Unfortunately, these agents have generally failed to promote significant proliferation of human 
beta cells. Evidence suggests that substantial proliferation of human beta cells appears to occur 
naturally only in the first year of life (Kassem et al., 2000; Meier et al., 2008; Gregg et al., 2012). 
There is longstanding evidence that insulin and glucose, both of which are elevated in obesity or 
insulin resistance, may directly stimulate beta cell proliferation (Kulkarni, 2005; Dadon et al., 
2012; Stamateris et al., 2016). But it remains unclear whether these are the key signals that drive 
islet hyperplasia. A potentially important advance has come from high-throughput compound 
screens that identified inhibitors of dual specificity tyrosine-phosphorylation-regulated kinase 1A 
(DYRK1A) as reagents that can potently stimulate proliferation of cultured human beta cells in 
vitro and transplanted human beta cells in vivo (Wang et al., 2015; Dirice et al., 2016; Shen et 
al., 2015). In addition, other pathways involved in human beta ell proliferation, such as 
calcineurin and SerpinB1, have been identified (El Ouaamari et al., 2017; Dai et al., 2017). To 
advance these reagents into clinics will require controlling the cell type specificity, targeting the 
intervention to islets, and ensuring that reagents that do not raise the problem of tumor 
formation. Ultimately, a true cure for diabetes will require the elucidation of the molecular and 





Figure 1-9. Strategies to generate new beta cells. (A) Directed differentiation using growth 
factors and small molecules can direct a pluripotent stem cell (red) through the stages of 
pancreatic differentiation in a manner that mimics normal development. Currently, functional 
beta cells can only be differentiated through an in vivo transplantation step, but deriving a bona 
fide beta cell fully in vitro (dashed line) is a major goal. A subset of important genes expressed at 
each stage is listed. (B) Reprogramming of terminally differentiated cell types, such as acinar or 
alpha cells, can be used to generate beta cells in vivo, using the overexpression or injury 
strategies listed. Reprogramming other mature cell types, such as hepatocytes, fibroblasts or 
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neurons, in vitro into beta cells (dashed line) remains to be achieved. (C) Inducing the replication 
of existing beta cells is the primary strategy for generating new endogenous beta cells. 
Replication may be recapitulated in vitro or induced in vivo with new small molecules or 







Genetic factors contributing to diabetes 
Decades of mouse research have yielded major advances in our understanding of factors 
influencing beta cell development, identity, and dysfunction. Specifically, these studies have 
revealed networks of transcriptional and chromatin regulators that drive beta cell lineage 
development (Oliver-Krasinski and Stoffers, 2008; Arda et al., 2013; van Arensbergen et al., 
2010; Bramswig et al., 2013; Xu et al., 2011), provide barriers against transdifferentiation or loss 
of beta cell identity (Talchai et al., 2012; Dhawan et al., 2011; Puri et al., 2013; Taylor et al., 
2013; Gao et al., 2014; Papizan et al., 2011; Swisa et al., 2017; Ediger et al., 2017; Collombat et 
al., 2009; Gutierrez et al., 2017), and are misregulated in T1DM and T2DM (Lu et al., 2018; 
Pedersen et al., 2017; Wang et al., 2015; Hou et al., 2017; Carrero et al., 2013). Additionally, 
advances in genome wide association studies (GWAS) have identified several genetic drivers of 
monogenic syndromes of beta cell dysfunction, as well as 113 distinct T2DM susceptibility loci 
and 60 loci associated with an increased risk of developing T1DM (McCarthy 2010; McCarthy 
2016; Scott et al., 2017; Zhao et al., 2017; Cropano et al., 2017; Soccio et al., 2015; Roman et 
al., 2017; Rusu et al., 2017; Maurano et al., 2012). 
 
Strikingly, these studies discovered that most T2DM and T1DM susceptibility loci fall outside of 
coding regions, which suggests a role for noncoding elements in the development of disease. 
Exceptions are a few variants in exons, which influence the function of the gene, such as 
SLC30A8 (Flannick et al., 2014), KCNJ11, and GCKR (Sladek et al., 2007; Saxena et al., 2007). 
Several studies have demonstrated that many causal variants of diabetes are significantly 
enriched in regions containing islet enhancers, promoters, and transcription factor binding sites; 
however, associations with these regulatory regions cannot explain all diabetes susceptibility. 
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This highlights our incomplete understanding of the islet regulome and suggests the need for 
detailed functional analyses of noncoding genes to precisely determine their contribution to 




IV. Noncoding RNAs 
Regulatory noncoding RNAs 
Advances in RNA sequencing (RNA-seq) technologies have revealed that mammalian genomes 
encode tens of thousands of RNA transcripts that have similar features to mRNAs, yet are not 
translated into proteins. While the percentage of non-protein coding RNAs that are functional is 
still unknown, detailed characterization of many of these transcripts has challenged the idea that 
the central role for RNA in a cell is to give rise to proteins. Instead, these RNA transcripts make 
up a class of molecules called noncoding RNAs (ncRNAs) that function either as 
“housekeeping” ncRNAs, such as transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), that 
are expressed ubiquitously and required for protein synthesis, or as “regulatory” ncRNAs that 
control gene expression. Regulatory ncRNAs are further subdivided according to size: 1) short 
ncRNAs (~20 nucleotides), such as micro RNAs (miRNAs) and small interfering RNAs 
(siRNAs); and 2) long noncoding RNAs (lncRNAs) that are defined as transcripts longer than 
200 nucleotides (Esguerra and Eliasson 2014). 
  
MicroRNAs in beta cell development and function  
MicroRNAs are the most well-characterized class of regulatory ncRNAs. MiRNAs are generally 
believed to negatively regulate gene expression through mRNA cleavage that is mediated by the 
Argonaute (Ago) family of proteins as part of the RNA-induced silencing complex (RISC) 
(Mendell and Olson, 2012). The finding that miRNAs only require short “seed” sequences in the 
5’ end of their transcript to direct Ago to target mRNAs implies that one miRNA can influence 
the expression of several target genes (Bartell 2009). It is therefore not surprising that miRNAs 
play essential regulatory roles in diverse cellular processes, including proliferation, 
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organogenesis, hormone secretion, and apoptosis (Esguerra and Eliasson 2014). Studies have 
also shown that the misexpression of miRNAs disrupts gene regulatory networks and contributes 
to disease states, such as cancer and diabetes (Mendell and Olson, 2012). In fact, several groups 
have identified essential roles for miRNAs in beta cell development, function, and disease. 
 
The requirement of miRNAs in beta cell development was initially demonstrated by removal of 
Dicer function during different stages of pancreas development (Figure 1-10). Given that Dicer is 
required for the formation of mature miRNAs, loss of Dicer ablates all miRNA function within a 
cell (Bernstein et al., 2003). The pan-pancreatic loss of Dicer using the Pdx1:Cre allele resulted 
in severe pancreatic agenesis and neonatal death (Lynn et al., 2007). The mutant mice also 
displayed a dramatic loss of all endocrine cell types, which was attributed to a reduction in the 
number of Ngn3+ endocrine progenitor cells (Lynn et al., 2007). In a more recent study, 
Ngn3:Cre was used to ablate Dicer function specifically in the endocrine progenitor population. 
The mutant mice had normal embryonic pancreas development; however, shortly after birth the 
mice developed hyperglycemia due to progressive loss of beta cells (Kanji et al., 2013). 
Surprisingly, the authors found that loss of miRNA function in endocrine progenitor cells caused 
upregulation of neuronal genes normally repressed by RE1-silencing transcription factor (REST) 
(Kanji et al., 2013). Thus, it appears that miRNAs maintain islet-cell identity by inhibiting 
expression of REST, thereby restricting expression of neuronal genes.  
 
While disruption of Dicer function shows that miRNAs are generally required for proper 
pancreas development and islet cell specification, individual miRNAs have also been implicated 
in beta cell specification (Figure 1-10). Kredo-Russo et al. showed that miRNA-7 (miR-7) is 
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expressed during endocrine pancreas development where it directly targets and controls 
expression levels of the essential pancreatic transcription factor, Pax6 (Kredo-Russo et al., 2012). 
Additionally, the miR-30 family functions during the epithelial-to-mesenchymal transition by 
inhibiting mesenchymal mRNAs, such as Vimentin and Snail1, to favor pancreatic epithelial 
development (Joglekar et al., 2009). Taken together, these studies define a requirement for 
miRNAs in several layers of beta cell development.  
 
Following beta cell specification, complex networks of regulatory factors, including miRNAs, 
are needed to maintain beta cell function. Two groups have examined the role of Dicer 
specifically in the developing beta cells by using the Rat Insulin Promoter (RIP):Cre (Kalis et al., 
2011; Mandelbaum et al., 2012). Unlike mice with Dicer deleted throughout the whole pancreas, 
the beta cell specific Dicer mutant mice survived postnatally, but developed a diabetic phenotype 
around 8-weeks of age due to an overall decrease of beta cell number and reduced insulin 
production and secretion (Kalis et al., 2011; Mandelbaum et al., 2012). Ultrastructural analysis 
demonstrated that the Dicer mutant beta cells had 50% fewer insulin granules than control beta 
cells (Kalis et al., 2011). Intriguingly, mutant islets also had a dramatic reduction in insulin 
transcript levels, suggestive of a defect in insulin gene transcription (Kalis et al., 2011). Global 
miRNA function also appears to be required for maintenance of beta cell identity. Ablation of 
Dicer in adult beta cells (Melkman-Zehav et al., 2011) using tamoxifen inducible 
RIP:CreER;Dicerfl/fl mice, resulted in hyperglycemia, glucose intolerance and a drastic reduction 
in beta cell number (Melkman-Zehav et al., 2011). The authors concluded that the loss of 
miRNA function caused the upregulation of several transcriptional repressors, including Sox6 
and Bhlhe22, which in turn triggered decreased insulin expression (Melkman-Zehav et al., 2011).  
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Individual miRNAs have also been shown to be essential for many aspects of beta cell function 
(Figure 1-10). The most highly expressed miRNA in mouse and human islets, miRNA-375, was 
first identified in a murine pancreatic beta cell line (MIN6) where it was shown to negatively 
regulate glucose-stimulated insulin secretion (Poy et al., 2004). Analyses in mice showed that 
genetic ablation of miR-375 resulted in hyperglycemia due to reduced beta cell mass (Poy et al., 
2009). This defect was attributed to a significant reduction in beta cell proliferation due to the 
upregulation of several genes that negatively regulate cell growth (Poy et al., 2009). Several 
miRNAs including miR-24, miR-26, miR-148, and miR-182 were also shown in vitro to 
negatively regulate insulin expression (Melkman-Zehavi et al., 2012). However, the relatively 
minimal effect seen with individual miRNA knockdown suggests that a combination of multiple 
miRNAs maintain insulin expression (Melkman-Zehavi et al., 2012). Interestingly, the 
evolutionarily conserved miRNA, miR-7a, was shown to be a negative regulator of both insulin 
secretion and beta cell proliferation through inhibition of mTOR signaling proteins, indicating 
that a single miRNA can also regulate multiple layers of beta cell function (Latreille et al., 2014; 
Wang et al., 2013).  
 
Consistent with recent implications that miRNAs maintain tissue homeostasis during a cellular 
response to stress, several studies have implicated miRNAs in beta cell stress and diabetes 
(Mendell and Olson, 2012). Recently, Latreille and colleagues elucidated the relationship 
between miR-7a expression levels and two well-known diabetes mouse models (Latreille et al., 
2014). Specifically, they determined that mice with a beta cell specific miR-7a deletion had a 
similar phenotype to genetically obese (ob/ob) mice; mice had enhanced pancreatic beta cell 
function due to compensatory mechanisms that allowed them overcome insulin resistance 
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(Latreille et al., 2014). This finding was supported by a corresponding 50% reduction in miR-7a 
transcript levels in compensating islets from ob/ob mice (Latreille et al., 2014). Remarkably, 
they found the opposite defect when they overexpressed miR-7a in vivo: hyperglycemia, reduced 
plasma insulin levels, and impaired glucose-stimulated insulin secretion (Latreille et al., 2014). 
Overexpression of miR-7a also caused decreased Ins1 and Ins2 expression, with a correlating 
decline in expression of several mature beta cell markers (Latreille et al., 2014). Of note, these 
phenotypes are strikingly similar to the metabolic phenotype of diabetic db/db mice, which 
develop hyperglycemia and have reduced plasma insulin levels over time due to beta cell 
dysfunction (Latreille et al., 2014). Mechanistically, miR-7a was shown to directly regulate 
genes that control late stages of insulin granule fusion with the plasma membrane, indicating a 
direct role for miRNAs in regulating beta cell function during disease (Latreille et al., 2014). 
Similarly, the finding that miR-375 is upregulated in islets isolated from ob/ob mice, combined 
with an established role for miR-375 in beta cell proliferation, suggests a mechanism whereby 
miR-375 enables beta cell proliferation to compensate for metabolic stress (Poy et al., 2009). 
Tattikota et al. further elucidated a mechanistic link between miR-375, Ago2, and another 
miRNA, miR-184 (Tattikota et al., 2014). This study determined that the onset of insulin 
resistance caused the silencing of miR-184, which then released its constraint on Ago2, a major 
component of the RNA-induced silencing complex (Tattikota et al., 2014). Ago2 is then able to 
orchestrate the suppressive function miR-375 thus enhancing beta cell proliferation to 
accommodate the physiological demand for insulin (Tattikota et al., 2014). Taken together, these 
studies have shown that miRNAs work to maintain beta cell function during metabolic stress, 
and aberrant miRNA expression can be a marker for beta cell dysfunction (Figure 1-10).  
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Characterizing miRNAs that regulate beta cell function may also reveal novel methods to treat 
diabetes. For example, the Let-7 miRNA family was shown to negatively regulate glucose-
stimulated insulin secretion (Zhu et al., 2011). A recent study sought to determine if global Let-7 
knockdown was sufficient to prevent or rescue impaired glucose intolerance in mice (Joglekar et 
al., 2009). Researchers put mice on a high fat diet for 10 weeks and then initiated weekly 
injections with a locked nucleic acid (LNA) modified anti-miR that ablated Let-7 function 
(Joglekar et al., 2009). After confirming strong reduction of Let-7 transcript in several tissues, 
researchers found that Let-7 knockdown was sufficient to prevent and treat impaired glucose 
tolerance brought on by a high fat diet (Joglekar et al., 2009). Overall, miRNAs have been shown 
to be critical regulators of beta cell development and function. Harnessing miRNA therapeutic 





Figure 1-10. The role of microRNAs in beta cell development, function, and disease. (A) A 
pictorial summary of the studies that identified a role for global miRNA function during beta cell 
development through temporal ablation of Dicer in the pancreas in vivo. Each major stage of 
pancreas development is represented along with the genotype of conditional Dicer ablation and 
corresponding phenotype. (B) Summary of a subset of individual miRNAs that regulate beta cell 
function. The indicated miRNAs regulate glucose-stimulated insulin secretion and/or play a role 




Long noncoding RNAs 
While the functional mechanisms of short regulatory ncRNAs, predominantly microRNAs 
(miRNAs), have been described in detail, the most abundant and functionally enigmatic 
regulatory ncRNAs are called long noncoding RNAs (lncRNAs) that are loosely defined as 
RNAs larger than 200 nucleotides (nt) and do not encode for protein (Derrien et al., 2012; Batista 
and Chang, 2013; Rinn and Chang, 2012). While using a definition based strictly on size is 
somewhat arbitrary, this definition is useful both bioinformatically (the need for an effective size 
gap to distinguish lncRNAs from the ~20 nt short ncRNAs) and technically (200 nt is 
approximately the retention size of most silica-based columns used in standard RNA extraction 
kits) (Cabili et al., 2011). Although the 200 nt size cutoff has simplified identification of 
lncRNAs, this rather broad classification means several features of lncRNAs, including 
abundance, cellular localization, stability, conservation, and function are inherently 
heterogeneous (Ponting et al., 2009; Wilusz et al., 2009; Guttman and Rinn, 2012). Although this 
represents one of the major challenges of lncRNA biology, it also highlights the untapped 
potential of lncRNAs to provide a novel layer of gene regulation that influences islet physiology 
and pathophysiology. 
 
Major efforts to unify the lncRNA field by clarifying nomenclature and identifying common 
attributes of lncRNAs have yielded several important conclusions about their shared 
characteristics (Guttman and Rinn, 2012). In general, despite a lack of translatable open reading 
frames, most lncRNAs are biochemically indistinguishable from their mRNA counter- parts: 
they are transcribed by RNA polymerase II (Pol II) from genetic loci that contain classic active 
chromatin marks at their promoters (H3K4me3) and gene bodies (H3K36me3), and they are 5’ 
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capped, spliced, and polyadenylated (Guttman et al., 2009). Beyond these common 
characteristics, lncRNAs represent a heterogeneous population of functional RNAs with diverse 
functions that have yet to be fully explored. As the lncRNA field has grown, several databases, 
such as NONCODE (Luo et al., 2017), lncRNAdb (Amaral et al., 2011), and LNCipedia 
(Volders et al., 2013), have emerged to provide researchers with catalogs of empirically 
identified lncRNAs (Figure 1-11). Additional attempts to categorize the myriad of newly 
identified lncRNAs have yielded several classifications based on genomic proximity to the 
nearest protein-coding gene (Mercer et al., 2009). Although it can be useful to have 
classifications that do not rely on functional annotation, the genomic contexts of lncRNAs do not 
necessarily provide insights into function. For example, two well-characterized lncRNAs, 
HOTTIP (HOXA transcript at the distal tip) and HOTAIR (HOX transcript antisense RNA), are 
both transcribed from the HOXA gene locus; however, HOTTIP regulates a nearby HOXA gene 
in cis, whereas HOTAIR recruits chromatin-modifying complexes to other chromosomes in trans 
(Wang et al, 2011; Rinn et al., 2007). Functional classification based on sequence alone has also 
been difficult because lncRNAs are not under the same evolutionary pressure as proteins to 
convey a genetic code (Smith and Mattick, 2007). Instead, information from the small number of 
well-characterized lncRNAs has been distilled to describe four non-mutually exclusive 
archetypes of lncRNA molecular mechanisms: signals, decoys, guides, and scaffolds (Wang and 
Chang, 2011). These archetypes emphasize the unique ability of lncRNAs to bind to DNA, RNA, 
and proteins to regulate all layers of gene expression. As more lncRNAs undergo functional 




V. Islet long noncoding RNAs 
Long noncoding RNAs and diabetes 
Although the role of miRNAs in diabetes has been well established (LaPierre and Stoffel, 2017), 
analyses of lncRNAs in islets have lagged behind their short ncRNA counterparts. However, 
several recent studies provide evidence that lncRNAs are crucial components of the islet 
regulome and may have a role in diabetes (Motterle et al., 2016). For example, a genome-wide 
association study examined T2DM susceptibility loci within unknown genomic associations and 
found that a significant percentage (> 16%) of T2DM loci contained islet lncRNAs within 150 
kb of the reported lead single nucleotide polymorphism (SNP) (Moran et al., 2012), suggesting 
lncRNAs are essential for normal pancreatic function. Furthermore, misexpression of several 
lncRNAs has been correlated with diabetes complications, such as diabetic nephropathy and 
retinopathy (Alvarez et al., 2011; Hanson et al., 2007; Awata et al., 2014). There are also 
preliminary studies suggesting that circulating lncRNAs, such as Gas5, MIAT1, and SENCR, 
may represent effective molecular biomarkers of diabetes and diabetes-related complications 
(Carter et al., 2015; de Gonzalo-Calvo et al., 2016). Finally, several recent studies have explored 
the role of lncRNAs in the peripheral metabolic tissues that contribute to energy homeostasis 
(reviewed in Giroud and Scheideler, 2017). 
 
In addition to their potential as genetic drivers and/or biomarkers of diabetes and diabetes 
complications, lncRNAs can be exploited for the treatment of diabetes. For example, although 
tremendous efforts have been dedicated to generating replacement beta cells for individuals with 
diabetes (Pagliuca et al., 2014; Russ et al., 2015), human pluripotent stem cell–based beta cell 
differentiation protocols remain inefficient, and the end product is still functionally and 
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transcriptionally immature compared with primary human beta cells (reviewed in Millman and 
Pagliuca, 2017). This is largely due to our incomplete knowledge of in vivo differentiation 
regulatory pathways, which likely include a role for lncRNAs. Once we gain additional 
understanding of lncRNA function during the pancreatic endocrine differentiation process, we 
can incorporate lncRNAs into the in vitro differentiation protocols to optimize the generation of 
beta cells derived from human pluripotent stem cells.  
 
Inherent characteristics of lncRNAs have also made them attractive candidates for drug 
targeting, which could be exploited for developing new diabetes therapies. LncRNAs can be 
targeted by antisense oligonucleotides (ASOs), which is technically simpler than small molecule 
screening or inhibitory antibody development. Also, as strategies to therapeutically target mRNA 
molecules date back to the 1970s, developing next-generation technologies to target lncRNAs is 
quite feasible and easily adapted from traditional mRNA targeting approaches. For example, 
several currently available biochemical modifications to ASOs, such as a LNA backbone, 
increase their stability and reduce toxicity (Adams et al., 2017). Unique features of lncRNAs also 
make them more amenable to targeting, including their highly tissue-specific expression and 
their relatively lower expression levels as compared with coding mRNAs, which may allow the 
use of lower doses of targeting molecules, thus alleviating drug toxicity (Derrien et al., 2012; 
Cabili et al., 2014). A study in human pancreatic islets found that although 9.4% of Ref-seq–
annotated protein-coding genes were islet specific, 55% of intergenic lncRNAs were expressed 
only in islets (Moran et al., 2012). Taken together, these findings suggest that lncRNAs could be 
easily targeted and their restricted expression profile would result in fewer unwanted pleiotropic 
phenotypes.  
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Identification of islet lncRNAs 
Although the rapid evolution of the lncRNA field has provided remarkable insight into lncRNA 
functions in many different organ systems and disease states (Derrien et al., 2012; Cabili et al., 
2011; Guttman et al., 2009; Mercer et al., 2009), these studies have also revealed important 
aspects of lncRNA biology that need be considered to optimize a discovery pipeline (Figure 1-
11). Unlike the discovery of novel coding genes, whose functions can be inferred from the 
functional protein domains they encode, a different set of strategies must be used for lncRNAs. 
To optimally characterize and exploit lncRNAs for treating diabetes, it will be useful to develop 
a common set of guidelines to most effectively identify those lncRNAs that are essential for 
pancreatic function. With this goal in mind, we will discuss studies that have identified mouse 
and human pancreatic lncRNAs, highlight the major steps of lncRNA discovery pipelines for 
diabetes-related lncRNAs, and identify the advantages and disadvantages of each approach. The 
information gained from these pioneering studies will inform the identification of functionally 
relevant islet-specific lncRNAs that can be exploited to promote the efficient generation or 
regeneration of beta cells or can be targeted for novel therapies to treat diabetes. The first 
systematic mapping of lncRNAs in the pancreas was described in 2012; Moran et al performed 
deep RNA-seq on human islets in combination with chromatin immunoprecipitation sequencing 
for three epigenetic markers of active transcription: H3K4me3, H3K36me3, and RNA Pol II 
(Moran et al., 2012). This strategy made it possible to leverage the histone marks to identify 
1128 human islet lncRNAs that showed classic marks of active transcription (Moran et al., 
2012). More recently, this same group reported a similar, updated set of parameters including the 
presence of H3K4me3 enrichment in a region +1 kb to -0.5 kb from a transcript’s 5’ end to 
identify 2226 human islet lncRNAs (Akerman et al., 2017). Subsequently, Fadista et al used 
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associations with disease loci to identify potential diabetes-related lncRNAs; genetic variants 
regulating gene expression, referred to as expression quantitative trait loci (eQTLs), that were 
implicated in altered glucose metabolism and insulin secretion determined that 33 out of 616 
diabetic eQTLs influenced the expression of human islet lncRNAs (Fadista et al., 2014). As the 
human diabetes field moves beyond exomic sequencing to whole-genome sequence analysis, it is 
likely that additional lncRNAs will be identified as contributing factors to the etiology of 
diabetes.   
 
Although using human pancreatic islets as a source of RNA has the advantage of identifying 
lncRNAs most relevant for human disease (Moran et al., 2012; Akerman et al., 2017; Fadista et 
al., 2014; Bramswig et al., 2013; Li et al., 2014), cadaveric islets are not only scarce but also 
often highly heterogeneous and have reduced RNA integrity, which can result in RNA artifacts 
and con- found the identification of bona fide lncRNA molecules. Furthermore, the options for 
downstream functional analyses of human lncRNAs are limited. As an alternative, several 
lncRNA screens have been performed in mouse islets (Ku et al., 2012; Benner et al., 2014; 
Motterle et al., 2017). This approach benefits from higher-quality starting material, increased 
sample homogeneity, and the ability to use cell-specific reporters to isolate purified islet cell 
populations. Rodent models also afford the option to interrogate lncRNA function in vivo. 
Furthermore, although lncRNAs are often poorly conserved at the nucleotide level between mice 
and humans, Moran et al reported that 70% of human islet lncRNAs had an orthologous mouse 
genomic region and that 47% of those orthologous mouse loci produced a corresponding 
lncRNA transcript (Moran et al., 2012). Currently, there is a paucity of information regarding the 
minimal amount of nucleotide conservation that would predict conserved function, especially as 
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the conservation may be at the level of RNA secondary structure (Ulitsky et al., 2011). However, 
the characterization of increased numbers of conserved orthologous lncRNAs will pave the way 
to understanding the contribution of lncRNA function to beta cell biology and inform whether 
lncRNAs that are identified and characterized in mice contribute to human beta cell function and 
disease pathologies.  
 
Expression patterns of islet lncRNAs 
As it remains difficult to use lncRNA nucleotide sequence as a predictor of functional activity, 
cell-specific and/or regulated expression can be used to predict lncRNA function. Although most 
transcriptional regulatory proteins are expressed in many different tissues and cell types, 
expression of functionally important lncRNAs tends to be much more restricted (Cabili et al., 
2011). This can present a challenge for the identification of lncRNAs as expression must be 
assessed in the correct cell type, but it also provides the exciting possibility that lncRNAs confer 
highly specialized cell-specific regulatory functions. To identify islet cell-type specific lncRNA 
transcripts, a study used beta cell-specific reporter mice (MIP:GFP) to compare the 
transcriptomes of MIP:GFP-positive mouse islet cells (beta cells) to MIP:GFP-negative (non-
beta cell) islet cells and discovered ~12% of islet lncRNAs were beta cell specific (Ku et al., 
2012). Similarly, studies have identified differentially expressed lncRNAs in human alpha versus 
beta cells (Bramswig et al., 2013) and at different stages of in vitro human pancreas 
differentiation (Jiang et al., 2015). Given the highly cell-type specific expression of lncRNAs, it 
is tempting to speculate that these molecules provide the regulatory specificity to gene networks 
that define cell-specific identities and functions. For example, the lncRNA βlinc1 is expressed 
exclusively in pancreatic beta cells, where it appears to regulate a beta cell-specific regulatory 
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program (Arnes et al., 2016). Coexpression and/or cross-regulation of lncRNAs with a nearby 
protein-coding gene can also provide important functional and regulatory information; the 
human islet lncRNA PLUTO had a highly correlated tissue-specific expression pattern with its 
neighboring gene, the essential pancreatic transcription factor PDX1, and was further shown to 
directly regulate PDX1 transcription (Akerman et al., 2017).  
 
Altered expression in pathophysiological conditions could also be a defining characteristic in the 
identification of functionally important lncRNAs. The lncRNAs Meg3 and Tug1 were both 
shown, in separate studies, to be downregulated in the NOD T1DM mouse model (Yin et al., 
2015; You et al., 2016). Similarly, a study in human islets found that two lncRNAs KCNQ1OT1 
and HI-LNC45 were significantly upregulated or downregulated in T2DM islets, respectively 
(Moran et al., 2012). Several groups also identified lncRNAs misregulated in islets exposed to 
altered stimuli or physiological challenges, such as high glucose (Benner et al., 2014), high-fat 
diet (Motterle et al., 2017), cytokines (Motterle et al., 2015), and pregnancy (Sisino et al., 2017). 
Interestingly, although exposure of mouse islets to inflammatory cytokines caused upregulation 
of four lncRNAs (Li et al., 2014), a study on human islets cultured in the presence or absence of 
cytokines found no differential expression of lncRNAs between the two conditions (Motterle et 
al., 2015), suggesting these analyses may be influenced by low lncRNA expression levels and 
detection limits of the assay.  
 
Subcellular localization can yield perhaps the most telling clues about how lncRNAs function 
mechanistically. Nuclear lncRNAs are more likely to regulate transcription, whereas cytoplasmic 
lncRNAs more often influence translation or mRNA stability (Wang and Chang, 2011). An 
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individual lncRNA can also be expressed in both the nucleus and cytoplasm and have a different 
function in each compartment (Kino et al., 2010). Although subcellular fractionation has 
traditionally been used to assess cellular localization, RNA fluorescent in situ hybridization 
(FISH) is a highly sensitive assay that can also provide crucial spatial information about lncRNA 
localization within the cell. For example, DEANR1 was shown to directly regulate the 
transcription factor FOXA2 in differentiated endoderm by using RNA-DNA-FISH experiments 
showing that DEANR1 localized to two punctae corresponding to the FOXA2 DNA locus (Jiang 
et al., 2015).  
 
Although expression analyses can be performed using a combination of quantitative reverse 
transcription PCR (qRT-PCR) and RNA in situ hybridization, in silico discovery of islet 
lncRNAs is also possible as a result of the comprehensive mapping of mouse alpha-, beta-, and 
delta-cell transcriptome (DiGruccio et al., 2016). Additionally, global expression information can 
often be obtained in silico through publically available data sets, such as BodyMap (Li et al., 
2017); however, these resources rarely include pancreas and/or islet RNA in their arrays due to 
challenges associated with pancreatic RNA integrity. Furthermore, standard RNA-seq 
parameters often lack the coverage needed to identify low abundant lncRNAs, many of which 
remain unannotated. Another obstacle to lncRNA discovery is the paucity of relevant tissue, 
given that islets make up only about 5–10% of the entire pancreas. As new molecular 
technologies with increased detection sensitivities are developed, these challenges will be 
overcome; however, this will also increase the importance of functional validation for newly 
identified pancreatic lncRNAs.  
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Functional Characterization of Islet lncRNAs  
With the advancement of high-throughput sequencing techniques, the list of islet-specific 
lncRNAs is growing exponentially; however, functional characterization is missing for the 
majority of these lncRNAs. Studies that have experimentally determined the function of an islet 
lncRNA have used several different approaches. The most straightforward strategy to test the 
regulatory function of islet lncRNAs is by loss-of-function assays using RNA interference 
(RNAi). Knockdown (KD) of the lncRNA βlinc1 in MIN6 cells demonstrated that βlinc1 is a 
novel cis regulator of the islet transcription factor Nkx2–2 (Arnes et al., 2016), whereas short 
hairpin RNA (shRNA) KD of the lncRNA DEANR1 led to a drastic downregulation of the 
nearby gene FOXA2 (Jiang et al., 2015). In vitro RNAi is also the optimal technique to identify 
lncRNAs that function in trans to regulate essential islet genes: HI-LNC25 was shown to regulate 
the distant islet transcription factor GLIS3 in EndoC-bH1 cells (Moran et al., 2012), the lncRNA 
Meg3 positively regulated Pdx1 and MafA in MIN6 cells (You et al., 2016), and the lncRNA-
ROR regulated insulin, Pdx1, and Glut2 in human amniotic epithelial cells differentiated into 
beta-like cells (Zou et al., 2016). Furthermore, KD of lncRNA Tug1 in NIT-1 cells was 
correlated with changes in beta cell function, including decreased glucose-stimulated insulin 
secretion (Yin et al., 2015). In a more comprehensive screen, Akerman and colleagues 
functionally interrogated 12 human lncRNAs with lentiviral vectors containing Pol II–
transcribed artificial miRNAs (coined amiRNAs) with perfect homology to the target lncRNA to 
elicit degradation via the RNAi pathway (Akerman et al., 2017). Remarkably, KD of 9 out of 12 
lncRNAs in EndoC-bH1 cells elicited significant gene expression changes, and KD of three of 
those lncRNAs led to impaired insulin secretion (Akerman et al., 2017).  
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Although siRNAs and shRNAs are well suited to downregulate the expression and/or translation 
of protein-coding genes, there is concern in the field about the use of cytoplasmic RNAi 
machinery to KD nuclear lncRNAs (Basset et al., 2014). Modified ASOs, such as LNA 
GapmeRs, are a valuable alternative for lncRNAs enriched in the nucleus. They are stable high-
affinity RNA analogs that readily permeate the nucleus and function by RNase H-dependent 
degradation of complementary RNA targets (Xing et al., 2014). Gain-of-function experiments, 
mainly lncRNA overexpression, should also be considered when overexpression more closely 
mimics an endogenous or diseased state, as was the case for four lncRNAs shown to be 
upregulated in MIN6 cells exposed to inflammatory cytokines (Motterle et al., 2015).  
 
Although in vitro functional analysis has been informative, there are caveats associated with 
using immortalized cell lines. For example, several lncRNAs with significant functions in vitro 
have had no phenotype when knocked out (KO) in mice (Bassett et al., 2014). This discrepancy 
may be due to improper use of KD tools or because lncRNA KO phenotypes can be subtle and 
may only appear after physiological stress. Genetic manipulation is the optimal approach for 
assessing lncRNA function in an endogenous in vivo context, although these studies face their 
own challenges. There are several commonly used gene-targeting strategies that vary in their 
efficiency and disruption of genomic contexts (i.e., enhancers), including deletions (whole gene 
or promoter), inversions (whole gene or promoter), and insertions (pre-mature termination 
sequence or reporter) (Bassett et al., 2014). βlinc1 is the first islet lncRNA that has been 
genetically disrupted at the DNA level to generate a KO mouse with no detectable βlinc1 RNA 
(Arnes et al., 2016). βlinc1 KO mice exhibited impaired glucose tolerance due to defects in 
insulin secretion (Arnes et al., 2016). A major caveat of gene deletion, however, is the possibility 
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that disruption of the genomic DNA, not the RNA, is responsible for any observed phenotype. 
Additional KD experiments were therefore required to show that the in vivo phenotype was not 
due to deletion of an enhancer for the nearby gene, Nkx2–2 (Arnes et al., 2016). As technologies 
for in vivo gene editing improve and become more widely implemented, it is likely that we will 
see a significant increase in lncRNA in vivo functional studies in complex animal models to 
further solidify their important functions in islet biology and diabetes.  
 
Molecular characterization of islet lncRNAs 
Tens of thousands of lncRNAs have been identified in different cell types and model organisms; 
however, their functions largely remain unknown. Although the tools for determining lncRNA 
function are technically restrictive, uncovering novel regulatory mechanisms will have the 
greatest impact on understanding islet function and identifying novel therapeutics for diabetes. 
To date, no biochemical assay has been used to directly determine the molecular mechanisms by 
which islet lncRNAs function, which highlights both the infancy of the field and the difficulty in 
implementing these techniques. The different lncRNA regulatory subtypes represent the 
mechanisms by which lncRNAs can act on DNA in cis or in trans, bind to complementary 
mRNA molecules to influence their translation, and recruit proteins to either enable or prevent 
their function (Wang and Chang, 2011). Based on lncRNA studies in other tissues, the most 
straightforward way to characterize the molecular activity of a lncRNA is to identify its 
interacting partners, using either protein-centric or RNA-centric approaches. Protein-centric 
methods, such as RNA immunoprecipitation (RIP) (Zhao et al., 2010) or cross-linking 
immunoprecipitation (CLIP) (Darnell, 2012), use antibodies to immunoprecipitate RNA binding 
protein complexes from cellular homogenate in vivo. LncRNAs stably associated with these 
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proteins, either directly (native RIP) or indirectly (CLIP), can be extracted and measured by 
quantitative PCR or unbiased identification by RNA-seq. If empirical evidence suggests lncRNA 
interaction with a specific protein, then these techniques are feasible. However, when functional 
data do not indicate a role for specific protein interactions, an RNA-centric approach is the ideal 
a priori strategy to probe lncRNA regulatory mechanisms. As the number of identified lncRNAs 
climbed exponentially, so did the need for RNA-centric biochemical purification methods. To 
address this technology gap, three techniques emerged almost concurrently: Capture 
Hybridization Analysis of RNA Targets (CHART) (Simon et al., 2011), Chromatin Isolation by 
RNA Purification (Chu et al., 2011), and RNA Antisense Purification (RAP) (Engreitz et al., 
2013). Differences between the protocols largely pertain to the cross-linking method and probe 
design: CHART uses probes designed based on empirical evidence of RNaseH accessibility, 
whereas ChIRP and RAP both tile the whole RNA molecule, albeit with different sized oligos, 
20-mer and 120-nt, respectively. The most powerful aspect of these protocols is that once RNA 
pull-down is successful, the readout can be tailored for tandem analyses of the DNA, RNA, or 
protein bound to a lncRNA in either a systematic or candidate-driven approach. For example, a 
comprehensive study used CHART to pull down lncRNAs NEAT1 and MALAT1, followed by 
both DNA sequencing to identify genome-wide DNA binding sites and mass spectrometry to 
identify all interacting proteins (West et al., 2014).  
 
Although identification of lncRNA molecular function is theoretically straightforward, the 
paucity of studies using either protein-centric or RNA-centric techniques on islet lncRNAs 
exemplifies the challenges associated with these tools. A major source of difficulty associated 
with these techniques is that they were all developed using ubiquitous lncRNAs with relatively 
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high endogenous expression levels, including roX2 (CHART), Xist (RAP), and roX2, TERC, and 
HOTAIR (ChIRP) (Simon et al., 2011; Chu et al., 2011; Engreitz et al., 2013). Furthermore, these 
lncRNAs had previously characterized regulatory mechanisms, which meant positive controls 
were already available to trouble-shoot RNA pull-downs. Conversely, the application of these 
techniques to characterize the molecular mechanism of novel cell-specific lncRNAs faces 
challenges associated with insufficient tissue (starting material), low abundant transcripts, and 
unknown binding partners. LncRNA overexpression or in vitro transcription may be an option 
when endogenous expression is too low; however, these approaches can also introduce 
experimental artifacts. Due to the infancy of the lncRNA field, most of the biochemical and 
genetic tools used to interrogate lncRNA function have only recently been developed or are 
adapted from techniques used to study protein-coding genes and we are only beginning to 
appreciate the limits and challenges of borrowing strategies from the protein-coding world. 
Given the growing appreciation for lncRNAs in biology, it is likely that increased efforts will be 
made to adapt and optimize these technologies to enable mechanistic characterization of all 
functional lncRNAs, regardless of their abundance.  
 
The discovery of lncRNAs as a novel class of tissue specific regulatory molecules has spawned 
an exciting new field of biology that will significantly impact our understanding of pancreas 
physiology and pathophysiology. As the field continues to grow, there is growing appreciation 
that lncRNAs will provide many of the missing components to existing molecular pathways that 
regulate islet biology and contribute to diabetes when they become dysfunctional. However, to 
date most of the experimental emphasis on lncRNAs has focused on large-scale discovery using 
genome wide approaches, and there remains a paucity of functional analysis. With improved 
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RNA-centric imaging and molecular technologies, combined with the advent of novel gene 
editing tools, it is likely that our knowledge of lncRNA functions in the islet will expand 
exponentially to rival what is currently known about canonical transcriptional regulatory 
programs. These advances will pave the way to a greater understanding of islet biology and 
enable the development novel therapies for the treatment of diabetes. 
 
Summary and Thesis Aims 
Several lines of evidence prompted us to explore the role of lncRNAs in the context of islet 
biology. First, genome wide association studies found that most T2DM and T1DM susceptibility 
loci fall outside of coding regions, which suggests a role for noncoding elements in the 
development of diabetes. Second, although decades of research elucidated many transcription 
factor networks required for pancreas development and function, the molecular mechanism 
mediating cell specific regulatory functions of those transcription factors remains poorly 
understood. Additionally, lncRNAs generally exhibit highly tissue specific expression patterns, 
especially compared to transcription factors expressed in multiple islet cell types or in several 
stages of pancreas development. Lastly, several groups have established lncRNAs as essential 
transcriptional regulators in development and disease (Batista and Chang, 2013). These findings 
formed the foundation of my thesis work, which aimed to explore novel lncRNA regulatory 







Figure 1-11. Overview of the lncRNA discovery and characterization pipeline. The lncRNA 
pipeline outlined in this section flows through four main phases: 1) identification of lncRNAs, 2) 
expression analyses, 3) functional interrogation, and 4) determination of a regulatory mechanism. 
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Highlighted are the tools and techniques (red), experimental parameters to consider (blue), and 
general strategies to characterize functional lncRNAs. 3P-seq, poly(A)-position profiling by 
sequencing; CAGE-seq; cap analysis gene expression; FPKM, fragments per kilobase million. 
Adapted from Singer and Sussel, 2018. 
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CHAPTER 2:  
The lncRNA Paupar confers cell specific regulatory functions on Pax6 
via alternative splicing 
 
All experiments described in this chapter were conceived and designed by Ruth Singer with 
guidance from Lori Sussel. All experiments described in this chapter were performed by Ruth 
Singer with the following exceptions: 1) Luis Arnes performed the initial lncRNA screen in 
e15.5 pancreas and adult islets 2) Jiguang Wang performed the computation analyses that 
identified pancreatic lncRNAs 3) Yi Cui performed all RNA FISH experiments and 4) Yuqian 
Gao, Kristin E. Burnum-Johnson, and Charles Ansong conducted the Mass Spectrometry 
following CHART and analyzed the peptide data. The data presented in this chapter will be 
published in a manuscript of which Ruth Singer is the first author (Singer et al., in submission). 
Lori Sussel assisted in writing the manuscript and offered guidance, support, and mentorship 
throughout the project.  
 
Summary 
A current challenge in the field of vertebrate gene regulation is understanding the mechanism by 
which broadly expressed transcription factors exert cell specific regulatory activities. Recently, 
long noncoding RNAs (lncRNAs) have been identified as essential gene regulators with highly 
restricted gene expression. In this study, comparative transcriptome analyses between embryonic 
mouse pancreas and adult mouse islets identified several pancreatic lncRNAs that lie in close 
proximity to essential pancreatic transcription factors, including the Pax6-associated lncRNA 
Paupar. We demonstrate Paupar is enriched in glucagon-producing alpha cells where it 
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promotes the alternative splicing of Pax6 to an isoform required for activation of essential alpha 
cell genes. Consistently, deletion of Paupar in mice resulted in dysregulation of PAX6 alpha cell 
target genes and corresponding alpha cell dysfunction. These findings illustrate a distinct 
mechanism by which cis-acting lncRNAs can contribute to cell-specific regulation of broadly 
expressed transcription factors to coordinate critical functions within a cell. 
 
Introduction 
Type 1 and type 2 diabetes mellitus (T1DM and T2DM) are chronic conditions with genetic, 
immunological, and environmental etiologies that occur due to the failure of the pancreatic islets 
to maintain glycemic control. Blood glucose homeostasis results from the coordinated, but 
opposing action of two pancreatic islet-derived hormones, insulin and glucagon. Nutrient 
ingestion stimulates insulin secretion from islet beta cells, which promotes glucose uptake and 
suppresses liver glucose production. Hypoglycemia stimulates glucagon secretion from islet 
cells, which promotes glucose production and release from the liver. While the majority of 
diabetes treatment options have focused on enhancing beta cell function to meet insulin 
demands, more recent work has shown that alpha cell dysfunction and hyperglucagonemia also 
contribute to disease pathophysiology (Unger and Cherrington, 2012; Brissova et al., 2018). 
Thus, a better understanding of the regulatory mechanisms required for the development and 
function of these highly-specialized islet endocrine cells will provide important novel 
information that could be applied to therapeutic treatments.  
 
The adult endocrine cell populations are all derived from Ngn3-expressing endocrine progenitor 
cells, and include insulin-producing beta cells, glucagon-producing alpha cells, somatostatin-
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producing delta cells, and pancreatic polypeptide-producing PP cells. A large number of 
transcriptional regulators that are essential for the islet cell lineage decisions have been identified 
and characterized. Many of these factors, including Pdx1 (Offield et al., 1996; Gao et al., 2014), 
Nkx2-2 (Sussel et al., 1998; Gutiérrez et al., 2017; Churchill et al., 2017), NeuroD1 (Anderson et 
al., 2009; Naya et al., 1997), and Glis3 (Kang et al., 2016), are expressed in several progenitor 
and/or islet cell populations and are continuously required in the adult for the maintenance of 
mature islet cell identity and function (Pan and Wright, 2011; Talchai et al., 2012; Gutiérrez et 
al., 2017; Ediger et al., 2017). One of the more well characterized broadly expressed islet 
transcriptional regulators is the paired and homeodomain transcription factor, PAX6 (St-Onge et 
al., 1997; Sander et al., 1997). Mice deleted for Pax6 in pancreatic progenitor cells are born with 
severely reduced numbers of alpha, beta, and delta cells, suggesting that PAX6 is necessary for 
the development of multiple islet endocrine cell types (Ashery-Padan et al., 2004; Hart et al., 
2013). Conditional deletion of Pax6 in mature alpha or beta cells demonstrated that PAX6 is also 
required to maintain the identity and function of mature islet endocrine cells (Ahmad et al., 2015; 
Gosmain et al., 2012; Mitchell et al., 2017; Swisa et al., 2017). Furthermore, a recent study 
showed that within mouse beta cells, PAX6 directly activates critical beta cell genes and 
represses genes that specify the alternative islet endocrine cell lineages (Swisa et al., 2017). 
PAX6 also has essential functions in the eye (Shaham et al., 2012) and central nervous system 
(Manuel et al., 2015). Studies in corneal and epithelial cell lines have shown that splice variants 
of PAX6 bind distinct DNA motifs (Epstein et al., 1994; Chauhan et al., 2004), yet the 
molecular mechanism mediating the tissue-, cell-, and gene-specific regulatory functions of 
PAX6, and other pancreatic transcription factors, remain poorly understood.  
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While the majority of transcriptional regulatory proteins are expressed in many different cell and 
tissue types, a recently discovered class of non-protein coding RNAs (ncRNAs), called long 
noncoding RNAs (lncRNAs), tend to be highly tissue and cell type specific and temporally 
regulated (Carninci et al., 2005; Derrien et al., 2012; Guttman et al., 2011), giving them the 
potential to confer cell type specificity on broadly expressed transcription factors. In the 
pancreas, thousands of lncRNAs have been identified in human islets (Moran et al., 2012; 
Akerman et al., 2017; Fadista et al., 2014; Li et al., 2014), purified human alpha and beta cells 
(Nica et al., 2013; Bramswig et al., 2013), mouse islets (Ku et al., 2012; Motterle et al., 2017), 
and purified mouse alpha and beta cells (Ku et al., 2012; Benner et al., 2014), where they exhibit 
properties consistent with functional genes (Singer and Sussel, 2018). Studies on individual islet 
lncRNAs have provided evidence that lncRNAs play a role in islet function, primarily through 
the regulation of essential islet transcription factors, such as HI-LNC25 on GLIS3 (Moran et al., 
2012), linc1 on Nkx2-2 (Arnes et al., 2016), and PLUTO on PDX1 (Akerman et al., 2017). 
These findings highlight a role for lncRNAs in islet biology and their highly restricted expression 
patterns further suggest that they can influence islet cell specific functions. 
 
To identify developmentally regulated pancreatic lncRNAs, we conducted comparative 
transcriptome analyses of embryonic mouse pancreas and adult mouse islets and identified 572 
dynamically expressed lncRNAs. Our analyses uncovered several pancreatic lncRNAs that lie in 
close proximity to essential pancreatic transcription factors, including the lncRNA Pax6 
Upstream Antisense RNA (Paupar), which mapped near the Pax6 genomic locus in mice and 
humans (Vance et al., 2014). Interestingly, we found that Paupar is enriched in glucagon-
producing alpha cells where it promotes the alternative splicing of Pax6 to an isoform 
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responsible for PAX6-dependent activation of essential alpha cell genes. Consistent with a role 
for Paupar in conferring the alpha cell specific functions of PAX6, deletion of Paupar in mice 
resulted in dysregulation of Pax6 alpha cell target genes and alpha cell dysfunction. Our findings 




Materials and Methods  
Cell line and cell culture  
AlphaTC1 clone 6 cells (ATCC, CRL-2934) were cultured in DMEM supplemented with 10% 
FBS, 15 mM Hepes, 0.1 mM non-essential amino acids, 0.02% BSA, 1.5 g/L sodium 
bicarbonate, 2.0 g/L glucose, and 1% antibiotic-antimycotic. The cells were passaged and 
maintained following standard techniques in 5% CO2 and 95% air. 
 
Generation of Paupar -/- mice  
The Paupar knockout allele was generated using BAC recombineering. First, Gibson assembly 
was used to clone H2BGFP (Kanda et al., 1998) and a polyA sequence and insert them together 
into the pL451 plasmid containing flox Neo flox (FNF) (Nam and Benezra, 2009). Short (80 bp) 
arms homologous to the regions flanking Paupar were then added to H2BGFPpA-FNF by PCR. 
The BAC clone (RP23-465J7; BAC-PAC Resources) was modified by insertion of the 
H2BGFPpA-FNF into the Paupar locus using Cre from SW106 cells, which was then retrieved 
into pMCS-DTA (a gift from Dr. Kosuke Yusa) with a 2 kb 5’ arm and a 5 kb 3’ rm. Positive 
clones were validated by PCR and DNA sequencing, and a correctly modified BAC was 
electroporated into mouse embryonic stem cells (129SV background) at Columbia University 
(Herbert Irving Comprehensive Cancer Center Transgenic Shared Resource). Potentially 
recombined clones were screened by PCR and two positive clones were used to generate 
chimeric mice that resulted in germline transmission. Chimeras were bred with FLPe transgenic 
mice (Jackson Laboratories) to excise the neomycin resistance cassette. Paupar +/- mice were 
backcrossed 10 generations into the C57BL/6J (Jackson Laboratories) background. 
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Mouse husbandry  
All mice were maintained on a mixed C57BL6/129SV genetic background. Mice were group-
housed in a 12-hour light/dark cycle (light between 07:00 and 19:00) with free access to water 
and food and maintained according to protocols (AAAQ3403) approved by the Columbia 
University Institutional Animal Care and Use Committee. Euthanasia was performed by CO2 
inhalation. Mouse age and sex are indicated in the figure legends or methods. Genotyping for the 
Paupar WT or KO allele was performed using primers P1, P2, and P3 (Figure 2-8A). 
Genotyping primers are listed in Table 2-4. 
 
LncRNA Identification  
To identify novel lncRNAs, we implemented an established pipeline for identifying lncRNAs 
from RNA-Seq data (Arnes et al., 2018; Pefanis et al., 2015). Briefly, rRNA-depleted total RNA 
from e15.5 embryonic mouse pancreata and 12-week-old mouse islets was prepared using the 
Ribo-Zero rRNA removal kit (Epicentre). Biological replicates indicate that each RNA-seq data 
set was generated from individual mice (islets) or 3-4 pooled e15.5 embryonic pancreata.  
Libraries were prepared with Illumina TruSeq RNA sample preparation kit and then sequenced 
with 60 million, 2 x 100 paired reads on an Illumina HiSeq 2000 V3 instrument at the Columbia 
Genome Center. To reconstruct the transcriptomes, we first mapped all reads of total RNAs to 
the mouse reference genome (mm9) with TopHat v1.3.2 (Trapnell et al., 2012). Cufflinks v1.2.1 
(Trapnell et al., 2012) was subsequently applied to assemble the whole transcriptome and to 
identify all possible transcripts. Then, the six transcriptomes from all samples was merged into a 
single gene transfer format (GTF) file with quantified gene RPKM values for each biological 
replicate. LncRNAs were then identified from the GTF file by removing transcripts if any of the 
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following criteria were met: (1) they were overlapped with genes annotated in Ensembl and not 
annotated as ‘lincRNA’, ‘non_coding’, ‘anti-sense’, ‘3prime_overlapping_ncrna’, 
‘processed_transcript’, ‘miRNA’, ‘misc_RNA’, or ‘pseudogene’; (2) overlapped with RefSeq 
genes (mm9) annotated as protein coding, where the RefSeq ID began with ‘NM’; (3) 
overlapped with pseudogenes from Pseudogene.org; (4) less than 200 nt in length; (5) predicted 
to have protein coding potential by the Coding Potential Assessment Tool (CPAT; coding 
probability >0.364); (6) gene-level maximum reads per kilobase of transcript per million mapped 
reads (FPKM) was less than 0.5. The 572 remaining transcripts are high-confidence pancreatic 
lncRNAs.  
 
RNA extraction and quantitative RT-PCR analysis 
Total RNA was extracted from tissue or cells using the RNeasy Plus Micro Kit (Qiagen) or the 
RNeasy Plus Mini Kit (Qiagen), depending on the sample. Purified RNA was quantified by 
Nanodrop (Thermo Fisher), which also determined RNA quality. 250 ng of total RNA was used 
to synthesize cDNA with the SuperScript III First-Strand Synthesis System (Invitrogen) and 
random hexamer primers. Resultant cDNA was diluted in water and 25 ng was used in each 
qRT-PCR reaction. Reactions were run on a Bio-Rad CFX96 Real Time System using either 
gene specific primers with iQ Sybr Green Supermix (Biorad) or TaqMan probes (Applied 
Biosystems). Expression levels were normalized to TATA-binding protein (TBP) and quantified 
using the ΔΔCT method. Sybr Green primers and AODs used are listed in Tables 2-4 and 2-5.  
 
Cytoplasmic and nuclear RNA fractionation  
AlphaTC cells were grown to confluency, detached by trypsinization, and pelleted. Half of the 
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pellet was used for total RNA isolation, and the other half was used for nuclear and cytoplasmic 
isolation using the PARIS kit (Ambion) following the manufacturer’s instructions. Assessment 
of Paupar expression in each compartment was done using qRT-PCR with Gapdh and Neat1 
used for cytoplasmic and nuclear controls, respectively.  
 
Single-molecule FISH (smFISH)  
Oligonucleotide FISH probes were designed to target the full length of Paupar transcript. All 
probes were designed as 20-nt long, with CG content of 40-60%, no self-repeats and inner loop 
structures. Probes are labeled with Alexa647 at the 3’ end and purchased from Integrated DNA 
Technologies. The sequence information of all FISH probes is provided in Table 2-4. The 
hybridization experiments were performed as previously described protocols (Raj et al., 2008; 
Lubeck and Cai, 2012; Cui et al., 2018). AlphaTCs were seeded onto collagen-coated, glass-
bottom petri dishes (#1.5 thickness, MatTek) and grown to 70% confluence. Then cells were 
fixed with fresh 4% paraformaldehyde and quenched with 0.1% sodium borohydride. Fixed cells 
were permeabilized and stored with 70% ethanol until final use. FISH probes were diluted to 10 
nM in hybridization solution (10% dextran sulfate, 10% formamide, 2× SSC, 0.02% RNase-free 
BSA, 2 mM ribonucleoside vanadyl complex). Hybridization was performed at 37°C overnight 
in a humid chamber. For cells co-stained with immunofluorescence, primary antibody was 
1:1000 diluted and added to the hybridization solution. The next day, cells were thoroughly 
rinsed with 10% formamide in 2× SSC, followed by staining with secondary antibody and DAPI. 
The antibody information is listed in Table 2-4. Images were taken from an Olympus IX71-based 
single-molecule microscope equipped with 405 nm, 488 nm, 542 nm, 594 nm and 640 nm solid 
lasers. A 100× oil immersion objective lens (NA 1.4) was used and images were captured with 
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an EMCCD camera (Andor iXon Ultra 897). A z-stack scanning was performed to cover the 
whole cell volume (e.g., 200 nm scanning step, 30-40 frames). In processing, RNA transcripts 
were identified at each scanning plane with Gaussian musk fitting algorithm and projected to the 
final reconstructed images. The processed images were subjected to counting with home-built 
MATLAB programs. Cell boundaries were determined and segmented based on the auto 
fluorescence background, in conjunction with DAPI staining. The source code for smFISH 
analysis is available upon request. 
 
Immunohistochemistry  
Tissues were fixed in 4% PFA in PBS overnight, washed in cold PBS, incubated in 30% sucrose, 
and cryopreserved. Immunofluorescence was performed on 7 mM sections. See Table 2-5 for a 
list of primary and secondary antibodies used. DAPI (1:1000) was applied for 15 min following a 
2-hour secondary antibody incubation. Images were acquired on a Zeiss Confocal LSM 710 
microscope.  
 
Morphometric analysis  
For all morphometric analysis, the entire pancreas was sectioned, and at least six evenly 
distributed sections were analyzed. To determine percentage hormone positive area over islet 
area, sections were stained with insulin, glucagon, and DAPI and five islets per section were 
imaged at 20X on a Zeiss Confocal LSM 710 microscope. Hormone positive area was measured 
using FIJI with a standardized signal threshold. Islet area was measured manually using FIJI 
based on morphology and guided by staining. Islets were arranged by size, and the total islet 
number was used to calculate the percentage represented in each size group. To determine the 
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percentage of proliferating alpha cells, sections were stained with glucagon, Ki67, and DAPI, 
and five islets per section were imaged for quantification. Data presented is from n=3 mice per 
genotype unless otherwise indicated.  
 
Islet isolation  
Mouse pancreatic islets were isolated by perfusion of the pancreas with Collagenase P (Roche) 
through the common hepatic bile duct at a concentration of 1 mg/ml in M199 medium 
(Invitrogen). Then pancreas was dissected out and dissociated at 37°C for 16 minutes. After 
several washes in M199 supplemented with 10% FBS (Gemini Bio Products), islets were then 
filtered (500 μm; Fisher Cat#NC0822591), hand-picked to avoid exocrine contamination, and 
processed for downstream applications.  
 
Assessment of islet function 
Glucose tolerance test  
Mice were fasted overnight, followed by an IP injection of 2 milligram D-glucose per gram 
mouse weight. Tail vein blood samples were collected at 0, 15, 30, 60, 90, and 120 minutes after 
the injection and glucose concentration was determined using the Accu-Chek Compact Plus 
Blood Glucose Meter (Roche).  
 
Insulin tolerance test 
Mice were fasted for 5 hours starting at 9 am. Insulin (Humalog in PBS) was injected IP at 0.75 
units per kg mouse weight. Tail vein blood samples were collected at 0, 15, 30, 60, 90, and 120 
minutes after the injection and glucose concentration was determined using the Accu-Chek 
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Compact Plus Blood Glucose Meter (Roche). To measure plasma glucagon during an insulin 
tolerance test, blood was collected into heparinized tubes immediately before, and 30 minutes 
after, an insulin injection. Plasma was separated from whole blood by centrifugation and 
glucagon concentration was measured by ELISA (Mercodia).  
 
Glucose stimulated glucagon secretion assays 
After isolation, duplicate samples of 20 islets per mouse were cultured overnight at 37°C in 
resting medium (RPMI 1640 with 10% FBS, 1% P/S, and 5.6 mM D-glucose). The next day, 
islets were transferred into modified Krebs buffer with 0.1% BSA and 20 mM D-glucose for 30 
minutes to equilibrate. Islets were then transferred to Krebs buffer with 20 mM glucose for 30 
minutes, followed by 2 mM glucose for 30 minutes. Lastly, islets were transferred to either 
Krebs buffer with 20 mM glucose or 10 mM L-Arginine for 30 minutes. Supernatant was 
collected following each treatment. Islets were then sonicated in 50 μl of lysis buffer (TE with 
0.1% SDS) and lysate was used to determine DNA concentration and measure glucagon content. 
Glucagon concentration in supernatant and islet lysate was measured by glucagon ELISA 
(Mercodia). 
 
RNA sequencing (RNA-seq)  
Total RNA from Paupar WT and Paupar KO mice was converted into cDNA libraries (TruSeq 
RNA sample preparation kit, Illumina) according to manufacturer’s instructions. Sequencing was 
performed to a depth of 30 million, single-end 100 nt reads in three biological replicates per 
genotype. Reads were aligned to the mouse genome (mm9) using HISAT2 v2.1.0 (Kim et al., 
2013). Aligned reads were assigned to genes using annotations from Ensembl 
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(Mus_musculus.GRCm38.73.gtf) and HTseq-count v0.10.0 (Anders et al., 2015). Differential 
expression across cohorts was assessed using DESeq2 v1.18 (Love, Huber, and Anders, 2014). 
All samples had RNA integrity (RIN) values > 8.0 as determined with Agilent Bioanalyzer 2100. 
Complete RNA-seq data are available through GEO accession numbers: GSE122033 (embryonic 
pancreas and islet lncRNAs) and GSE121884 (Paupar WT and KO islets).   
 
RNA interference  
The day before transfection, 500,000 alphaTCs were plated in each well of a 12-well plate. Cells 
were transfected in triplicate with 40 nM Paupar or control ASOs (IDT) using Lipofectamine 
2000, per the manufacturer’s instructions (Thermo Fisher). Cells were harvested for RNA 48 
hours post transfection. ASO sequences are listed in Table 2-4.  
 
Capture Hybridization Analysis of RNA Targets (CHART) enrichment and analysis 
CHART enrichment experiments were performed as previously described (Simon et al., 2011). 
Briefly, CHART extract was prepared from approximately 5 x 107 alphaΤC cells per CHART 
reaction and hybridized with 120 pmol biotinylated capture oligonucleotides (COs) (Table 2-4) 
overnight with rotation at room temperature. Complexes were captured using MyOne 
Streptavidin C1 beads (Invitrogen). Bound material was stringently washed and eluted using 
RNase H (New England Biolabs) for 15 minutes at room temperature. For RNA analysis, 
CHART-enriched material was incubated with XLR buffer (final concentrations: 2 mg/mL 
Proteinase K (Ambion), 33.3 mM Tris pH 7.2, 0.33% SDS, 16.7 mM EDTA) at 55°C for 1 hour 
and 65°C for 1 hour to reverse cross-links. RNA was purified using Trizol LS according to the 
manufacturer’s instructions. qPCR analysis utilized iTaq Universal SYBR Green One-Step Kit to 
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quantify Paupar enrichment compared to control genes. For analysis of CHART enriched 
proteins, eluate was precipitated using trichloroacetic acid and resuspended in SDS (4.25%), Tris 
pH 8.8 (529 mM), EDTA (64 mM) and -mercaptoethanol (1.37 M). Samples were incubated at 
98°C for 30 minutes and 65°C for 2 hours to reverse cross-links. Samples (including 1%, 2.5%, 
and 5% input) were resolved by SDS-PAGE and transferred to nitrocellulose membranes. 
Membranes were incubated with antisera to detect PAX6 (Biolegend) and bands visualized with 
SuperSignal West Pico PLUS Chemiluminescent Substrate. 
 
CHART-MS 
Following CHART pulldown, samples were precipitated overnight at -20 °C with 4 volumes of 
cold acetone. The precipitated sample was centrifuged for 20 min at 16,000 x g at 4 °C and the 
supernatant discarded. The remaining pellet was washed with 1 mL cold acetone, centrifuged for 
5 min at 16,000 x g at 4 °C, and the supernatant discarded. The remaining pellet was dried under 
vacuum. The protein pellet was digested to peptides using the TFE digest protocol (Wang et al., 
2005) and peptide samples were analyzed by mass spectrometry. For LC-MS/MS analysis, 5 μl 
of 0.1 μg/μl of peptides per sample were analyzed by reverse phase separation (C18) using a 
Waters nanoEquityTM UPLC system interfaced with a QExactive Plus Orbitrap mass 
spectrometer (Fort et al., 2018). LC-MS/MS datasets were converted to peak lists (DTA files) 
using the DeconMSn software (Mayampurath et al., 2008) and searched with MS-GF+ software 
(Kim, Gupta, and Pevzner, 2008; Kim and Pevzner, 2014) against Uniprot/SwissProt mus 
musculus database. The identified spectra were filtered based on their MSGF+ QValue score, 
which represents the false discovery rate of peptide-spectrum-matches (PSMs). PSMs with 
QValue less than 0.01 were retained. Proteins were quantified using the spectral counting 
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quantification approach (Wang et al., 2008). Downstream analyses identified Paupar binding 
proteins that were enriched > 2-fold over controls, excluding proteins found in > 75% of control 
experiments listed in the Contaminant Repository for Affinity Purification (CRAPome; 
Mellacheruvu et al., 2013). We used Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) (Szklarczyk et al., 2017) to identify known and predicted protein-protein interaction 
networks among our Paupar-interacting proteins.  
 
ChIP-qPCR 
The ChIP-IT High Sensitivity kit (Active Motif) was used according to the kit instructions. 
Briefly, 48 hours post ASO transfection (after ensuring efficient Paupar KD), cells were 
crosslinked, lysed, and sonicated to obtain DNA fragments with an average length of 200–1200 
bp. Supernatant containing DNA-protein complexes was used for immunoprecipitations 
reactions consisting of 30 μg chromatin and 4 μg rabbit anti-PAX6 antibody (Biolegend) or 
rabbit IgG control antibody (included in kit). Immunoprecipitated chromatin was collected using 
protein G agarose beads, then washed, eluted, and purified according to kit instructions. ChIP-
qPCR were performed using the iQ Sybr Green Supermix (Biorad) and primers against MafB and 
Glucagon promoter regions. Data were normalized to the input signal and IgG values.  
 
Quantification and Statistical Analyses  
Graphs were generated in GraphPad Prism 7 and statistical analyses were performed using 
Graphpad Prism 7. Statistical parameters including the value of n, statistical test used, and 
significance (p-value) are reported in the figures and their legends. For studies involving mouse 
tissues, replicates refer to samples derived from different mice, unless otherwise specified. For 
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studies involving cell culture, replicates refer to transfections performed on different days. 
Unpaired two-tailed t tests were used to assess significance when comparing qRT-PCR 
expression values of 2-3 genes between two conditions. Linear regression analysis was used to 
determine if two variables were significantly correlated to each other. The Fisher’s exact test was 
used to examine the significance of the association (contingency) between two types of 
classifications. For differential expression of global measurements (RNA-seq), the DESeq2 
software (Love et al., 2014) generated adjusted p-values using the Benjamini-Hochberg 
procedure to correct for multiple-hypothesis testing. The accession numbers for the sequencing 
data reported in this chapter are GSE122033 (embryonic pancreas and islet lncRNAs) and 




Identification of developmentally regulated lncRNAs in the mouse pancreas 
To identify temporally and spatially regulated lncRNAs in the pancreas, we performed RNA-
sequencing (RNA-seq) on adult mouse islets and embryonic day 15.5 (e15.5) mice pancreas (EP) 
(n=3 per stage) to obtain 60 million paired-ended reads per sample. We analyzed these datasets 
using a computational pipeline (Pefanis et al., 2015) designed to identify putatively functional 
mouse pancreatic lncRNAs (Figure 2-1A) (Singer and Sussel, 2018). A set of stringent criteria 
was used to define 2728 pancreatic lncRNAs: (1) > 200 nucleotides (nt) in length; (2) no overlap 
with protein coding regions; (3) no overlap with pseudogenes (Karro et al., 2006); and (4) low 
predicted coding probability (Wang et al., 2013) (Figure 2-1B). We then filtered out genes with 
an FPKM < 0.5 to enrich for lncRNAs amenable to molecular analyses (Figure 2-1C). These 
parameters yielded 572 high-confidence pancreatic lncRNAs that clustered according to 
developmental stage (Figure 2-1D). Remarkably, comparative transcriptomics between the two 
stages showed that approximately half (279 or 48.7%) of all pancreatic lncRNAs were 
developmentally regulated: 108 lncRNAs were significantly enriched in EPs and 171 lncRNAs 
were significantly enriched in adult islets (Figure 2-1E). 
 
Previous studies have shown that subsets of lncRNAs regulate, or are co-regulated with, nearby 
protein-coding genes (Cabili et al., 2011; Moran et al., 2012). To gain insight into the function of 
these lncRNAs, we utilized Genomic Regions Enrichment of Annotations Tool (GREAT) 
(McLean et al., 2010) to identify nearby protein-coding genes (Figure 2-1F). Several lncRNAs 
mapped within 5 kb of a nearby transcriptional start site (TSS), suggesting they might function as 
bidirectional lncRNAs (Mercer, Dinger, and Mattick, 2009), while the majority of lncRNAs were 
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located in intergenic regions (> 50 kb from a TSS) (Figure 2-2A). Gene ontology analyses of all 
neighboring genes showed a significant enrichment of genes involved in “endocrine pancreas 
development” and “pancreas development” (Figure 2-1G), including nine essential pancreas 
transcription factors: Pax6, Foxa2, Nkx6.1, NeuroD1, Hes1, Foxo1, Mnx1, Meis2, and Hnf6 
(Table 2-1).  
 
Paupar is a nuclear lncRNA enriched in pancreatic alpha cells  
One of the more differentially regulated lncRNAs (~40x higher in islets compared to EP; Figure 
2-1E) was the Pax6 Upstream Antisense RNA (Paupar), a previously characterized lncRNA 
located near the Pax6 locus (Vance et al. 2014) with an orthologous transcript in human islets 
(HI-LNC101) (Moran et al., 2012). Paupar is a 3482 bp gene transcribed 8 kb upstream and 
antisense from Pax6 and contained within the first intron of Pax6os1, an antisense RNA with no 
known function (Figure 2-3A). Paupar lies in a syntenically conserved region on chromosome 2 
in mice and chromosome 11 in humans (LiftOver). Paupar is also highly conserved at the 
nucleotide level across mammals (89% in humans; Table 2-1), both in its gene body and regions 
located at the putative promoter region (Figure 2-3A), similar to many functional lncRNAs 
(Carninci et al. 2005). Comparative sequence analysis of Paupar across species did not reveal 
any conserved ORFs, reinforcing the computational prediction that Paupar lacks protein-coding 
potential (PhyloCSF -6.5127; CPC 0.2666; CPAT 0.2086).  
 
Paupar was previously identified as a single exonic lncRNA in the neuroblastoma N2A cell line, 
where it appears to have PAX6-dependent and independent functions (Vance et al., 2014). To 
more globally characterize Paupar expression, we performed extensive analysis of published 
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RNA-seq datasets from 25 different mouse tissues (Lin et al., 2014) and found that Paupar was 
expressed exclusively in the pancreas, eye, and brain (Figure 2-4A). These datasets also 
confirmed the findings of our initial screen, showing enrichment of Paupar in adult islets 
compared to embryonic pancreas (Figure 2-1E). Furthermore, expression data from alphaTC and 
MIN6 cell lines suggested restricted expression in islet alpha cells (Figure 2-4A). Surprisingly, in 
contrast to what was reported in N2A neuroblastoma cells, in the context of islet alpha cells, 
Paupar appears to contain three exons and two introns (Figures 2-4A-C). 
 
We confirmed the RNA-Seq data using qRT-PCR on RNA from 11 different mouse tissues to 
demonstrate that Paupar was significantly enriched in adult mouse islets, compared to the eye 
(~3.5-fold) and brain (~25-fold) (Figure 2-3B). Expression analysis in whole pancreata at several 
embryonic and postnatal developmental time points also revealed that onset of Paupar 
expression occurs between postnatal day 7 (P7) and P14 (Figure 2-3C), which is a critical 
window of postnatal development associated with the functional maturation of endocrine cells  
(Nishimura et al., 2006; Hang and Stein, 2011). Given that PAX6 has known regulatory roles in 
both alpha and beta cells (Gosmain et al., 2010; Swisa et al., 2017), we wanted to confirm the 
alphaTC and MIN6 expression data that suggested Paupar expression was restricted to the alpha 
cell lineage. Analysis of published RNA-seq datasets from FACS purified mouse alpha and beta 
cells (DiGruccio et al., 2016) confirmed Paupar was enriched 3-fold in alpha cells compared to 
beta cells (Figure 2-3D), in contrast to Pax6, which is expressed equally in both cell types 
(Figure 2-3E). Expression levels of MafB and MafA, essential alpha and beta cell transcription 
factors, respectively, are shown to demonstrate the purity of each dataset (Figure 2-3E).  
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LncRNA localization within a cell can also yield important mechanistic insight; nuclear 
lncRNAs often regulate transcription and pre-mRNA processing, while cytoplasmic lncRNAs 
more likely influence mRNA stability and translation (Batista and Chang, 2013). Expression 
analyses on alphaTCs following cell fractionation revealed a significant enrichment of Paupar in 
the nucleus compared to the cytoplasm (Figure 2-3F). Nuclear localization of Paupar in alphaTC 
cells was confirmed by single-molecule fluorescent in situ hybridization (smFISH) using 
oligonucleotide probes targeting the full length Paupar transcript. In comparison, glucagon 
protein is localized to the cytoplasm (Figure 2-3G). Analysis of Paupar smFISH images 
determined that the average copy number for Paupar is 54 ± 31 transcripts per alphaTC cell 
(Figure 2-4D). Taken together, these results demonstrate Paupar is a conserved lncRNA 
predominantly localized to the nuclei of mature pancreatic alpha cells.   
 
Paupar regulates Pax6 alpha cell target genes  
The expression profile of Paupar prompted us to investigate its regulatory function in alpha 
cells. Three unique sets of antisense oligonucleotides (ASO) successfully downregulated Paupar 
RNA in alphaTC cells by an average of 57% (Figure 2-5A). In contrast to what has been 
previously reported in N2A cells, we observed no change in Pax6 expression following Paupar 
knockdown (Figure 2-5A), suggesting that Paupar RNA does not influence Pax6 transcription. 
We were surprised then, to discover that Paupar knockdown led to the downregulation of several 
canonical Pax6 alpha cell target genes, including Gcg, MafB, Arx, and NeuroD1 (Gosmain et al., 
2010) (Figure 2-5A). Furthermore, the amount of Paupar KD was positively correlated with the 
reduction in both Gcg (Figure 2-5B) and MafB (Figure 2-5C) expression. These findings suggest 
that Pax6-mediated regulation of alpha cell genes is sensitive to the level of Paupar present in 
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alphaTCs. Foxa2, an alpha cell gene that is not a target of PAX6, was not regulated by loss of 
Paupar, further suggesting the activity of Paupar is restricted to PAX6 target genes (Figure 2-
5A).  
 
Paupar lncRNA interacts with nuclear proteins involved in alternative splicing 
To investigate the molecular mechanism by which Paupar regulates alpha-cell Pax6 target 
genes, we performed Capture Hybridization Analysis of RNA Targets (CHART) (Simon et al., 
2011) to identify the Paupar interactome. We used two unique sets of biotinylated capture oligos 
(COs) to pull down Paupar, in addition to scrambled and Paupar sense control COs. Both sets of 
Paupar COs retrieved Paupar RNA from alphaTC nuclear extract (Figure 2-5D). Importantly, 
Paupar COs did not pull down Gapdh or TBP, nor did control COs retrieve Paupar (Figures 2-
5D and 2-5E). The lack of Paupar enrichment with sense COs, which cannot directly target the 
RNA but have sequence identity to the DNA locus, demonstrates that the CHART-based 
enrichment is RNA mediated (Figure 2-6A).  
 
To identify Paupar-interacting proteins, we performed CHART followed by mass spectrometry 
(CHART-MS), and identified 56 Paupar binding proteins that were enriched > 2-fold over 
control COs (Table 2-2). Surprisingly, unlike in N2A cells, we were not able to detect an 
interaction between Paupar and PAX6 protein (Figure 2-6B). Analysis of the Paupar interacting 
proteins using a database of known and predicted protein-protein interaction networks (Search 
Tool for the Retrieval of Interacting Genes/Proteins (STRING); Szklarczyk et al., 2017) 
identified 25/56 proteins that interact with at least one other Paupar interacting protein (Figure 
2-5F). These protein complexes were significantly enriched in several pathways (Figure 2-5G), 
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including RNA splicing (Figure 2-5F, blue circles), regulation of gene expression (Figure 2-5F, 
red circles), and DNA binding (Figure 2-5F, green circles). Since the largest complex of 
interacting proteins contained canonical regulators of alternative splicing, we compared the set of 
Paupar interacting proteins with those retrieved by NEAT1 and MALAT1, two nuclear lncRNAs 
with established roles in alternative splicing (West et al., 2014). This identified 50.6% and 51.7% 
overlap with NEAT1 and MALAT1 interacting proteins, respectively (Figure 2-6C). In contrast, 
similar comparison to proteins or lncRNAs that are not involved in alternative splicing 
mechanisms, MAFA (Scoville et al., 2015), NEUROD1 (Romer et al., 2018) and Xist (Chu et al., 
2015), showed limited overlap (Figure 2-6C). 
 
Consistent with a direct interaction between Paupar and 8 of the 12 annotated serine and 
arginine rich splicing factors (SRSFs) (Figure 2-5F; Table 2-2), we used a computational tool 
(RBPmap; Paz et al., 2014) to demonstrate that the full-length Paupar transcript had 1685 
predicted SRSF binding sites above a stringent z-score threshold (> 2). Notably, several of the 
top SRSF sites with the highest z-scores were located within a region of high sequence 
conservation across placental mammals (Figure 2-5H, grey rectangle). To address the possibility 
that SRSF binding occurs because Paupar is a spliced transcript, we compared the z-scores for 
Paupar SRSF binding sites to Nkx2-2, an mRNA that is spliced but does not regulate RNA 
splicing, as well as Malat1, a lncRNA that is not spliced but regulates SRSF-mediated RNA 
splicing. We found that Paupar had more SRSF binding sites with higher z-scores than both 
Nkx2-2 and Malat1 (Figure 2-5H). SRSF binding sites for the full ~7 kb Malat1 locus is shown 
in Figure 2-6D. Taken together, these findings suggest that Paupar functions in the alpha cell to 
regulate alternative splicing. 
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Paupar promotes the alternative splicing of Pax6 to the isoform required for activation of 
Pax6 alpha cell target genes 
Previous studies have demonstrated that the regulatory role of Paupar in N2A cells is partially 
mediated through PAX6 (Vance et al., 2014; Pavlaki et al., 2017). The identification of 
interactions between Paupar and the SRSF family of proteins, and the knowledge that Pax6 has 
two well-characterized isoforms with distinct regulatory functions (Epstein et al., 1994; Chauhan 
et al., 2004; Kiselev et al., 2012; Sasamoto et al., 2017) (Figure 2-7A), led us to examine a 
possible role for Paupar-mediated alternative splicing of Pax6. The two major Pax6 isoforms, 
termed Pax6 (Figure 2-7A, red lines) and Pax6 5a (Figure 2-7A, blue lines), differ from each 
other by an alternatively spliced exon, “5a”, that adds 14 amino acids to the paired DNA-binding 
domain of PAX6 protein and alters Pax6 DNA binding recognition (Kiselev et al., 2012). Since 
PAX6 regulates distinct target genes in alpha versus beta cells (Gosmain et al., 2010; Gosmain et 
al., 2012), it is possible that its cell-specific regulatory activities could be mediated through its 
different isoforms. Consistently, computational analysis of alternative splicing events in alpha 
versus beta cell transcriptomes (DiGruccio et al., 2016) identified the Pax6 5a isoform as 
significantly enriched in alpha cells (p < .0001; Table Appendix-1). While non-quantitative RT-
PCR analysis detects both isoforms in alpha cells (Figure 2-7B), we could only quantify 
expression of Pax6 5a, given that amplification of the longer Pax6 isoform produces both 
isoform products, which confounds qRT-PCR analysis. To directly test whether Paupar 
promotes alternative splicing of Pax6, we performed qRT-PCR on RNA from Paupar-deficient 
alphaTCs. Strikingly, while Paupar KD did not induce a change in total Pax6 mRNA levels 
(Figure 2-5A), we did observe a significant and specific reduction (45%) of Pax6 5a (Figure 2-
7C). We also determined that Paupar-mediated regulation of Pax6 splicing occurs directly 
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though RNA-RNA interaction, rather than indirectly through SR splicing factors, since the 
association between Paupar and Pax6 RNA that could be partially ablated by RNase treatment 
(Figure 2-7D). 
 
A study in non-pancreatic cell lines that stably expressed Pax6 or Pax6 5a showed that the two 
proteins have different DNA binding specificities (Kiselev et al., 2012). To determine whether 
Paupar mediated-alternative splicing of Pax6 5a is necessary for the PAX6 activation of alpha 
cell target genes, we performed PAX6 ChIP in alphaTC cells with normal or reduced amounts of 
Paupar and assessed changes in PAX6 occupancy on the promoters of Gcg and MafB, two genes 
directly activated by PAX6 (Gosmain et al., 2007; Gosmain et al., 2010). As expected, in control 
alphaTCs there was a greater than 30-fold enrichment of PAX6 over IgG on Gcg and MafB 
regulatory DNA (Figure 2-7E). Strikingly, Paupar KD induced a 34% reduction in PAX6 
occupancy on the Gcg promoter and a 58% reduction in PAX6 occupancy on the MafB promoter, 
directly demonstrating that Paupar is required for normal PAX6 binding and activation of Gcg 
and MafB in alphaTCs (Figure 2-7E). Taken together, these results show that Paupar confers the 
alpha-cell specific activating function of Pax6 5a via alternative splicing.  
 
Paupar knockout mice have impaired alpha cell development and function  
To determine whether Paupar’s regulation of Pax6 isoform selection affected alpha cell function 
in vivo, we generated Paupar null (KO) mice by replacing the endogenous Paupar locus with 
the histone-fusion GFP (H2B:GFP) reporter gene (Kanda et al., 1998) (Figure 2-8A). Expression 
analysis of islets from Paupar KO mice confirmed the complete loss of Paupar RNA (Figure 2-
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8B), and immunofluorescence analyses indicated that the GFP reporter recapitulated endogenous 
Paupar expression specifically in the glucagon-producing alpha cells (Figures 2-8C and 2-8D).  
Paupar KO mice are viable, fertile, and indistinguishable from their WT littermates with respect 
to weight (Figure 2-10A), ad libitum blood glucose (Figure 2-10B), and glucose tolerance 
(Figures 2-10C-F). These findings are not surprising given the restricted expression of Paupar in 
alpha cells; several studies have shown that mice are highly resistant to perturbations in alpha 
cell function (Furuta et al., 2001; Shiota et al., 2003; Heller et al., 2004; Hancock et al., 2010; 
Wilcox et al., 2013). We therefore utilized an in vivo insulin tolerance test (ITT) to induce 
hypoglycemia, a physiological trigger for glucagon secretion from alpha cells. Strikingly, at all 
assayed time points, 6-week-old Paupar KO mice were significantly hypoglycemic compared to 
WT mice, suggesting KO mice were less efficient at returning to baseline blood glucose levels 
(Figure 2-10A and 2-10B). To differentiate between enhanced insulin sensitivity and an inability 
to properly respond to hypoglycemia, we measured plasma glucagon before and during an ITT. 
Thirty minutes after an insulin injection, Paupar KO mice had ~3-fold decrease in plasma 
glucagon relative to WT mice (Figure 2-10C), demonstrating that Paupar KO mice secrete 
significantly less glucagon in response to insulin-induced hypoglycemia.  
 
The physiological response to an insulin challenge is complex and involves several non-
pancreatic tissues, including liver, muscle, and fat. Although Paupar is not expressed in those 
tissues (Figure 2-4A), to eliminate the possibility that the impaired response of Paupar KO mice 
to hypoglycemia was due to increased uptake of glucose by the peripheral tissues, we performed 
ex vivo glucagon secretion assays. Cultured islets from 6-week-old Paupar KO mice secreted 
~60% less glucagon than WT mice in response to low glucose (2 mM) and ~47% less glucagon 
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than WT mice in response to 10 mM arginine, both potent glucagon secretagogues (Gerich, 
Charles, and Grodsky, 1974) (Figure 2-9D). This blunted glucagon secretion could be due to 
several factors, including impaired glucose sensing, membrane depolarization, glucagon 
production, and granule exocytosis. To distinguish between these defects, we began by 
measuring total islet glucagon content and found that Paupar KO islets had dramatically less 
(56%) total glucagon than controls (Figure 2-9E). These findings demonstrate that decreased 
glucagon content in Paupar KO islets contributes to impaired alpha cell physiological function. 
 
Consistent with the physiological phenotype, morphometric analysis on 6-week-old Paupar WT 
and KO pancreata revealed that while alpha cells made up 13.74% ± 0.79 of Paupar WT islets 
(Figure 2-9F), they comprised only 6.11% ± 0.71 of Paupar KO islets (Figure 2-9G), 
corresponding to an average 2.25-fold decrease in the alpha cell population (Figures 2-9F-H). 
We also observed a modest increase in beta cell area relative to islet area in Paupar KO mice 
(79.4% ± 1.92) compared to WT mice (Figures 2-9I-K). There was no measurable difference in 
average islet size between Paupar WT and KO mice (Figures 2-9L-N). Examination of islet 
morphology in 7-month-old WT and KO mice showed that Paupar KO mice had significant 
alpha cell (Figures 2-11A and 2-11B) and islet hyperplasia (Figures 2-11C) due to increased 
alpha cell proliferation (Figures 2-11D-F). This compensation phenomenon has been well 
documented in several mouse models of alpha cell dysfunction (Gelling et al., 2003; Conarello et 
al., 2007; Hayashi et al., 2009; Courtney et al., 2013; Solloway et al., 2015) and provides further 
evidence that Paupar functions similarly to canonical alpha cell regulatory proteins. Taken 
together, these results demonstrate that Paupar is required for normal alpha cell development 
and function.  
89 
Paupar regulates essential alpha cell genes in vivo  
To validate the in vitro studies which used an RNA knockdown approach to disrupt Paupar 
activity in alphaTC cells, we performed global transcriptome analyses on 6-week-old isolated 
islets from Paupar WT and KO mice to reveal 3106 dysregulated genes (p < .05) across cohorts 
(Figure 2-12A). Consistent with the alpha-cell specific phenotype, the differentially expressed 
genes (DEGs) represented > 10% of the documented alpha cell enriched genes (DiGruccio et al., 
2016) (Figure 2-12B). Furthermore, the DEGs contained many factors required for alpha cell 
function and many known PAX6 alpha cell targets, including transcription factors (Arx, MafB, 
Irx1, and Irx2) (Table 2-3), voltage-gated ion channels (Slc41a2, Kcnq2, Kcnip3), and exocytotic 
machinery (Sytl5 and Sytl2) (Figure 2-12C). In addition, the majority (63/75) of the dysregulated 
alpha-cell specific genes were downregulated in Paupar KO mice, indicating that Paupar 
predominantly regulates gene activation in alpha cells. Also consistent with our in vitro studies, 
in vivo transcriptome analyses of Paupar KO islets did not show dysregulation of total Pax6 
mRNA, suggesting Paupar-mediated regulation of PAX6 alpha-cell target genes is downstream 
of Pax6 transcription. Given the low abundance of alpha cells in mouse islets, and that the RNA-
seq was performed on whole islets, the downregulation of Pax6 5a specifically in alpha cells 
could not be assessed. Of note, Paupar KO islets had normal levels of Pax6os1, as well as genes 
within 100 kb of Paupar, suggesting that the Paupar KO mouse phenotype is not due to deletion 
of an important DNA regulatory element. Based on these cumulative studies, we propose a 
model that Paupar promotes alpha cell function via alternative splicing of the Pax6 5a isoform 




During the past 20 years, a major focus of diabetes research has been directed towards 
identifying the complex transcription factor networks required for the specification and function 
of pancreatic islet cells. Yet, how these broadly expressed transcription factors acquire unique 
regulatory functions at different stages of pancreas development and in different islet cell types 
remains poorly understood. In this study we uncover a novel mechanism by which the lncRNA, 
Paupar, confers cell specific regulatory function on the essential pancreatic transcription factor, 
PAX6, by promoting the alternative splicing of Pax6 to the 5a isoform that is required for the 
activation of downstream alpha cell target genes (Figure 2-13). We have shown that the loss of 
Paupar blunts the production of Pax6 5a isoform, causing diminished activation of PAX6 target 
genes and impaired glucagon-mediated glucose homeostasis (Figure 2-13). These findings 
uncover a novel layer of islet gene regulation and provide further evidence that lncRNAs are 
fundamental players in islet development and function.    
 
Paupar was first identified in neuroblastoma N2A cells as a single exon lncRNA that regulated 
genes independently and through direct interaction with PAX6. Surprisingly, our expression 
analyses showed that Paupar was most highly enriched in pancreatic islets compared to all other 
tissues examined, including the eye, brain, and N2A cells. Furthermore, unbiased mapping of the 
adult islet transcriptome showed evidence of splicing within the Paupar locus; cloning and 
sequencing confirmed that the Paupar transcript has three exons and two introns. We also 
discovered that Paupar does not directly interact with PAX6, nor does it regulate Pax6 
expression at the transcript level. These discrepancies between our findings and previous studies 
in N2A cells possibly reflect tissue-specific regulation and functional activities of Paupar. 
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Furthermore, although Paupar is also expressed in the mouse eye and brain, we did not observe 
any gross abnormalities or phenotypes associated with these tissues in Paupar KO animals. It is 
also not likely that the loss of Paupar in the brain contributes to the alpha cell phenotype, since 
we observed impaired glucose-induced glucagon secretion and a significant decrease in glucagon 
content in isolated islets of Paupar KO mice. Lastly, Paupar-mediated regulation of alpha cell 
genes in vitro was consistent with in vivo phenotypes.  
 
Within the pancreas, Pax6 is expressed in several islet cell types, while Paupar expression is 
restricted to maturing alpha cells. Intriguingly, the onset of Paupar pancreatic expression 
between P7 and P14 corresponds to a critical developmental window during which cells acquire 
mature transcriptional profiles. For example, during this postnatal window the transcription 
factors MafA and MafB become restricted to mature beta and alpha cells, respectively. These 
findings, along with the dramatic reduction in alpha cells seen in 6-week-old Paupar KO mice, 
and experiments showing reduced PAX6-activation of MafB in Paupar-deficient alphaΤC cells, 
demonstrate that Paupar is required for the differentiation of mature alpha cells by promoting 
PAX6-mediated activation of MafB. 
 
Previous studies have shown that PAX6 functions as a transcriptional activator and a repressor; 
however, the mechanism that mediates this dual capability in a single cell type is unknown. The 
discovery that Paupar expression specifically in alpha cells promotes the alternative splicing of 
Pax6 to an isoform with altered DNA binding specificity raises the interesting possibility that the 
different PAX6 isoforms have unique functions. Since were able to detect both the Pax6 and 
Pax6 5a isoforms within alpha cells, it is possible that the ratio of each isoform is crucial for 
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proper gene regulation. This idea is supported by our finding that reduction of the Pax6 5a 
isoform in Paupar-deficient alpha cells corresponded to reduced expression of several canonical 
PAX6-activiated alpha cell genes, including glucagon and MafB (Gosmain et al., 2007; Gosmain 
et al., 2010), while ghrelin, the only gene known to be repressed by PAX6 in alpha cells (Ahman 
et al., 2015), was not upregulated in Paupar KO islets or in Paupar-deficient alphaTC cell line 
(Figure 2-12 and data not shown).  
 
The majority of Paupar molecular analysis was performed in the alphaTC cell line, which is an 
appropriate, but imperfect model for endogenous alpha cells. A current challenge in the alpha 
cell field is the paucity of data characterizing transcription factor binding and chromatin structure 
in endogenous mouse alpha cells. This is at least partially due to the relatively low proportion of 
alpha cells in the mouse islet; it is difficult to collect sufficient material from isolated alpha cells 
for biochemical analysis and data generated from whole islet preparations largely represent the 
exceedingly abundant beta cell population. However, with the continual development of novel 
technologies to perform high throughput molecular analyses on low abundant cell populations, 
these barriers will soon be reduced. In the future, the ability to perform ChIP-Seq on purified 
islet alpha and delta cells will likely highlight the distinct islet cell specific regulatory 
mechanisms to inform both normal islet cell type specification, and the dedifferentiation and 
reprogramming events that have recently been associated with diabetic islets in mice and humans 
(Talchai et al., 2012; Lu et al., 2018). 
 
While several lncRNAs have been shown to generally influence alternative splicing through their 
direct interactions with splicing factors (reviewed in Romero-Barrrios et al, 2018), this study 
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demonstrates for first time a specific interaction between a cell-restricted lncRNA and its cis-
related gene that in turn influences the production of distinct protein isoforms. In particular, the 
presence of Paupar in islet alpha cells skews the alternative splicing of Pax6 to favor a PAX6 
isoform required for alpha cell specific gene activation. These results highlight an important 
mechanism through which tissue restricted lncRNAs influence transcription factor target 
selection to confer cell specific activities. The identification and characterization of additional 
cell restricted lncRNAs will be instrumental in determining the extent of this gene regulatory 
mechanism. We predict that additional evidence of cis lncRNA-regulation of tissue-specific 
mRNA splicing will emerge, since many lncRNAs function in the same pathway as their 
neighboring gene, even though there is often no evidence of co-regulation at the transcriptional 
level. In summary, our extensive molecular and functional characterization of an alpha cell 
enriched lncRNA suggest that lncRNAs could represent important tissue and/or cell restricted 
therapeutic targets to regulate the production and function of cell-specific isoforms of more 





Figure 2-1. Systematic identification of developmentally regulated lncRNAs in the mouse 
pancreas. (A) Overview of lncRNA discovery pipeline. A total of 2728 lncRNA genes (3623 
transcripts) were identified from e15.5 embryonic mouse pancreata and 12-week-old adult mouse 
islets. 572 lncRNAs with an FPKM > 0.5 were included in downstream analyses. (B) Histogram 
plot showing the number of lncRNAs corresponding to a range of Coding Potential Assessment 
Tool (CPAT) scores. Cutoff for inclusion in list of putative lncRNAs was CPAT score < 0.364 
(shown by dotted grey line). (C) Plot showing number of lncRNAs corresponding to a range of 
FPKM values. Cutoff for the final list of putative lncRNAs was FPKM > 0.5 (shown by dotted 
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grey line). (D) Heat map of 572 candidate lncRNAs with corresponding FPKMs from e15.5 
pancreas samples (n=3) and 12-week-old adult isolated islet samples (n=3). Z-scores were 
calculated using Pearson distance measurements. Heat map was generated with Heatmapper 
(http://heatmapper.ca/). (E) Volcano plot showing Log2 fold change (e15.5 pancreas/islets) and –
log10 p-value for 572 candidate lncRNAs. 171 lncRNAs were upregulated in islets (red circles) 
and 108 lncRNAs were upregulated in embryonic pancreas (blue circles). Genes that did not 
meet the significance cutoff (p > 0.05, indicated by dotted grey line) are shown as black circles. 
Paupar lncRNA is indicated by a green square. (F) Overview of how GREAT analysis identifies 
set of “associated genes” within 1 MB of each lncRNA (G) GREAT outputs gene ontology 
analysis for set of associated genes. Each category listed is significant and shown is –log10 





Figure 2-2. Related to Figure 2-1, Properties of pancreatic lncRNAs. (A) GREAT analysis on 
lncRNA candidates showing distribution of the distance between lncRNAs and the 





Figure 2-3. Paupar is a nuclear lncRNA enriched in pancreatic alpha cells. (A) Screenshot of 
UCSC mm10 genome browser showing tracks for GENCODE M16, placental mammalian 
conservation by PhyloP, Multiz alignments, and PhyloCSF scores. (B) qRT-PCR analysis of 
Paupar RNA from 12-week-old mouse tissues, n=3. (C) qRT-PCR analysis of Paupar RNA 
from whole pancreas at indicated developmental time points and 12-week-old isolated islets n=3. 
(D) Plots showing Paupar RPKM in published datasets from adult mouse FACS purified alpha 
(green bar) and beta cells (red bar), n=3. (E) RPKM for MafA, MafB and Pax6 based on the same 
published datasets used for (D) from adult mouse FACS purified alpha (green bar) and beta cells 
(red bar), n=3. (F) qRT-PCR analysis of Paupar RNA extracted from alphaTCs following cell 
fractionation. Gapdh and Xist are included for cell fractionation control, n=3. (G) Single 
molecule RNA fluorescent in situ hybridization (smFISH) images in alphaTCs showing Paupar 
(red) co-localized with antibody staining for Glucagon (green) and DAPI (blue). Scale bar 
indicates 10 μm. Images are representative of 3 replicate experiments. Data for (B) and others 
like it in the following figures are mean ± SEM, t test, NS p > 0.05, * p < 0.05, ** p < 0.01, *** 





Figure 2-4. Related to Figure 2-3, Expression analysis of Paupar lncRNA. (A) IGV 
screenshot showing reads mapping to the Paupar locus in 25 different tissues and cell types. Y-
axis maximum is set at 50 in all samples except for adult islets (top), which is set to 233 and 
corresponds to maximum observed Paupar expression (B) RT-PCR cloning of the mature 
Paupar transcript in alphaTCs using primers spanning intron/exon boundaries. (C) The full 
Paupar sequence with exons show in blue letters and introns show in lowercase black letters, 
mm10. (D) Single molecule FISH of Paupar RNA and DAPI in alphaTCs (left panel). The right 
panel shows processed Paupar signal that was then quantified according to the protocol outlined 





Figure 2-5. Paupar lncRNA regulates PAX6 alpha cell target genes and interacts with 
several nuclear proteins involved in alternative splicing. (A) qRT-PCR analysis of Paupar, 
Pax6, Glucagon (Gcg), MafB, Arx, NeuroD1, and Foxa2 RNA from alphaTCs following control 
ASOs or Paupar ASO KD; n=4 for each condition. (B) Linear regression plot showing 
significant positive correlation between percent Paupar KD and percent Gcg reduction. (C) 
Linear regression plot showing significant positive correlation between percent Paupar KD and 
percent MafB reduction. (D) Graph of qRT-PCR analysis on CHART done with control COs or 
Paupar COs showing percent RNA retrieval relative to input for Paupar, Gapdh, and TBP. (E) 
CHART RT-PCR images showing retrieval of Paupar, Gapdh, and TBP from pull downs with 
control COs, Paupar COs, or Paupar COs treated with RNase. (F) Diagram showing output 
from STRING analysis of Paupar interacting proteins found by CHART-MS. Colored nodes 
correspond to the categories highlighted in (G). (G) Results of GO analyses on Paupar 
interacting proteins from (G). (H) Results from RBPmap showing z-scores for predicted SRSF 
binding sites mapped to Paupar (green dots), Malat1 (red dots), and Nkx2-2 (blue dots) loci. 
Graph is aligned to UCSC screenshot showing the Paupar locus and corresponding placental 
mammalian basewise conservation. Grey rectangle highlights the region of Paupar with high 




Figure 2-6. Related to Figure 2-5, Results of Paupar CHART-MS. (A) Graph of qRT-PCR 
analysis on CHART samples showing Fold Enrichment of Paupar, Gapdh, and TBP in 
experiments using Paupar COs compared to sense COs. (B) Representative image of a western 
blot for PAX6 on control CO or Paupar CO CHART eluate, along with varying amounts of 
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alphaTC input extract, 5 μg BSA, and a no protein control. (C) Plot showing percentage of 
unique and overlapping proteins between Paupar-MS and proteins retrieved by pull downs 
indicated on the x-axis. (D) Results from RBPmap showing z-scores for predicted SRSF binding 







Figure 2-7. Paupar promotes the alternative splicing of Pax6 to the isoform required for 
activation of PAX6 alpha cell target genes. (A) Schematic of the Pax6 genomic locus with 13 
constitutive exons and exon 5a. Schematic of Pax6 cDNA with red lines showing the alternative 
splicing that produces the Pax6 5a isoform and blue lines showing the alternative splicing that 
produces the longer Pax6 isoform. Black filled-in arrows are RT-PCR primers used in (B) to 
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amplify both isoforms. Black outlined arrows are qRT-PCR primers used in (C) and (D) to 
specifically amplify Pax6 5a RNA. (B) RT-PCR analysis showing amplification of both Pax6 
isoforms using primers indicated by black filled-in arrows shown in (A). (C) qRT-PCR analysis 
of Paupar and Pax6 RNA from alphaTCs following control or Paupar KD. (D) CHART qRT-
PCR showing the enrichment of Pax6 5a isoform in experiments using Paupar COs or Paupar 
COs with RNaseA treatment, compared to control COs. Primers used are shown by black 
outlined arrows in (A). (E) ChIP-qPCR analysis showing the fold enrichment for PAX6 antibody 
over IgG at intergenic, Gcg, and MafB DNA elements conducted in alphaTCs following control 





Figure 2-8. Related to Figure 2-9, Generation of Paupar KO mice. (A) Overview of Paupar 
knockout (KO) construct. The 3.7 kb Paupar locus is replaced by H2BGFP-PGKpA using BAC 
recombineering in mouse embryonic stem cells (mESCs). (B) Genotyping PCR strategy using 
P1, P2, and P3. The WT band is 251 bp and the KO band is 358 bp. (C) qRT-PCR on mouse 
islets showing loss of Paupar RNA. (D) Immunohistochemistry showing Paupar:H2BGFP co-
localization in Paupar KO islets. (E) Quantification of GFP+ nuclei in insulin, glucagon, and 







Figure 2-9. Paupar knockout mice have impaired alpha cell development and function. (A) 
Graph showing percent baseline blood glucose for six time points during an insulin tolerance 
tests on 6-week-old Paupar WT (black) and Paupar KO (red) mice. n=7-8 for each genotype. 
(B) Area under the curve (AUC) calculations for (A). (C) Plot showing plasma glucagon levels 
(pg/mL) measured by glucagon ELISA at time 0 and 30 minutes after the insulin injection during 
an ITT. Data points are relative values corrected for the % baseline blood glucose achieved by 
each animal in (A). (D) The amount of glucagon secreted by isolated islets in response to 
indicated stimuli. Glucagon values were measured by ELISA and are relative to μg islet DNA. 
Values are presented as relative to secretion during initial 20 mM glucose incubation. n=4 mice 
were used for each genotype and duplicate batches of 20 islets each were used for each mouse. 
(E) Average glucagon content measured by ELISA. n=4 mice for each genotype. (F-M) 
Immunofluorescence analysis of Paupar WT (F, I, L) and Paupar KO (G, J, M) pancreata 
showing glucagon-producing alpha cells (F, G), insulin-producing beta cells, (I, J), and merged 
channels with DAPI (L, M). Scale bar indicates 50 μm. Images are representative of 3 replicate 
experiments. (H) Quantification of immunofluorescence images showing percentage alpha cell 
area relative to islet area in WT (plain green bar) and KO mice (green striped bar). Data 
represents an average quantification of 15-20 islets from each mouse, n=3 mice per genotype. 
(K) Same as (H) but showing percentage beta cell area relative to islet area in Paupar WT (plain 
red bar) and Paupar KO mice (red striped bar). (N) Same as (H) but showing average islet in 






Figure 2-10. Relative to Figure 2-9, Phenotypic characterization of Paupar KO mice. (A) 
Graph showing body weight in grams for Paupar WT and KO mice at different ages; n=10-20 
per genotype. (B) Graph showing blood glucose (in mg/dL) for the same Paupar WT and KO 
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mice in (A); n=10-20 per genotype. (C-F) Results of glucose tolerance tests on Paupar WT and 





Figure 2-11. Relative to Figure 2-9, Aged Paupar KO mice develop islet and alpha cell 
hyperplasia. (A) Immunohistochemistry analyses of 7-month-old Paupar WT and KO mice 
showing insulin (red), glucagon (green), and DAPI (blue). (B) Morphometric analyses 
quantifying glucagon positive cells relative to islet area. (C) Quantification of islet size 
distribution in 7-month old Paupar WT and KO mice. (D) Quantification of Ki67 and glucagon 
double positive in 7-month old Paupar WT and KO islets. (E) Immunohistochemistry analyses 
of 7-month-old Paupar WT and KO mice showing insulin (red), glucagon (green), Ki67 (white) 
and DAPI (blue) (F) Magnified image of (E) showing a Paupar KO islet showing Ki67+ 






Figure 2-12. Paupar regulates essential alpha cell genes in vivo. (A) Volcano plot showing 
Log2FC (WT/KO) and –log10 p-value highlighting 3106 differentially expressed genes (DEGs) 
in Paupar KO vs. WT mice. Stringency cutoff was p-value < 0.5 and log2FC > 2 or < 0.5, which 
yielded 144 upregulated genes (blue dots) and 429 genes downregulated genes (red dots). Also 
shown are genes with a p-value < 0.5 but with a log2FC 0.5-1 (green dots) or FC 1-2 (orange 
dots). Genes with a p-value > 0.5 are shown by grey dots. (B) Venn diagram showing DEGs 
from Paupar KO RNAseq compared to genes enriched > 2-fold in alpha cells compared to beta 
cells. Fisher exact t-test was used to quantify the significance of the overlapping 75 genes. (C) 
Plots showing log2 fold change values for the 75 alpha cell genes dysregulated in Paupar KO 






Figure 2-13. Mechanisms identified in this study through which Paupar regulates essential 
alpha cell genes. Paupar (red RNA molecule) is enriched in glucagon-producing alpha cells 
where it interacts with SR proteins (green circles) to promote the alternative splicing of the Pax6 
5a isoform. We demonstrate that Pax6 5a is required for activation of the essential alpha cells 
genes, Gcg and MafB. Deletion of Paupar in vivo resulted in dysregulation of PAX6 alpha cell 




Table 2-1. Detailed information on “pancreatic transcription factor associated” lncRNAs,  






































































































































Table 2-2. Proteins enriched by Capture Hybridization Analysis of RNA Targets using 







Paupar COs_1 Paupar COs_2 
HNRH1 Hnrnph1 0 1 50 40 
EF1A1 Eef1a1 1 0 21 15 
SRSF3 Srsf3 0 0 9 7 
DDX Ddx17 0 0 10 5 
G3P Gapdh 1 1 15 13 
GLUC Gcg 0 0 7 7 
HS90A Hsp90aa1 0 0 9 3 
ROA0 Hnrnpa0 7 6 44 43 
H4 Hist1h4a 5 6 37 37 
1433 Ywhab 0 0 8 3 
FUS Fus 0 0 6 5 
IF4A1 Eif4a1 0 0 9 2 
RBM14 Rbm14 1 0 13 3 
FUBP1 Fubp1 0 0 5 5 
PPIA Ppia 0 0 6 4 
YBOX1 Ybx1 0 0 8 2 
H2A Hist2h2ab 5 5 31 23 
CLH1 Cltc 0 0 6 3 
HMGB1 Hmgb1 0 0 6 3 
NUCL Ncl 0 0 6 3 
PYC Pc 0 0 7 2 
H1 Hist1h1a 5 8 30 34 
ALDOA Aldoa 0 0 5 3 
MCM2 Mcm2 0 0 6 2 
SRSF7 Srsf7 0 0 4 4 
HMGN1 Hmgn1 1 2 16 2 
MATR3 Matr3 0 0 4 3 
PRDX1 Prdx1 0 0 3 4 
SFPQ Sfpq 0 1 4 6 
ALRF2 Alyref2 0 0 3 3 
NDKA Nme1 0 0 3 3 
SRRM1 Srrm1 0 0 4 2 
SRSF2 Srsf2 0 0 3 3 
ACLY Acly 0 0 3 2 
CH60 Hspd1 0 0 5 0 
DHX9 Dhx9 0 0 2 3 
DX39A Ddx39a 0 0 2 3 
GSTP1 Gstp1 0 0 2 3 
MYEF2 Myef2 0 0 3 2 
PCBP1 Pcbp1 0 0 4 1 
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PGK1 Pgk1 0 0 3 2 
PUR6 Paics 0 0 3 2 
STMN1 Stmn1 0 0 2 3 
TADBP Tardbp 0 0 1 4 
H2B Hist1h2bp 15 19 36 38 
EIF3A Eif3a 0 0 4 0 
ELAV1 Elavl1 0 0 3 1 
LC7L2 Luc7l2 0 0 3 1 
NUP93 Nup93 0 0 2 2 
SARNP Sarnp 0 0 2 2 
SF3B1 Sf3b1 0 0 3 1 
SRSF4 Srsf4 0 0 3 1 
SYDC Dars 0 0 2 2 
TCEA1 Tcea1 0 0 4 0 
TIF1B Trim28 0 0 1 3 




Table 2-3. The misexpression of canonical alpha cell transcription factors in Paupar KO vs. 











Pax6 6363.059389 6632.967471 1.042417 0.651773473 
Arx 599.440673 395.488637 0.659776 1.10E-05 
Mafb 2497.636452 1858.399089 0.744067 0.000406464 
Irx1 474.594955 286.584016 0.603858 0.000533321 






Table 2-4. Oligonucleotides used in Chapter 2. 
Generation of Paupar KO mouse  
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Amplify 
H2BGFP_overla
p for pA-_REV 
gacttacagTTACTTGTACAG
CTCGTCCATG 
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Genotyping 
P1_FWD primer 




This study Figures 2-8A and 2-8B 
P2_REV primer 
in WT Paupar 
CCAGGATAGCGATTCTCT
CG 






This study Figures 2-8A and 2-8B 
FLPe_FWD CACTGATATTGTAAGTAG
TTTGC 
This study  
FLPe_REV CTAGTGCGAAGTAGTGA
TCAGG 
This study  
NeoR_FWD CGATGATCTCGTCGTGAC
CC 
This study FWD primer in Neo of 
Paupar KI to determine Neo 
has been FLPed out 
PauparNeo_REV CTTTGAGCCGTCTGAAGA
GC 
This study REV primer in Paupar 3' 
gene to determine Neo has 
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This study Figures 2-4A and 2-4B 





This study Capture oligos were 
modified at the 3' end with 
"/iSp18//3BioTEG/" and 
ordered from IDT 
Paupar_CHART ACGACCAGAACTGCGCT This study Capture oligos were 
126 
_2 TCT modified at the 3' end with 
"/iSp18//3BioTEG/" and 
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ChIP-qPCR  
Negative control 














Negative control for alphaTC 
cells 
Gcg ChIP FWD AAGCAGATGAGCAAAGT
GAGTG  
Schaffer 
et al 2013 
Gcg promoter 
Gcg ChIP REV AGGCTGTTTAGCCTTGCA
GATA 
Schaffer 








et al. 2015 
MafB promoter 









Table 2-5. Key Resources used in Chapter 2. 








Santa Cruz Cat#sc-514592; 
RRID:AB_2629431 






Rabbit polyclonal anti-Ki67 EMD Millipore Cat#AB9260; 
RRID:AB_2142366 
Alexa Fluor 488 anti-rabbit Jackson ImmunoResearch Cat#711-545-152;  
RRID:AB_2313584 
Cy3 anti-guinea pig Jackson ImmunoResearch Cat#706-165-148; 
RRID:AB_2340460 
Alexa Fluor 647 anti-rabbit Jackson ImmunoResearch Cat#711-605-152; 
RRID:AB_2492288 
Alexa Fluor 647 anti-rat Jackson ImmunoResarch Cat#712-605-153; 
RRID:AB_2340694 




Rabbit IgG for ChIP Millipore Sigma Cat#I5006; 
RRID:AB_1163659 
Bacterial and Virus Strains  
One Shot TOP10 Chemically 
Competent E. coli 
Invitrogen Cat#3879S 
SW106 cells Warming et al., 2005 N/A 
Biological Samples 
Mouse embryonic stem cells 
(mESCs) 
129SV background N/A 
Chemicals, Peptides, and Recombinant Proteins 
Proteinase K  Promega  Cat#MC5005 
Q5 HiFi DNA polymerase NEB Cat#M0491S 
Gibson assembly kit NEB Cat#E2611S 
Terrific Broth (TB) Difco Cat#243820 
LB Agar Difco Cat#240110 
RNase H NEB Cat#M0297S 
DpnI NEB Cat#R0176S 
EcoRI-HF NEB Cat#R3101S 
HindIII-HF NEB Cat#R3104S 
Go Taq DNA Polymerase Promega Cat#M3001 
dNTPs nucleotide mix Roche Cat#11581295001 
Sodium borohydride Millipore Sigma Cat#452882 
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Formamide Roche Cat#11814320001 
Sucrose Millipore Sigma Cat#S0389 
DMEM media Thermo Fisher Cat#11995  
Penicillin-Streptomycin  Thermo Fisher Cat#15140163  
HEPES buffer Gibco Cat#15630-080 
Non-essential amino acids 
solutions 
Sigma Cat#M7145 
Bovine Serum Albumin Thermo Fisher Cat#15260037 
Sodium bicarbonate Thermo Fisher Cat#MT25035CI 
Antibiotic-Antimycotic Thermo Fisher Cat#15240062 
M199 media Invitrogen Cat#11150067 
Fetal Bovine Serum Gemini Bio Products Cat#100106 
Precision plus protein 
kaleidoscope protein standard 
Bio-rad Cat#1610375 
Lipofectamine 2000 transfection 
Reagent 
Thermo Fisher Cat#11668-019  
D-Glucose Millipore Sigma Cat#G8270 
L-Arginine Millipore Sigma Cat#A5006 
Insulin (NovoLog)  Novo Nordisk U-100 
iQ Sybr Green Supermix Bio-rad Cat#1708880 
Real Time PCR Mastermix for 
Taqman 
Eurogentec Cat#RTQP2X0315+ 
iTaq Universal SYBR Green 
One-Step Kit  
Bio-rad Cat#1725150 
Collagenase P Millipore Sigma Cat#11213857001 
Donkey Serum Sigma Cat#D9663 
Dynabeads MyOne Streptavidin 
C1 
Invitrogen  Cat#65001 
Paraformaldehyde EM Grade Polysciences, Inc. Cat#00380 
Trizol LS Invitrogen  Cat#10296010 
Critical Commercial Assays 
RNeasy Plus Mini Kit Qiagen Cat#74134 
RNeasy Plus Micro Kit Qiagen Cat#74034 
TruSeq Stranded Total RNA 
(with Ribo-Zero)  
Illumina Cat#RS-122-2201  
Pierce BCA protein assay kit  Thermo Fisher Cat#23225  
SuperScript III First-Strand 
Synthesis System 
Invitrogen Cat#18080051 
Protein and RNA Isolation 
System (PARIS) Kit 
Ambion Cat#AM1921 
Glucagon ELISA Mercodia Cat#10-1281-01 
ChIP-IT High Sensitivity kit Active Motif Cat#53040 
Deposited Data 
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Raw and processed e15.5 
embryonic mouse pancreas 
RNA-sequencing data 
This study GEO: GSE122033 
Raw and processed 12-week-old 
adult mouse islets RNA-
sequencing data 
This study GEO: GSE122033 
Raw and processed 6-week-old 
Paupar WT and KO RNA-
sequencing data 
This study GEO: GSE121884 
ENCODE RNA-sequencing data ENCODE Project 
Consortium. 2012 
PRJNA66167 
RNA-seq FACS purified mouse 
alpha and beta cells 
DiGruccio et al., 2015 GEO: GSE80673 
RNA-seq FACS purified human 
alpha and beta cells 
Ackermann et al., 2016 GEO: GSE76268 
 
Experimental Models: Cell Lines 
alpha TC1 clone 6 (TC) cells  American Type Culture 
Collection 
CRL-2934 
Mouse Insulinoma (MIN6) cells Miyazaki et al., 1990 N/A 
Experimental Models: Organisms/Strains 
Paupartm(H2BGFP)Suss This study N/A 
C57BL/6J Jackson Laboratories Cat#000664 
FLPe transgenic mice Jackson Laboratories Cat#003946 
Oligonucleotides  
Genotyping primers This study Table 2-4 
smFISH probes This study (IDT) Table 2-4 
Antisense Oligonucleotide 
(ASO) sequences 
This study (IDT) Table 2-4 
qRT-PCR primers This study Table 2-4 
CHART capture 
oligonucleotides (COs) 
This study (IDT) Table 2-4 
ChIP-qPCR primers Keller et al 2007; Schaffer 
et al 2013; Menéndez-
Gutiérrez et al. 2015 
Table 2-4 
Pax6 TaqMan AOD Thermo Fisher Mm00443081_m1 
Glucagon TaqMan AOD Thermo Fisher Mm00801712_m1 
MafB TaqMan AOD Thermo Fisher Mm00627481_s1 
Arx TaqMan AOD Thermo Fisher Mm00545903_m1 
NeuroD1 TaqMan AOD Thermo Fisher Mm01946604_s1 
Foxa2 TaqMan AOD Thermo Fisher Mm01976556_s1 
Recombinant DNA 
Paupar BAC clone BAC-PAC resources RP23-465J7 
H2B:GFP Kanda et al., 1998 Addgene Cat#11680 
pL451 Nam and Benezra, 2009 Addgene Cat#22687 
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pMCS-DTA Generous gift from Kosuke 
Yusa, Osaka University, 
Japan 
N/A 
Software and Algorithms 






GraphPad Prism 7 GraphPad Software  https://www.graphpad.com
/scientific-software/prism/  
ImageJ NIH https://imagej.nih.gov/ij/  
Photoshop CC 2018  Adobe N/A 
Illustrator CC 2018 Adobe N/A 
R Software Package 3.3.1  The R Foundation https://www.r-project.org/  
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CHAPTER 3: Conclusions and Future Perspectives 
 
Understanding the mechanisms underlying pancreatic islet cell development and function has 
important implications for the discovery of new therapies for diabetes. For my thesis work, I 
conducted comparative transcriptome analyses between embryonic mouse pancreas and adult 
mouse islets and identified several pancreatic lncRNAs that lie in close proximity to essential 
pancreatic transcription factors, including the Pax6-associated lncRNA Paupar. I demonstrated 
that Paupar is enriched in glucagon-producing alpha cells where it promotes the alternative 
splicing of Pax6 to an isoform required for activation of essential alpha cell genes. Consistently, 
deletion of Paupar in mice caused dysregulation of PAX6 alpha cell target genes and 
corresponding alpha cell dysfunction, including blunted glucagon secretion. Taken together, my 
findings illustrate a distinct mechanism by which a pancreatic lncRNA can coordinate glucose 
homeostasis by cell-specific regulation of a broadly expressed transcription factor. In this 
chapter, I will discuss the implications of these findings, caveats of our experimental method, 
and research questions that remain.  
 
The lncRNA Paupar: illustrating challenges and opportunities 
Paupar was first identified in neuroblastoma N2A cells as a single exon lncRNA that regulated 
genes independently and through direct interaction with PAX6 (Vance et al., 2014). In fact, part 
of the motivation for focusing on Paupar and not other pancreatic lncRNA candidates was that 
several molecular characteristics of Paupar had already been experimentally determined. 
Interestingly, even though PAX6 has a well-established role in the pancreas, the authors of the 
original Paupar study did not include any pancreatic tissues in their expression panel. This 
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highlights one of the many challenges in studying lncRNAs in the context of pancreatic islets: 
(1) isolation of high quality RNA from the pancreas is technically difficult given that the 
pancreas is one of the richest sources of RNases; (2) pancreatic tissues are therefore rarely 
included in expression panels used in individual studies or in publically available databases, such 
as BioGPS and BodyMap; (3) even if the pancreas is in included in a tissue panel, it is often as 
whole pancreas; (4) islets of Langerhans constitute only ~1-2% of pancreas volume; and (5) 
lncRNAs are expressed at low levels (an average log10 fold lower than protein coding genes). 
Taken together, these issues likely contributed to the absence of pancreatic tissues in the Vance 
study and many other existing studies documenting the tissue specificity of lncRNAs. 
 
When we conducted our own expression analyses, we found that Paupar was most highly 
enriched in pancreatic islets compared to all other tissues examined, including the eye, brain, and 
N2A cells. Surprisingly, unbiased analysis of the N2A transcriptome showed almost no reads 
mapping to the Paupar locus. In contrast, in the adult islet transcriptome there was robust signal 
at the Paupar locus. Furthermore, unlike what was reported in N2A cells, in adult islets Paupar 
has three exons and two introns. We also discovered that within alpha cells Paupar does not 
directly interact with PAX6, nor does it regulate Pax6 expression at the transcript level. These 
discrepancies between our findings and those published by Vance and colleagues possibly reflect 
tissue-specific regulation and function. Importantly, these inconsistencies highlight both the 
importance of identifying the right cell type in which to analyze lncRNA function and the benefit 
of rigorous and unbiased techniques to investigate lncRNA expression and function.  
 
Noncoding RNAs  
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While my thesis work focused on lncRNAs, other types of ncRNAs paved the way for our 
understanding of RNA-mediated gene regulation. The last decade of the 20th century witnessed 
the birth of the ncRNA revolution, as the first indications of a broad layer of gene regulation 
ncRNAs began to take shape. In fact, ncRNAs had already been implicated in gene expression; 
in the 1950s the central role of ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs) in protein 
synthesis was firmly established. However, it was not until the early 1980s that the first ncRNAs, 
the small nuclear RNAs (snRNAs), emerged as possible participants in the excision of introns. 
After their acceptance as building blocks of the spliceosome, the revolution gained huge 
momentum in the 1990's, when puzzling observations in plants, worms, and flies culminated in 
the revelation that exogenously supplied ncRNAs could silence the expression of just about any 
gene of interest through a process aptly named RNA interference (RNAi). Research on these 
small ncRNAs, now called microRNAs (miRNAs), has shown that these endogenous ~23 nt 
RNAs play important gene-regulatory roles by pairing to mRNAs to direct their 
posttranscriptional repression (Bartel 2009). The comparison between miRNAs and lncRNAs 
activities can tell us much about their respective functions. MicroRNAs are highly conserved 
across species, likely because their sequence directly determines their downstream mRNA target. 
In contrast, most lncRNAs are poorly conserved across species, at least at the nucleotide level, 
likely because they only require short sequences of conservation to maintain secondary structures 
and interact with target factors. In terms of length, as their name suggests, lncRNAs are much 
longer than miRNAs, allowing them to have multiple binding motifs for DNA, RNA, and 
protein. Furthermore, the evolutionary purpose of miRNAs compared to lncRNAs needs to be 
considered. The metazoan miRNA pathway appears to have been present in the last common 
ancestor of eukaryotes and continues to defend against viruses and transposons in many 
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eukaryotes (Bartel 2009). Given the well-established role of miRNAs in developmental biology, 
perhaps it was important for organisms to evolve a method to reliably inhibit gene expression 
during cell specification. There are also many more identified lncRNA genes than there are 
miRNAs, and many different modes of molecular functions, which is consistent with lncRNAs 
acting through much more diverse lncRNA regulatory mechanisms required to maintain species 
complexity.   
 
Noncoding RNAs and Species Complexity  
Predictions of the estimated number of protein-coding genes in the human genome prior to 
Human Genome Project ranged from as low as 50,000 to as high as 140,000. To everyone’s 
surprise, sequencing analyses in humans identified only ~20,000 protein-coding genes, similar to 
other vertebrates such as the mouse and chicken. Furthermore, the nematode worm C. elegans, 
which comprises only 1,000 cells, has 50% more annotated protein-coding genes (~19,300 
genes) than far more complex insects (~13,500 genes) and nearly as many genes as currently 
estimated for vertebrates. Moreover, despite their considerable developmental and neurological 
complexity, mammals do not appear to have any more protein-coding genes than plants such as 
A. thaliana (~26,000) and rice (~37,000), or protists such as P. tetraurelia (~40,000) and T. 
thermophila (~27,000). This post-genomic realization that increased developmental complexity 
is not reflected in an increased number of protein-coding genes has been termed the G-value 
paradox (Hahn and Wray, 2002). Part of this paradox can be explained by an increased 
utilization of alternative splicing, as higher organisms utilize alternative splicing mechanisms 
more extensively and in a more complicated manner than lower organisms (Nagasaki et al., 
2005). Indeed, there is ample evidence that complex organisms utilize a wide range of gene 
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regulatory processes in addition to alternative splicing, including chromatin architecture, 
promoter selection, RNA modification and editing, RNA localization, translation, and RNA 
stability (Taft et al., 2007). However, as deep sequencing technologies have been applied to a 
wide-range of organisms, it has become clear that the G-value paradox in complex organisms is 
mostly due to the expansion of cis-acting regulatory elements acting at multiple levels 
(chromatin architecture, transcription, splicing, mRNA translation, and RNA stability), and the 
expansion of non-protein-coding genes specifying ncRNAs that fulfill a wide range of regulatory 
functions (Taft et al., 2007). This concept has interesting relevance for my thesis work on 
Paupar and PAX6. Specifically, Pax6 is highly conserved across bilaterian species, with an 
established regulatory role in Drosophila (eyeless), C. elegans (Pax-6), Xenopus (pax6), mice 
(Pax6), and humans (PAX6). In contrast, the lncRNA Paupar appears to be conserved only in 
placental mammals. Taken together with my findings, the presence of a ncRNA (Paupar) in 
more complex species enables PAX6 to achieve more specialized and diverse functions than 
required in less complex organisms.   
 
LncRNAs, transcription factors, and alternative splicing 
Francis Crick’s central dogma of molecular biology inspired decades of research structured 
around the idea that RNA served merely as a messenger between DNA and protein (Crick, 
1970). As a result, most cellular processes were studied in a protein-centric manner. This 
included the regulation of gene expression, which can be divided into two major categories: 
transcription and translation. Both of these processes tightly control how much of each gene gets 
expressed in a specific cell type at a specific point in time. Prior to the discovery of regulatory 
noncoding RNAs, research focused on how proteins orchestrate proper transcription and 
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translation. Remarkably, in the past decade, lncRNAs have emerged as essential regulators of 
basically every level of gene expression. For my thesis work, this posed a challenge in that 
mechanistically, there was no guidelines dictating which pathways might be involved. 
Conversely, the multitude of possible lncRNA functions made this project incredibly exciting at 
every turn. This was especially true for our discovery that Paupar was involved in alternative 
splicing.  
 
In the pre-genomics era, alternative splicing (AS) of a gene was considered an unusual event. 
However, next generation RNA-seq identified that ~95% of multi-exon human genes are 
alternatively spliced (Pan et al., 2008; Wang et al., 2008), suggesting AS is a key mechanism that 
may underlie the diversification of proteins encoded in the mammalian genome. Such 
diversification may be essential for biologic complexity, because the number of protein coding 
genes is lower than predicted before the genome sequence was known (Kim et al., 2014; Lander 
et al., 2001). Recently, there has been increasing interest in the role of AS in human diseases, 
including the dysfunction of islet endocrine cells in diabetes (Juan-Mateu et al., 2015). There are 
also several studies implicating lncRNAs in different aspects of the AS pathway; however, these 
studies mainly focused on the role of lncRNAs in forming nuclear structures important for AS 
(nuclear speckles and paraspeckles), instead of identifying downstream alternatively spliced 
genes (Tripathi et al., 2010; West et al., 2014). The establishment of lncRNAs in AS is especially 
interesting from an evolutionary perspective for several reasons; lncRNAs are very cell type 
specific, allowing for different AS patterns in different cell types; lncRNAs bind easily to other 
RNA molecules; and lncRNAs are more abundant in complex species and can therefore handle 
the increased need for highly specialized splicing machinery. 
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Following our identification of several SRSF proteins as potential Paupar binding partners 
(Chapter 2), we used an unbiased strategy to identify possible downstream targets of Paupar-
mediated alternative splicing. I initially analyzed the RNA-seq dataset from Paupar WT versus 
Paupar KO islets with the goal of trying to find differentially spliced genes that could explain 
the alpha cell defect seen in Paupar KO mice (data not shown). While this analysis yielded a 
large number of significantly alternatively spliced genes, none stood out genes capable of 
explaining the Paupar KO phenotype. We then took a step back and hypothesized that if Paupar 
was indeed involved in alternative splicing, it was likely controlling the splicing of a gene 
required for alpha cell development and function. Since my previous splicing analysis was done 
on whole islets, it was possible that the non-alpha islet cell types were masking changes in alpha 
cell genes. To circumvent this technical issue, I analyzed published RNA-seq datasets from 
FACS purified mouse alpha and beta cells (DiGruccio et al., 2016). Surprisingly, Pax6 emerged 
as one of the most highly alternatively spliced genes in alpha versus beta cells. This was 
especially exciting not only because of Paupar’s genomic proximity to Pax6, but also because 
PAX6 is a classic example of a pancreatic transcription factor that has unique regulatory 
functions in different islet cell types. For example, several studies have shown that PAX6 has 
distinct regulatory targets in alpha cells compared to beta cells (Gosmain et al., 2007; Gosmain et 
al., 2007). We therefore initially hypothesized that the Pax6 5a isoform was the “alpha cell” 
isoform and that the canonical Pax6 isoform was the “beta cell” isoform. Yet, expression 
analyses in alphaTC cells showed the presence of both Pax6 isoforms, which suggested that each 
isoform had unique intracellular functions, rather than unique intercellular functions. These 
findings also suggested that perhaps the relative ratio of each isoform is critical for proper gene 
regulation. This fit well with recent work from Yuval Dor’s lab, which demonstrated that PAX6 
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acts as both a repressor and an activator within pancreatic beta cells (Swisa et al., 2017): PAX6 
activated canonical beta cell genes, such as Ins2, MafA, and Nkx6-1, and repressed beta cell 
disallowed genes, such as Gcg and Ghrl.  
 
There were two barriers to teasing out of the function of each Pax6 isoform. First, we could only 
quantify the expression of the Pax6 5a isoform, which produced a single qRT-PCR product. In 
contrast, qRT-PCR of the canonical Pax6 isoform amplified both isoforms. Second, 
commercially available PAX6 antibodies recognize both isoforms, meaning that we had to infer 
PAX6 5a activation of Gcg and MafB based on reduced expression levels. To summarize our 
findings from Chapter 2, we next showed that in alpha cells, Paupar promotes the alternative 
splicing of Pax6 pre-mRNA to the Pax6 5a isoform, which in turn is required for the activation 
of essential alpha cell genes. These findings have several implications for our understanding of 
the mechanisms underlying regulation of gene expression. First, methods used to understand 
lncRNA function should be as unbiased as possible. LncRNAs can physically interact with 
DNA, other RNAs, and protein, and although these sequencing and proteomic experiments can 
be costly and time-consuming, visualizing the lncRNA interactome will provide the lncRNA 
field with the information it needs to build an evidence-based classification system. Second, 
differential expression analysis does not always tell the whole story behind a complex 
phenotype. Prior to our discovery that Paupar interacted with splicing factors, we had ruled out 
that Paupar regulated Pax6 because we did not see misregulation of Pax6 in Paupar-deficient 
cells at the whole gene level. This study taught me how incredibly complex biology can be and 
how important it is to allow the data to inform the hypothesis and not the other way around. 
Finally, this study adds to the foundation of knowledge showing that lncRNAs are key regulators 
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of gene expression, and provides early evidence that lncRNAs are essential for islet development 
and function. Furthermore, I hope that these findings motivate all scientists, even the skeptics, to 
reexamine their biological questions in the context of a role for RNA.  
 
Future directions 
My thesis furthered our understanding of the mechanisms mediating alpha cell development and 
function; however, several important research questions remain. First, while Paupar confers the 
alpha cell specific function on Pax6, what is the mechanism underlying the cell specific 
expression of Paupar? In other words, what regulates Paupar? The onset of Paupar expression 
during alpha cell maturation suggests that Paupar activation is mediated by a maturation factor. 
Interestingly, establishment and maintenance of alpha and beta cell identity is regulated by a 
complex interplay of transcription factors (Benner et al., 2014). Comparative transcriptome 
analyses of postnatal maturing alpha and beta cells showed that immature alpha cells are first 
marked by Arx, Isl1, NeuroD1, and Pax6 (Benner et al., 2014). A few days later, maturation 
induces the expression of Gcg, Irx1, Irx2, MafB, and Brn4 (Benner et al., 2014). Our findings 
that Paupar activates the expression of Gcg and MafB suggests that activation of Paupar occurs 
in early immature alpha cells, possibly by the transcription factors Arx, Isl1, NeuroD1, or Pax6. 
Future experiments could assess Paupar expression following knockdown of these transcription 
factors in alphaTCs. We could also use bioinformatics to look for transcription factor binding 
sites in the putative Paupar promoter. Unfortunately, information that may elucidate alpha cell 
specific promoters and enhancers, such as ChIP-seq for histone marks, is currently unavailable 
for islet alpha cells. Hopefully this will change soon with the increased attention on islet alpha 
cells in diabetes and improved sequencing technologies better suited for rare cell populations. 
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A major goal of our research is to better understand and treat diabetes in humans; however, how 
well our findings in mice translate to humans is not always clear. One of the characteristics of 
Paupar that suggested it warranted further study was its high level of conservation in humans: 
Paupar is conserved both syntentically and by a majority (84%) of its nucleotide sequence. I 
have confirmed that PAUPAR is expressed in human islets, but it seems to exhibit slightly higher 
expression in beta cells compared to alpha cells (data not shown). This finding is interesting 
given that unlike in mice, MAFB is expressed in both human alpha and beta cells. Perhaps the 
mechanism of Paupar-mediated activation of MafB is conserved in humans and that is why 
Paupar is also expressed in beta cells. Future experiments could test this by knocking down 
Paupar in the EndoB1C human beta cell line or during in vitro hESC to beta cell differentiation. 
Experiments using the latter would also allow us to test whether human PAUPAR was required 
for the specification of human alpha and/or beta cells.    
 
LncRNAs have been shown to be attractive candidates for drug targeting, which could be 
exploited for developing new diabetes therapies. For example, lncRNAs can be targeted by 
antisense oligonucleotides (ASOs), which is technically simpler than small molecule screening 
or inhibitory antibody development. Furthermore, the highly tissue specific expression of 
lncRNAs also allows the use of lower doses of targeting molecules, thus alleviating drug 
toxicity. In the context of Paupar, due to the recently renewed appreciation of the role of 
hyperglucagonemia in diabetes (Brissova et al., 2018), there is a great interest in diabetes 
therapies that can reduce glucagon secretion. Significantly, our finding that knockdown of 
Paupar causes reduced glucagon secretion in vivo suggests reducing Paupar in diabetic islets 
could be a promising method to reduce diabetic hyperglycemia. As previously mentioned, we 
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would first have to show that Paupar-mediated regulation of glucagon secretion is conserved in 
humans. We could then knockdown Paupar in human diabetic islets and test whether this 
corrected hyperglucagonemia. Taken together, Paupar is an appealing gene candidate for 
specific treatment of hyperglycemia seen in diabetes.   
 
Concluding Remarks 
Noncoding RNAs are increasingly recognized as essential regulators of a wide range of 
biological processes. LncRNAs are the most abundant type of ncRNA and a large number of 
islet-specific lncRNAs have been identified; however, their functional characterization in the 
pancreas is lacking. During my thesis work, I conducted extensive molecular and functional 
characterization of an alpha cell enriched lncRNA. My findings suggest that lncRNAs could 
represent important cell restricted therapeutic targets to regulate cell-specific functions of more 
widely expressed proteins. Expansion of these findings to additional lncRNAs will further our 
understanding of islet development and function and help identify novel therapeutic targets for 
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Identification of alternatively spliced genes between alpha and beta cell transcriptomes  
 
All experiments described in the Appendix were conceived and designed by Ruth Singer with 
guidance from Lori Sussel. Ruth Singer performed all analyses described in this section. 
 
Introduction 
Pre-mRNA alternative splicing (AS) is a key post-transcriptional regulatory mechanism that 
affects gene expression, acting as a major generator of proteomic diversity (Juan-Mateu, 2016). 
This process regulates the incorporation of alternative sets of exons into mature mRNA 
molecules, allowing single genes to produce multiple, structurally distinct mRNA and protein 
isoforms. This tightly regulated process provides cells with the ability to rapidly adapt their 
transcriptome and proteome in response to intra and extracellular cues. Furthermore, the 
prevalence and extent of AS correlates with organismal complexity, suggesting that AS plays a 
key role for the development of complex phenotypic traits during evolution (Kim et al, 2007). 
AS regulation plays an important role in virtually all biological processes, including cell growth 
and death, development stage, pluripotency, differentiation, circadian rhythms, response to 
stimuli and disease. While some studies have suggested a role for AS in the development of 
T1DM (Juan-Mateu, 2016), genes that undergo AS are only beginning to gain attention in the 
field of islet biology. Given our findings described in Chapter 2, that Paupar interacts with 
several splicing factors, we decided to analyze alpha and beta cells isolated from mouse and 
human islets. Through these analyses, we hoped to determine differentially spliced genes that 
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Replicate Multivariate Analysis of Transcript Splicing (rMATS) is a computational tool to detect 
differential alternative splicing events from RNA-Seq data (Shen et al., 2014). The statistical 
model of rMATS calculates the p-value and false discovery rate (FDR) that the difference in the 
isoform ratio of a gene between two experimental conditions exceeds a statistical threshold. The 
rMATS algorithm can automatically detect and analyze alternative splicing events corresponding 
to all major types of alternative splicing patterns, including 5’ alternative splice site (5’ASS), 3’ 
alternative splice site (3’ASS), mutually exclusive exons (MXE), skipped exon (SE), and 
retained intron (RI) (Figure Appendix-1). I analyzed 2 different datasets using rMATS; FACS 
purified mouse alpha versus beta cells (DiGruccio et al., 2016) and FACS purified human alpha 
versus beta cells (Ackermann et al., 2016). For these analyses, I used a cutoff p-value of < 0.05 
to determine significantly differentially spliced genes between alpha and beta cells.  
 
Results 
Differently spliced genes in mouse alpha versus beta cells 
To identify genes that are differently spliced between mouse alpha and beta cells, I performed 
rMATS analyses on RNA-seq data from FACS purified cell populations (DiGruccio et al., 2015). 
This bioinformatic analyses yielded 2555 alternatively spliced genes (p-value < 0.05) (Figure 
Appendix-2). Interestingly, the majority of splicing events were skipped exons (1034 genes or 
40.47%), followed by retained intron (899 genes or 35.19%), 3’ ASS (319 genes 12.49%), 5’ 
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ASS (237 genes or 9.28%), and MXE (66 genes or 2.58%). Only the top 600 alternatively 
spliced genes (for space considerations) and information about their loci and statistical 
significance are listed in Table Appendix-1.  
 
Differently spliced genes in human alpha versus beta cells 
To identify genes that are differently spliced between mouse alpha and beta cells, I performed 
rMATS analyses on RNA-seq data from FACS purified cell populations (Ackermann et al., 
2016). This bioinformatic analyses yielded 588 alternatively spliced genes (p-value < 0.05) 
(Figure Appendix-2). Unlike the mouse data, the majority of splicing events were retained 
introns (236 genes or 40.14%), followed by skipped exons (205 genes or 34.867%), 5’ ASS (63 
genes or 10.71%), 3’ ASS (60 genes 10.20%), and MXE (24 genes or 4.08%). All 588 
alternatively spliced genes and information about their loci and statistical significance are listed 
in Table Appendix-2.  
 
Discussion  
Our findings described in this section establish alternative splicing as a mechanism contributing 
to transcriptional diversity between islet alpha and beta cells. As previously mentioned, we 
implanted these analyses to further understand the alpha cell dysfunction seen in Paupar KO 
mice. We were surprised and excited to discover that Pax6 was one of the genes alternatively 
spliced between mouse alpha and beta cells. Specifically, alpha cells are enriched for Pax6 5a 
isoform, compared to the Pax6 isoform. While some studies in cell lines have shown that the two 
splice variants of PAX6 bind distinct DNA motifs (Epstein et al., 1994; Chauhan et al., 2004), 
the regulatory role of each isoform in islets had yet to be described. Importantly, these analyses 
for the basis of our mechanistic experiments showing that Paupar promotes the alternative 
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splicing of Pax6 to the Pax6 5a isoform, which is in turn required for the activation of alpha cell 
genes.  
  
These analyses also uncover surprising differences between human and mouse islet endocrine 
cells. For example, Pax6 is significantly alternatively spliced between mouse alpha and beta 
cells, but not in human alpha versus beta cells. Furthermore, the number of alternative spliced 
genes between human alpha and beta cells (588) was much lower than the number of genes 
obtained from mouse alpha and beta cells (2555) (Figure Appendix-2), which could be due to 
cellular heterogeneity of different human donors leading to larger statistical variation. For my 
thesis work, downstream analyses of this data was limited to Pax6; however, this list of 
alternatively spliced genes warrant further investigation. Taken together, unveiling the role of AS 
in specification of cellular identity will increase our understanding of islet function and 





Figure Appendix-1. Regulation of alternative splicing (AS). Major types of AS events. Exons 
are represented by boxes and introns by solid lines; constitutive exons are shown in yellow while 
alternative exons are shown in red or blue; dashed lines represent different splicing events. 




Figure Appendix-2. Breakdown of significantly spliced genes in mouse and human alpha 
and beta cells by type of splicing event. 5’ alternative splice site (5’ASS), 3’ alternative splice 








Table Appendix-1. List of genes significantly alternatively spliced between mouse alpha 
and beta cells. Only the top 600 genes are included below. 
Splicin
g Event 
Gene Chr Strand Exon_Start Exon_End PValue FDR 
RI Pafah1b1 chr11 - 74673949 74679614 0.000000 0.000000 
RI Tmem57 chr4 - 134802758 134806691 0.000000 0.000000 
RI Anapc5 chr5 - 122799338 122800593 0.000000 0.000000 
RI Sec11c chr18 + 65812664 65814957 0.000000 0.000000 
RI Eif4a2 chr16 + 23110579 23111263 0.000000 0.000000 
RI Eif4a2 chr16 + 23111125 23111592 0.000000 0.000000 
RI Rbm3 chrX - 8143847 8144679 0.000000 0.000000 
RI Enpp5 chr17 + 44082743 44086567 0.000000 0.000000 
RI Maged1 chrX - 94537675 94538065 0.000000 0.000000 
RI Atp6v0a1 chr11 + 101027266 101029258 0.000000 0.000000 
SE Bicdl1 chr5 - 115651155 115651264 0.000000 0.000000 
SE Rps24 chr14 + 24495429 24495449 0.000000 0.000000 
SE Rbm3 chrX - 8144174 8144445 0.000000 0.000000 
SE Ptprf chr4 - 118218011 118218044 0.000000 0.000000 
SE Gnas chr2 + 174336746 174336791 0.000000 0.000000 
RI Mt1 chr8 + 94179822 94180327 0.000000 0.000000 
SE Srsf1 chr11 + 88049411 88049598 0.000000 0.000000 
SE Clta chr4 + 44031399 44031435 0.000000 0.000000 
RI Rab3gap2 chr1 + 185275911 185277221 0.000000 0.000000 
5' ASS Gnas chr2 + 174328107 174330434 0.000000 0.000000 
RI Copa chr1 + 172091163 172092354 0.000000 0.000000 
RI Bcas2 chr3 + 103175618 103177419 0.000000 0.000000 
RI Celf3 chr3 + 94486793 94487284 0.000000 0.000000 
RI Sec31a chr5 - 100363376 100363947 0.000000 0.000000 
RI Abcc8 chr7 - 46107237 46108214 0.000000 0.000000 
RI Mapkapk3 chr9 - 107262422 107263764 0.000000 0.000000 
SE Morf4l2 chrX - 136740945 136741119 0.000000 0.000000 
RI Pafah1b1 chr11 - 74684405 74686064 0.000000 0.000000 
MXE Slc7a2 chr8 + 40908055 40908195 0.000000 0.000000 
RI Mpp3 chr11 - 102023701 102025154 0.000000 0.000000 
RI Dnaja1 chr4 + 40726104 40728183 0.000000 0.000000 
RI Nrip2 chr6 + 128404934 128406572 0.000000 0.000000 
RI Eif4a2 chr16 + 23109984 23110343 0.000000 0.000000 
SE Nptn chr9 + 58618662 58619010 0.000000 0.000000 
RI St7 chr6 + 17850356 17852412 0.000000 0.000000 
RI Arglu1 chr8 - 8681383 8683973 0.000000 0.000000 
RI Dcaf6 chr1 - 165338187 165340023 0.000000 0.000000 
RI Napb chr2 - 148707158 148709433 0.000000 0.000000 
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SE Sorbs2 chr8 + 45794977 45796558 0.000000 0.000000 
3' ASS Banp chr8 + 122007090 122007162 0.000000 0.000000 
RI Tmem87b chr2 + 128845460 128846799 0.000000 0.000000 
RI 43350 chr9 + 25303716 25306265 0.000000 0.000000 
SE Peg3 chr7 - 6712949 6713012 0.000000 0.000000 
RI Thoc7 chr14 - 13953410 13954656 0.000000 0.000000 
RI Klhdc10 chr6 + 30447940 30449630 0.000000 0.000000 
SE Syne2 chr12 + 76100027 76100096 0.000000 0.000000 
SE Stox1 chr10 - 62724262 62724432 0.000000 0.000000 
RI Ugdh chr5 - 65420248 65422782 0.000000 0.000000 
SE Arglu1 chr8 - 8681840 8681948 0.000000 0.000000 
RI Nupl1 chr14 - 60240773 60242657 0.000000 0.000000 
SE Uqcr10 chr11 - 4703903 4703989 0.000000 0.000000 
5' ASS Piga chrX + 164422583 164423672 0.000000 0.000000 
SE Clta chr4 + 44030214 44030268 0.000000 0.000000 
RI Hypk chr2 + 121457645 121458043 0.000000 0.000000 
RI Snx5 chr2 - 144257099 144257993 0.000000 0.000000 
3' ASS Ogg1 chr6 + 113329145 113329408 0.000000 0.000000 
RI Eif5b chr1 + 38050186 38051284 0.000000 0.000000 
SE Khk chr5 + 30927021 30927156 0.000000 0.000000 
RI Becn1 chr11 - 101294000 101295164 0.000000 0.000000 
RI 43352 chr11 + 117356612 117359470 0.000000 0.000000 
RI Cdk4 chr10 + 127065154 127066003 0.000000 0.000000 
RI Srprb chr9 - 103197537 103198866 0.000000 0.000000 
RI Becn1 chr11 - 101289782 101290499 0.000000 0.000000 
RI Gdpd3 chr7 + 126770987 126771213 0.000000 0.000000 
RI Eif4a1 chr11 - 69667694 69668111 0.000000 0.000000 
MXE Khk chr5 + 30926687 30926822 0.000000 0.000000 
RI Krt7 chr15 + 101413968 101416281 0.000000 0.000000 
RI Fam32a chr8 + 72219940 72221981 0.000000 0.000000 
RI Abcc8 chr7 - 46105808 46106688 0.000000 0.000000 
RI Adipor1 chr1 + 134423957 134424922 0.000000 0.000000 
RI Txnrd1 chr10 + 82881722 82884006 0.000000 0.000000 
RI Eif4a1 chr11 - 69668195 69668548 0.000000 0.000000 
RI Pmpcb chr5 + 21743378 21746090 0.000000 0.000000 
RI Clcn3 chr8 - 60922789 60927418 0.000000 0.000000 
MXE Slc39a14 chr14 - 70313600 70313770 0.000000 0.000000 
SE Ctage5 chr12 + 59144698 59144770 0.000000 0.000000 
RI Atg4b chr1 + 93775627 93778364 0.000000 0.000000 
RI Anxa11 chr14 + 25872511 25874031 0.000000 0.000000 
SE Rps19 chr7 + 24886106 24886187 0.000000 0.000000 
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SE Shc1 chr3 + 89424189 89424243 0.000000 0.000000 
5' ASS Sri chr5 + 8062383 8063000 0.000000 0.000000 
3' ASS Tpm1 chr9 - 67022592 67024565 0.000000 0.000001 
RI Mbtps1 chr8 - 119538843 119541694 0.000000 0.000000 
RI M6pr chr6 + 122313258 122315166 0.000000 0.000000 
RI Eif4a2 chr16 + 23108587 23108851 0.000000 0.000000 
RI Ppib chr9 + 66062988 66065671 0.000000 0.000000 
RI Ipo7 chr7 + 110044617 110046251 0.000000 0.000000 
SE 43167 chr6 + 116401336 116402182 0.000000 0.000000 
5' ASS Nop56 chr2 + 130277031 130277314 0.000000 0.000000 
SE Usp54 chr14 - 20581456 20581627 0.000000 0.000000 
SE Rab12 chr17 - 66504988 66505178 0.000000 0.000000 
3' ASS Arid5a chr1 + 36317203 36317662 0.000000 0.000001 
SE Epb41l3 chr17 + 69283884 69284007 0.000000 0.000001 
MXE Slc25a3 chr10 - 91121921 91122043 0.000000 0.000000 
RI Gdi1 chrX + 74309075 74310134 0.000000 0.000000 
RI Lmbrd1 chr1 + 24743882 24744358 0.000000 0.000000 
RI Hmgn3 chr9 - 83109947 83111106 0.000000 0.000000 
3' ASS Nsun3 chr16 - 62776287 62776631 0.000000 0.000001 
SE Ptprf chr4 - 118227818 118227845 0.000000 0.000001 
SE 2310035C23Rik chr1 + 105741012 105741095 0.000000 0.000001 
RI Rnf167 chr11 + 70649674 70650017 0.000000 0.000000 
SE Lrch3 chr16 + 32995805 32995913 0.000000 0.000001 
RI Anapc2 chr2 + 25272914 25273932 0.000000 0.000000 
RI Ptprd chr4 - 76085460 76086599 0.000000 0.000000 
RI Ddx5 chr11 - 106782468 106784018 0.000000 0.000000 
3' ASS Eef1b2 chr1 + 63178022 63178565 0.000000 0.000002 
RI Eef2 chr10 + 81181227 81181625 0.000000 0.000000 
SE Atp6v0a1 chr11 + 101049458 101049476 0.000000 0.000002 
SE Oas1b chr5 + 120813210 120813362 0.000000 0.000002 
RI Srsf5 chr12 + 80947795 80949168 0.000000 0.000000 
SE Psme4 chr11 + 30866035 30866279 0.000000 0.000002 
SE R3hdm2 chr10 + 127462187 127462283 0.000000 0.000002 
RI Mrps10 chr17 + 47372575 47375109 0.000000 0.000000 
SE Ppfibp1 chr6 + 146999661 146999694 0.000000 0.000003 
RI Sharpin chr15 - 76348085 76348435 0.000000 0.000001 
SE Hmgn3 chr9 - 83110787 83110874 0.000000 0.000004 
SE Gm26881 chr4 + 43052944 43053051 0.000000 0.000004 
RI Srsf6 chr2 + 162931993 162933550 0.000000 0.000001 
SE Khk chr5 + 30926687 30926822 0.000000 0.000004 
RI Adam8 chr7 - 139987178 139987737 0.000000 0.000001 
186 
SE Baz2b chr2 - 59983781 59983970 0.000000 0.000005 
RI Bcas2 chr3 + 103174339 103177419 0.000000 0.000001 
SE Spata13 chr14 + 60636367 60636646 0.000000 0.000006 
SE Inpp4a chr1 + 37383338 37383371 0.000000 0.000006 
RI Utp4 chr8 + 106917581 106918805 0.000000 0.000001 
RI Hps1 chr19 - 42756257 42757906 0.000000 0.000001 
RI Ufd1 chr16 + 18826254 18827106 0.000000 0.000001 
RI Trappc11 chr8 - 47513282 47513808 0.000000 0.000001 
RI 0610037L13Rik chr4 + 107894872 107897118 0.000000 0.000001 
RI Taz chrX + 74288177 74288513 0.000000 0.000001 
SE Adgrl1 chr8 + 83924205 83924355 0.000000 0.000008 
RI Pak1ip1 chr13 + 41009447 41011282 0.000000 0.000001 
RI Copg1 chr6 + 87892632 87893953 0.000000 0.000001 
5' ASS Capn7 chr14 + 31360124 31361245 0.000000 0.000012 
RI Dnajc8 chr4 + 132544055 132544751 0.000000 0.000001 
RI Ptpa chr2 + 30438228 30439764 0.000000 0.000001 
RI Bub3 chr7 + 131561536 131563485 0.000000 0.000001 
SE Etl4 chr2 + 20759546 20759651 0.000000 0.000011 
RI Ttc39a chr4 + 109422445 109422942 0.000000 0.000002 
5' ASS Thoc7 chr14 - 13954538 13954656 0.000000 0.000012 
SE Snrnp70 chr7 - 45381824 45383184 0.000000 0.000011 
RI Rnpepl1 chr1 + 92916710 92917746 0.000000 0.000002 
RI Cnbp chr6 - 87845121 87845793 0.000000 0.000002 
5' ASS Gtf2a2 chr9 + 70016818 70017191 0.000000 0.000012 
SE Srsf6 chr2 + 162932814 162933082 0.000000 0.000012 
RI Map1lc3b chr8 + 121593489 121596092 0.000000 0.000002 
5' ASS Firre chrX - 50580580 50580949 0.000000 0.000012 
SE Arhgap21 chr2 - 20853957 20854232 0.000000 0.000013 
RI Nabp1 chr1 - 51477477 51478399 0.000000 0.000002 
RI Apbb1 chr7 - 105565532 105565951 0.000000 0.000002 
SE R3hdm2 chr10 + 127462205 127462283 0.000000 0.000014 
RI N4bp1 chr8 - 86846814 86848554 0.000000 0.000002 
RI Nrip2 chr6 + 128407685 128408932 0.000000 0.000002 
RI Diablo chr5 - 123517736 123518065 0.000000 0.000002 
5' ASS Alkbh8 chr9 + 3335477 3335748 0.000000 0.000015 
5' ASS 2900076A07Rik chr7 + 81523570 81523723 0.000000 0.000015 
RI Aebp2 chr6 + 140650755 140652826 0.000000 0.000003 
RI Txndc9 chr1 - 37993991 37995841 0.000000 0.000003 
RI Tmem214 chr5 + 30871419 30871855 0.000000 0.000003 
SE Spire1 chr18 - 67512840 67512879 0.000000 0.000021 
RI Lss chr10 + 76544464 76545501 0.000000 0.000003 
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RI Stk25 chr1 - 93626050 93627133 0.000000 0.000003 
3' ASS Grin1 chr2 - 25291180 25292484 0.000000 0.000046 
RI Usp7 chr16 - 8697892 8698586 0.000000 0.000004 
SE Ap3d1 chr10 - 80710088 80710292 0.000000 0.000025 
RI Mocs2 chr13 + 114825210 114826281 0.000000 0.000004 
RI Rabggtb chr3 - 153910260 153910888 0.000000 0.000004 
RI Timm10b chr7 + 105640761 105641228 0.000000 0.000004 
3' ASS Celf2 chr2 - 6539704 6546779 0.000000 0.000055 
5' ASS Nabp1 chr1 - 51477721 51478399 0.000000 0.000025 
RI Slc30a9 chr5 + 67342093 67344569 0.000000 0.000005 
RI Gas5 chr1 + 161035982 161036244 0.000000 0.000005 
RI Sppl2b chr10 + 80866499 80868708 0.000000 0.000005 
RI Nub1 chr5 + 24694699 24695590 0.000000 0.000006 
SE Gnas chr2 + 174328107 174330434 0.000000 0.000043 
RI Tmbim1 chr1 - 74291430 74291734 0.000000 0.000006 
RI Arhgef2 chr3 + 88632912 88633367 0.000000 0.000006 
RI Strip1 chr3 - 107615760 107616608 0.000000 0.000006 
SE Orc3 chr4 - 34598982 34599140 0.000000 0.000047 
MXE Slc25a3 chr10 - 91121921 91122043 0.000000 0.000026 
3' ASS Srsf5 chr12 + 80947115 80947381 0.000000 0.000077 
RI Habp4 chr13 + 64182106 64184758 0.000000 0.000007 
RI Rnpepl1 chr1 + 92917146 92917746 0.000000 0.000007 
RI Rundc3a chr11 + 102399614 102400045 0.000000 0.000007 
3' ASS Snrnp70 chr7 - 45380716 45383184 0.000000 0.000078 
RI Sdccag3 chr2 - 26385497 26386063 0.000000 0.000008 
RI Rpl10 chrX + 74271659 74271907 0.000000 0.000008 
RI Zfp940 chr7 - 29846468 29846960 0.000000 0.000008 
RI Mapre3 chr5 + 30862497 30863405 0.000000 0.000008 
SE Armc10 chr5 + 21647307 21647448 0.000000 0.000060 
SE Magi1 chr6 - 93704276 93704360 0.000000 0.000060 
SE Ahi1 chr10 + 21070287 21070543 0.000000 0.000067 
RI Cnn3 chr3 + 121449948 121450358 0.000000 0.000009 
RI Hnrnph1 chr11 + 50379467 50379964 0.000000 0.000009 
SE 1810014B01Rik chr10 + 86688533 86689138 0.000000 0.000067 
RI Med24 chr11 - 98716413 98718142 0.000000 0.000009 
RI Stard7 chr2 + 127284094 127284581 0.000000 0.000010 
SE Srsf3 chr17 + 29039453 29039909 0.000000 0.000068 
RI Gas5 chr1 + 161036207 161036579 0.000001 0.000010 
SE Atp13a3 chr16 - 30321805 30321895 0.000001 0.000068 
SE Srsf6 chr2 + 162932814 162932979 0.000001 0.000068 
SE Nf2 chr11 - 4780577 4780622 0.000001 0.000068 
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RI Dhx30 chr9 - 110115035 110115582 0.000001 0.000010 
RI Neu1 chr17 + 34932565 34934185 0.000001 0.000010 
SE Srrm2 chr17 + 23811816 23812077 0.000001 0.000070 
SE Wbp1 chr6 - 83120771 83120876 0.000001 0.000070 
5' ASS Kat2a chr11 - 100710249 100710636 0.000001 0.000062 
RI Gdi1 chrX + 74307671 74308261 0.000001 0.000012 
SE Plekha1 chr7 + 130904318 130904557 0.000001 0.000081 
3' ASS Crlf2 chr5 - 109555506 109555660 0.000001 0.000139 
RI Hace1 chr10 + 45700953 45709994 0.000001 0.000013 
RI Lrrc56 chr7 + 141196981 141198361 0.000001 0.000014 
RI Cfap20 chr8 - 95422782 95424696 0.000001 0.000015 
3' ASS Tnfsfm13 chr11 - 69684217 69684336 0.000001 0.000148 
RI Srrm1 chr4 - 135344498 135346857 0.000001 0.000015 
SE Elavl4 chr4 - 110255418 110255505 0.000001 0.000106 
RI Zswim8 chr14 + 20719379 20720036 0.000001 0.000016 
SE Itgb3bp chr4 - 99802096 99802232 0.000001 0.000106 
SE Pex5l chr3 - 33024695 33024800 0.000001 0.000106 
RI Ppp1cc chr5 + 122172731 122173280 0.000001 0.000017 
SE Wbp1 chr6 - 83120771 83120873 0.000001 0.000108 
RI Pdhb chr14 - 8171422 8172817 0.000001 0.000018 
RI Slc31a1 chr4 + 62387866 62391769 0.000001 0.000019 
SE Gba chr3 + 89203191 89203360 0.000001 0.000120 
RI Tpr chr1 + 150447511 150449238 0.000001 0.000019 
5' ASS Celf3 chr3 + 94487134 94487388 0.000001 0.000106 
RI Mroh1 chr15 + 76421139 76423835 0.000001 0.000019 
RI Cul5 chr9 - 53632272 53633839 0.000001 0.000019 
RI R3hdm1 chr1 + 128181985 128184654 0.000001 0.000019 
RI Stk16 chr1 + 75212599 75213006 0.000001 0.000020 
SE Wnk1 chr6 - 119953770 119954232 0.000001 0.000130 
SE Mcfd2 chr17 - 87258749 87258881 0.000001 0.000131 
SE Nnat chr2 + 157560447 157560535 0.000001 0.000137 
RI Thoc7 chr14 - 13953410 13954656 0.000001 0.000022 
3' ASS Psap chr10 + 60299091 60299229 0.000001 0.000223 
SE Arid5a chr1 + 36317203 36317324 0.000001 0.000146 
5' ASS Taz chrX + 74288450 74289019 0.000001 0.000133 
SE Atp11a chr8 + 12861639 12861724 0.000001 0.000156 
RI Cops8 chr1 + 90604374 90605512 0.000002 0.000026 
SE Npr2 chr4 + 43643334 43643409 0.000002 0.000165 
RI Orc3 chr4 - 34597307 34598756 0.000002 0.000027 
5' ASS Ccdc84 chr9 - 44413442 44413533 0.000002 0.000138 
RI Xab2 chr8 - 3613158 3613499 0.000002 0.000027 
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RI Trim2 chr3 - 84190512 84192261 0.000002 0.000027 
RI Cacfd1 chr2 + 27018887 27021089 0.000002 0.000028 
RI Xpc chr6 - 91496087 91498190 0.000002 0.000028 
RI Ddx23 chr15 - 98650143 98650818 0.000002 0.000028 
SE Tm2d3 chr7 + 65693865 65693943 0.000002 0.000185 
RI Gas5 chr1 + 161038224 161038539 0.000002 0.000029 
RI Rps18 chr17 - 33952220 33952591 0.000002 0.000029 
RI Nabp1 chr1 - 51477477 51478399 0.000002 0.000029 
RI Vac14 chr8 + 110712747 110715577 0.000002 0.000030 
SE Jade3 chrX + 20487297 20487422 0.000002 0.000200 
RI Timm44 chr8 - 4265225 4266680 0.000002 0.000031 
3' ASS Scnn1b chr7 + 121917349 121917575 0.000002 0.000341 
SE Mynn chr3 + 30612468 30612552 0.000002 0.000218 
5' ASS Nabp1 chr1 - 51477721 51478399 0.000002 0.000176 
RI Smurf1 chr5 - 144880624 144881819 0.000002 0.000035 
RI Cers4 chr8 + 4519462 4520682 0.000002 0.000035 
3' ASS Mrpl4 chr9 + 21007363 21007540 0.000002 0.000351 
SE Scmh1 chr4 + 120462012 120462155 0.000002 0.000236 
SE Zfp322a chr13 - 23362579 23362654 0.000002 0.000236 
RI Anxa11 chr14 + 25874209 25874784 0.000002 0.000038 
RI Fbxw7 chr3 + 84967439 84969301 0.000003 0.000039 
SE Tmem234 chr4 + 129601406 129601625 0.000003 0.000252 
SE Sipa1l1 chr12 + 82422660 82423095 0.000003 0.000252 
RI Flt3l chr7 - 45132227 45134026 0.000003 0.000040 
RI Fancg chr4 - 43006983 43007403 0.000003 0.000041 
RI Celf2 chr2 - 6539704 6547213 0.000003 0.000041 
SE Fdft1 chr14 - 63159237 63159359 0.000003 0.000261 
SE Gas5 chr1 + 161037123 161037164 0.000003 0.000264 
SE Dis3l2 chr1 + 86812511 86812589 0.000003 0.000270 
RI Ist1 chr8 - 109675375 109676850 0.000003 0.000044 
SE Fbxo34 chr14 + 47500793 47500870 0.000003 0.000277 
5' ASS Nabp1 chr1 - 51477824 51478399 0.000003 0.000255 
RI Mau2 chr8 - 70028618 70029235 0.000004 0.000054 
RI Zc3h14 chr12 + 98785317 98785741 0.000004 0.000055 
3' ASS Rnf216 chr5 - 143098378 143098505 0.000004 0.000544 
5' ASS Pts chr9 - 50525152 50525284 0.000004 0.000292 
SE Trrap chr5 + 144810150 144810204 0.000004 0.000377 
RI Idh3g chrX - 73780573 73781030 0.000004 0.000063 
RI Usp5 chr6 - 124816983 124817471 0.000005 0.000067 
RI Lcmt1 chr7 + 123421537 123422798 0.000005 0.000071 
RI Ddx54 chr5 + 120624537 120625844 0.000005 0.000072 
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SE Eno2 chr6 - 124766530 124766664 0.000005 0.000451 
RI Eno2 chr6 - 124762652 124763206 0.000005 0.000074 
3' ASS Mrpl4 chr9 + 21007327 21007540 0.000005 0.000671 
SE Khk chr5 + 30926687 30926822 0.000005 0.000451 
SE Scamp5 chr9 - 57447076 57447233 0.000005 0.000467 
RI Mms19 chr19 - 41949454 41949837 0.000006 0.000080 
RI Mta2 chr19 + 8946266 8946750 0.000006 0.000081 
SE Macf1 chr4 - 123354478 123354580 0.000006 0.000496 
RI Cdk5 chr5 - 24422331 24422558 0.000006 0.000085 
5' ASS Sat1 chrX - 155215119 155215684 0.000006 0.000424 
SE Pcmtd1 chr1 + 7155079 7155271 0.000006 0.000532 
RI Dnajc2 chr5 - 21761540 21763515 0.000006 0.000090 
SE Hnrnpdl chr5 - 100035634 100035739 0.000007 0.000549 
RI Camk2g chr14 - 20764860 20765479 0.000007 0.000093 
SE Nisch chr14 - 31182498 31182640 0.000007 0.000555 
RI Slc35b4 chr6 - 34163588 34166423 0.000007 0.000093 
RI Rhbdf2 chr11 - 116605242 116606232 0.000007 0.000093 
SE Khk chr5 + 30927021 30927156 0.000007 0.000556 
RI Usp11 chrX + 20716746 20717804 0.000007 0.000093 
RI Wdr75 chr1 + 45817262 45818264 0.000007 0.000097 
SE Senp7 chr16 + 56187469 56187570 0.000007 0.000583 
5' ASS Nabp1 chr1 - 51478300 51478399 0.000007 0.000472 
RI Atl2 chr17 - 79850886 79852956 0.000007 0.000099 
RI Mbtps1 chr8 - 119515577 119518279 0.000008 0.000103 
5' ASS 4833420G17Rik chr13 + 119473832 119474194 0.000008 0.000479 
RI Nol11 chr11 - 107180041 107181101 0.000008 0.000105 
SE Atg13 chr2 - 91679919 91679997 0.000008 0.000631 
RI Ppfibp1 chr6 + 147010862 147012518 0.000008 0.000105 
SE Rbm39 chr2 - 156177751 156177906 0.000008 0.000631 
5' ASS Zfp446 chr7 + 12979884 12980993 0.000008 0.000494 
RI Psmd3 chr11 + 98690462 98691019 0.000008 0.000112 
MXE Wnk2 chr13 - 49044373 49044418 0.000008 0.000613 
SE Hps5 chr7 - 46775153 46775284 0.000009 0.000677 
SE Tnk2 chr16 + 32680899 32680995 0.000009 0.000688 
5' ASS Slc25a37 chr14 - 69248882 69249622 0.000009 0.000505 
RI Sf3b1 chr1 - 55014482 55016490 0.000009 0.000125 
5' ASS Pabpc4 chr4 + 123295201 123295321 0.000010 0.000519 
3' ASS Rtel1 chr2 + 181355309 181355552 0.000010 0.001187 
RI Slc25a37 chr14 - 69247580 69249622 0.000010 0.000126 
RI Ddx46 chr13 + 55659019 55660799 0.000010 0.000126 
SE Prr3 chr17 - 35978710 35978781 0.000010 0.000756 
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SE Mtmr14 chr6 + 113277830 113277945 0.000010 0.000756 
SE Sft2d2 chr1 - 165186721 165186888 0.000010 0.000762 
SE Rap1gap chr4 + 137723745 137723823 0.000010 0.000762 
RI Tmem214 chr5 + 30874850 30875886 0.000010 0.000133 
RI Nabp1 chr1 - 51469819 51471411 0.000010 0.000133 
RI Vps11 chr9 - 44353836 44354291 0.000011 0.000135 
SE Josd2 chr7 + 44469982 44470172 0.000011 0.000779 
RI Ipo7 chr7 + 110048944 110049693 0.000011 0.000135 
RI Becn1 chr11 - 101295533 101296316 0.000011 0.000135 
SE Dnajc24 chr2 - 105980981 105981120 0.000011 0.000788 
SE Rbm5 chr9 - 107755852 107755913 0.000011 0.000788 
5' ASS Rnf141 chr7 - 110837076 110837270 0.000011 0.000567 
3' ASS Mtmr7 chr8 - 40554270 40554601 0.000011 0.001280 
SE Mdm1 chr10 + 118156833 118156863 0.000012 0.000832 
5' ASS Angel2 chr1 + 190940873 190941458 0.000012 0.000582 
SE Hnrnpd chr5 - 99962097 99962204 0.000012 0.000844 
3' ASS Mus81 chr19 - 5483634 5483763 0.000012 0.001335 
RI Taz chrX + 74288177 74288513 0.000012 0.000157 
3' ASS Zfp68 chr5 - 138616469 138616614 0.000013 0.001349 
RI Hsd3b7 chr7 + 127801074 127801616 0.000013 0.000162 
SE Pabpc4 chr4 + 123295749 123295836 0.000014 0.000955 
3' ASS Gigyf2 chr1 + 87407534 87407723 0.000014 0.001354 
3' ASS 1500009L16Rik chr10 + 83759592 83759630 0.000014 0.001354 
RI Msmo1 chr8 - 64722463 64723736 0.000014 0.000176 
5' ASS Usp35 chr7 - 97315079 97315178 0.000014 0.000685 
SE Ggps1 chr13 - 14058923 14059211 0.000014 0.001006 
5' ASS Gtf2a2 chr9 + 70016818 70017191 0.000015 0.000687 
SE Mgat1 chr11 + 49251549 49251674 0.000015 0.001024 
SE Rbm6 chr9 - 107861622 107861729 0.000015 0.001025 
SE Tm2d3 chr7 + 65693850 65693943 0.000016 0.001052 
SE Mtmr14 chr6 + 113277789 113277945 0.000016 0.001063 
RI Slc50a1 chr3 - 89269826 89270139 0.000016 0.000197 
RI 1810022K09Rik chr3 - 14606288 14607293 0.000016 0.000197 
RI Rab4b chr7 - 27175778 27176238 0.000017 0.000202 
RI Pigq chr17 - 25931673 25932231 0.000017 0.000203 
3' ASS Dclk2 chr3 - 86816357 86816433 0.000017 0.001565 
SE Anapc16 chr10 - 59996447 59996614 0.000017 0.001159 
5' ASS Trerf1 chr17 + 47319351 47319678 0.000018 0.000789 
RI Ilf2 chr3 + 90486850 90487097 0.000018 0.000218 
SE Ppp2r1b chr9 + 50873196 50873308 0.000018 0.001193 
SE Mcfd2 chr17 - 87264140 87264365 0.000018 0.001196 
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RI Ttc12 chr9 - 49471861 49472543 0.000019 0.000224 
5' ASS Tmem234 chr4 + 129600982 129601243 0.000019 0.000843 
RI Ostf1 chr19 - 18584641 18586625 0.000020 0.000236 
3' ASS Uap1 chr1 - 170147995 170148046 0.000020 0.001755 
RI Rccd1 chr7 - 80320301 80321181 0.000020 0.000242 
SE Entpd5 chr12 - 84399339 84399412 0.000021 0.001336 
SE Atp9b chr18 - 80736811 80736844 0.000021 0.001336 
RI Ufl1 chr4 - 25269027 25270618 0.000021 0.000248 
RI Dusp12 chr1 - 170880129 170881041 0.000021 0.000248 
SE Ctbp2 chr7 - 133025712 133025872 0.000021 0.001340 
SE Nrf1 chr6 + 30140215 30140271 0.000021 0.001340 
SE 43354 chr5 + 93173469 93173537 0.000021 0.001345 
5' ASS Ankrd16 chr2 + 11781476 11781533 0.000022 0.000896 
RI Ipo8 chr6 - 148770682 148775093 0.000022 0.000253 
RI Eif4a1 chr11 - 69668195 69668753 0.000022 0.000253 
RI Pex14 chr4 - 148967523 148970635 0.000022 0.000255 
5' ASS Nfatc1 chr18 - 80635401 80636076 0.000022 0.000896 
SE Mcf2l chr8 + 13013914 13014007 0.000022 0.001392 
RI Myl6 chr10 - 128490860 128492136 0.000023 0.000264 
RI Mat2a chr6 - 72432798 72435114 0.000023 0.000265 
3' ASS Trp53i13 chr11 - 77509075 77509367 0.000023 0.001982 
RI Zranb2 chr3 + 157541699 157543244 0.000024 0.000278 
RI Leng8 chr7 + 4144052 4144813 0.000024 0.000278 
SE Glis3 chr19 - 28540200 28540408 0.000026 0.001579 
RI Cers4 chr8 + 4519462 4520308 0.000026 0.000295 
RI Npepl1 chr2 + 174120543 174121124 0.000026 0.000296 
RI Dcaf11 chr14 + 55565097 55565541 0.000026 0.000297 
RI Trafd1 chr5 - 121373137 121374067 0.000026 0.000297 
RI Napa chr7 + 16113349 16113560 0.000027 0.000299 
SE Os9 chr10 - 127096914 127097079 0.000027 0.001673 
3' ASS Pts chr9 - 50524722 50524964 0.000027 0.002205 
3' ASS 1300002E11Rik chr16 + 21800714 21800836 0.000028 0.002205 
RI Usp19 chr9 + 108493560 108494238 0.000028 0.000308 
MXE Adam22 chr5 - 8095072 8095180 0.000028 0.001745 
SE Samd4 chr14 + 47052849 47053113 0.000030 0.001781 
SE Ctage5 chr12 + 59146335 59146362 0.000030 0.001781 
SE Slmap chr14 - 26416202 26416292 0.000030 0.001781 
RI Tcirg1 chr19 - 3901890 3902556 0.000030 0.000330 
SE Srrt chr5 - 137301317 137301647 0.000031 0.001802 
RI Stau1 chr2 - 166951270 166952472 0.000031 0.000338 
SE Dctn4 chr18 + 60545356 60545377 0.000031 0.001823 
193 
RI Faah chr4 - 115999498 116000088 0.000031 0.000342 
3' ASS Vps50 chr6 + 3601367 3603315 0.000031 0.002413 
RI Mtfr1l chr4 - 134530274 134530789 0.000033 0.000361 
RI Ncaph2 chr15 + 89370394 89370675 0.000033 0.000361 
RI Cap1 chr4 - 122862622 122863085 0.000034 0.000363 
SE Epb41l3 chr17 + 69283884 69284007 0.000034 0.001959 
5' ASS Tmem214 chr5 + 30872686 30872904 0.000034 0.001332 
RI Tpp1 chr7 - 105750179 105751729 0.000034 0.000364 
RI Las1l chrX - 95953221 95955211 0.000034 0.000367 
SE Tmem57 chr4 - 134836766 134837034 0.000034 0.001980 
SE Ubfd1 chr7 + 122074466 122074557 0.000035 0.001986 
RI Uqcc1 chr2 - 155910356 155911836 0.000035 0.000370 
RI Ugt2b34 chr5 - 86889766 86892962 0.000036 0.000377 
SE Smarcc1 chr9 + 110236715 110236828 0.000036 0.002036 
RI Ppp1r12a chr10 + 108261244 108262431 0.000036 0.000382 
SE Prpf4b chr13 + 34893316 34893422 0.000037 0.002092 
RI Wdr1 chr5 - 38545673 38547091 0.000038 0.000395 
RI Stx5a chr19 + 8743079 8743423 0.000038 0.000395 
RI Peli1 chr11 + 21140563 21142657 0.000039 0.000403 
RI Npr2 chr4 + 43643605 43644187 0.000039 0.000409 
RI Mettl26 chr17 + 25876660 25877169 0.000040 0.000416 
3' ASS Neo1 chr9 - 58906870 58907094 0.000040 0.002992 
SE Rbm25 chr12 + 83651645 83651750 0.000040 0.002253 
SE Spaca6 chr17 + 17837669 17837769 0.000041 0.002253 
RI Mms19 chr19 - 41945732 41947103 0.000041 0.000417 
SE Mkrn2os chr6 - 115589344 115589394 0.000041 0.002284 
RI Mtx1 chr3 - 89210106 89210448 0.000041 0.000424 
RI Dusp1 chr17 - 26506984 26507719 0.000042 0.000425 
RI Fam214b chr4 - 43035835 43037206 0.000042 0.000425 
SE Runx1t1 chr4 + 13771375 13771545 0.000043 0.002339 
3' ASS Chd6 chr2 - 161041984 161042132 0.000043 0.003095 
RI Nrbp1 chr5 + 31244165 31244559 0.000044 0.000443 
RI Acaa1a chr9 + 119344465 119346568 0.000044 0.000445 
RI Cnbp chr6 - 87845121 87845557 0.000045 0.000446 
RI Tbrg1 chr9 - 37654215 37655092 0.000045 0.000448 
RI Fibp chr19 + 5463786 5464215 0.000045 0.000448 
SE Zfp952 chr17 + 32994554 32994703 0.000045 0.002439 
SE Cep164 chr9 - 45785777 45785921 0.000045 0.002439 
SE Nfu1 chr6 + 87016175 87016394 0.000046 0.002465 
SE Ppid chr3 + 79596091 79596198 0.000046 0.002465 
SE Bptf chr11 - 107095001 107095190 0.000047 0.002467 
194 
SE Sema4d chr13 - 51734506 51734570 0.000049 0.002541 
RI Tank chr2 + 61643714 61644422 0.000049 0.000481 
MXE Epb41l2 chr10 + 25501577 25501631 0.000049 0.002588 
3' ASS Wbp1 chr6 - 83120184 83120876 0.000049 0.003442 
SE Pkm chr9 + 59658998 59659153 0.000050 0.002573 
SE Sh2d5 chr4 + 138253611 138253689 0.000050 0.002573 
RI Mapk7 chr11 - 61492903 61494266 0.000050 0.000491 
SE Necap2 chr4 - 141071580 141071695 0.000050 0.002586 
SE Tnk2 chr16 + 32678668 32678713 0.000051 0.002586 
RI Zfas1 chr2 + 167065433 167065862 0.000051 0.000500 
RI A230050P20Rik chr9 + 20869603 20871235 0.000051 0.000502 
RI Spag7 chr11 - 70664987 70665364 0.000052 0.000503 
5' ASS Ythdc1 chr5 + 86827954 86829479 0.000052 0.001989 
RI Sgsm3 chr15 + 81008288 81008908 0.000052 0.000504 
RI Trabd chr15 + 89084902 89085446 0.000052 0.000504 
RI Rbm7 chr9 - 48488700 48490938 0.000052 0.000504 
SE Gripap1 chrX + 7803593 7803686 0.000054 0.002719 
SE Mtmr6 chr14 + 60290705 60290819 0.000054 0.002724 
SE Eml5 chr12 - 98819860 98819869 0.000055 0.002724 
5' ASS Srrt chr5 - 137301317 137302314 0.000055 0.002010 
5' ASS Traf2 chr2 - 25538844 25539084 0.000056 0.002010 
RI Gas5 chr1 + 161035751 161036014 0.000057 0.000541 
SE Hnrnpa2b1 chr6 - 51467390 51467426 0.000057 0.002828 
SE Golga4 chr9 + 118576222 118576356 0.000058 0.002864 
RI Sel1l chr12 - 91813831 91814693 0.000059 0.000557 
SE Sgms1 chr19 - 32156569 32156647 0.000059 0.002876 
RI Ampd2 chr3 - 108080266 108080774 0.000059 0.000561 
MXE Ankrd6 chr4 - 32818604 32818709 0.000059 0.002588 
RI Gtf2h2 chr13 - 100486070 100486524 0.000060 0.000564 
5' ASS Thoc2 chrX - 41813416 41814008 0.000060 0.002095 
SE Spaca6 chr17 + 17837664 17837771 0.000060 0.002901 
MXE Snap25 chr2 + 136769742 136769860 0.000060 0.002588 
RI Baz2b chr2 - 59920294 59922217 0.000060 0.000567 
SE Mcf2l chr8 + 13013914 13013998 0.000062 0.002988 
RI Snhg1 chr19 + 8724402 8724721 0.000062 0.000583 
SE Rnps1 chr17 + 24418037 24418218 0.000062 0.002988 
RI Pfkfb2 chr1 - 130697696 130698743 0.000063 0.000589 
SE Znhit1 chr5 - 136986125 136986255 0.000063 0.003018 
RI Nfx1 chr4 + 41015202 41016150 0.000064 0.000592 
RI Rpl3 chr15 - 80080895 80081783 0.000064 0.000595 
SE Arhgef1 chr7 + 24919183 24919351 0.000064 0.003045 
195 
SE Tjap1 chr17 - 46264093 46264190 0.000065 0.003061 
RI Snx19 chr9 + 30432234 30433430 0.000065 0.000604 
SE Fnip2 chr3 - 79507838 79507928 0.000067 0.003150 
SE Golga2 chr2 + 32293314 32293395 0.000069 0.003170 
SE Dhx57 chr17 - 80278222 80278381 0.000069 0.003170 
RI Aup1 chr6 + 83055128 83055690 0.000069 0.000632 
RI Fam53a chr5 - 33600355 33608227 0.000069 0.000632 
5' ASS Cyb561d1 chr3 - 108200626 108200834 0.000070 0.002391 
SE Clip1 chr5 - 123613067 123615335 0.000070 0.003218 
RI Odf2l chr3 + 145126092 145127890 0.000071 0.000643 
RI Tmem214 chr5 + 30872686 30873144 0.000072 0.000655 
RI Aifm1 chrX - 48483154 48484635 0.000074 0.000666 
RI Mrps2 chr2 + 28468242 28468950 0.000074 0.000666 
RI Iws1 chr18 + 32086272 32087152 0.000074 0.000666 
SE Zfp961 chr8 + 71966099 71966160 0.000074 0.003376 
SE Dock6 chr9 - 21829473 21829578 0.000075 0.003376 
RI Slc35f6 chr5 + 30655494 30656100 0.000075 0.000672 
SE Pramef8 chr4 + 143415348 143415413 0.000078 0.003517 
RI Bsdc1 chr4 + 129465229 129466990 0.000078 0.000697 
3' ASS Sorbs2 chr8 + 45823728 45823835 0.000079 0.005361 
RI Ubr2 chr17 - 46980319 46981442 0.000079 0.000706 
SE Spaca6 chr17 + 17837664 17837769 0.000080 0.003548 
SE Necap2 chr4 - 141071580 141071717 0.000080 0.003548 
RI Asb6 chr2 - 30824640 30825560 0.000080 0.000707 
RI Zcchc9 chr13 - 91800610 91801016 0.000080 0.000707 
SE Bsg chr10 + 79708696 79709044 0.000081 0.003592 
RI Nob1 chr8 - 107416105 107417091 0.000081 0.000715 
RI Zer1 chr2 - 30108220 30110381 0.000083 0.000726 
SE Erbin chr13 - 103830187 103830331 0.000083 0.003660 
RI Brd8 chr18 - 34608417 34609949 0.000083 0.000726 
3' ASS Dync2h1 chr9 - 7111424 7111592 0.000084 0.005467 
RI Parl chr16 - 20285764 20287069 0.000084 0.000730 
RI Ankrd54 chr15 - 79054495 79055416 0.000085 0.000736 
SE Ddx31 chr2 + 28846762 28846871 0.000085 0.003695 
SE Kctd12b chrX - 153695623 153695678 0.000085 0.003695 
5' ASS Arhgap26 chr18 + 39357552 39357828 0.000086 0.002840 
RI Tpp2 chr1 + 44001318 44003000 0.000087 0.000748 
RI Hcfc1 chrX - 73946709 73947050 0.000089 0.000761 
5' ASS Hdac10 chr15 - 89126629 89126706 0.000089 0.002840 
MXE Fam184a chr10 - 53634301 53634395 0.000090 0.003526 
RI Atp11b chr3 + 35837485 35839214 0.000090 0.000770 
196 
SE Arhgef1 chr7 + 24918519 24919351 0.000091 0.003920 
5' ASS Zmynd8 chr2 - 165807518 165807929 0.000091 0.002840 
5' ASS Ankrd16 chr2 + 11783640 11783756 0.000092 0.002840 
RI Srp19 chr18 + 34331749 34334364 0.000092 0.000782 
RI Tbrg1 chr9 - 37652614 37653169 0.000092 0.000782 
RI Tfe3 chrX + 7770994 7772596 0.000092 0.000782 
SE Nubp1 chr16 + 10421870 10421985 0.000093 0.003990 
RI Slc25a22 chr7 - 141432020 141432753 0.000096 0.000811 
SE Ttc13 chr8 - 124699655 124699721 0.000097 0.004152 
RI Ppid chr3 + 79595201 79597873 0.000098 0.000825 
SE Anapc16 chr10 - 60002417 60002467 0.000099 0.004212 
RI Wdr77 chr3 + 105965764 105966425 0.000100 0.000837 
RI Hps5 chr7 - 46774813 46775951 0.000102 0.000851 
MXE Gria3 chrX + 41654809 41654924 0.000102 0.003681 
3' ASS Ddx49 chr8 - 70294686 70294835 0.000104 0.006631 
RI Fxyd5 chr7 - 31032729 31033018 0.000107 0.000888 
RI Mfsd11 chr11 + 116863905 116865956 0.000107 0.000890 
SE Atp11b chr3 + 35843570 35843696 0.000109 0.004603 
5' ASS Ankrd16 chr2 + 11779676 11779897 0.000110 0.003309 
SE Taz chrX + 74288983 74289019 0.000110 0.004611 
SE Sidt2 chr9 - 45946505 45946568 0.000111 0.004628 
RI Fam102a chr2 + 32558317 32560155 0.000112 0.000927 
SE Tmem192 chr8 + 64964197 64964532 0.000113 0.004680 
RI Hdac3 chr18 - 37941378 37941766 0.000113 0.000931 
RI Hsd3b7 chr7 + 127802235 127803802 0.000114 0.000935 
RI 1110032A03Rik chr9 - 50764223 50764926 0.000115 0.000940 
RI Nudt13 chr14 + 20306231 20307799 0.000116 0.000940 
RI Psmd5 chr2 - 34856447 34857829 0.000116 0.000940 
MXE Pkm chr9 + 59675028 59675195 0.000116 0.003863 
RI Nbr1 chr11 + 101574998 101575416 0.000117 0.000947 
SE Ap3m1 chr14 - 21044652 21044824 0.000118 0.004851 
RI Psmd4 chr3 - 95032704 95033546 0.000118 0.000949 
SE Srrm1 chr4 - 135345195 135345477 0.000120 0.004907 
SE Ncapd3 chr9 + 27030622 27030830 0.000120 0.004907 
RI Hmgn3 chr9 - 83109947 83111106 0.000120 0.000966 
5' ASS Fam229b chr10 - 39133822 39133900 0.000122 0.003544 
SE Pax6 chr2 + 105684886 105685429 0.000123 0.003544 
RI Traf4 chr11 - 78161286 78161622 0.000124 0.000989 
SE Lpgat1 chr1 + 191718428 191718597 0.000124 0.005024 
RI Zswim8 chr14 + 20722459 20723006 0.000125 0.000996 
RI Metap2 chr10 - 93879539 93880138 0.000126 0.001002 
197 
3' ASS Nfya chr17 - 48392339 48392506 0.000127 0.007833 
RI Dpp7 chr2 - 25354892 25355721 0.000129 0.001022 
RI Gas5 chr1 + 161037504 161038037 0.000130 0.001028 
RI Prpf18 chr2 - 4637147 4638995 0.000132 0.001040 
3' ASS Trip10 chr17 + 57262353 57262472 0.000132 0.007833 
RI Med25 chr7 - 44879390 44880104 0.000134 0.001047 
3' ASS Helq chr5 - 100768281 100768699 0.000134 0.007833 
RI Dcp1b chr6 + 119214769 119217979 0.000134 0.001047 
SE Dtx2 chr5 + 136026469 136026607 0.000135 0.005464 
SE 2010111I01Rik chr13 + 63300604 63300793 0.000137 0.005490 
RI Zfp384 chr6 + 125024032 125025082 0.000138 0.001074 
RI E130309D02Rik chr5 - 143311710 143314399 0.000138 0.001074 
SE Bptf chr11 - 107086711 107086897 0.000139 0.005545 
3' ASS Jkamp chr12 + 72089314 72089406 0.000139 0.007888 
3' ASS Zzz3 chr3 + 152449012 152449128 0.000142 0.007888 
5' ASS Katnal2 chr18 - 77011983 77012104 0.000142 0.004004 
MXE Pfkp chr13 - 6593100 6593253 0.000142 0.004390 
RI Abtb1 chr6 - 88840709 88840900 0.000144 0.001115 
SE Aamdc chr7 - 97575587 97575691 0.000146 0.005779 
SE Rdh13 chr7 - 4443736 4443771 0.000146 0.005779 
5' ASS Selenoi chr5 + 30257711 30257820 0.000147 0.004075 
SE Nt5c2 chr19 - 46898327 46898521 0.000148 0.005810 
SE Nt5c3 chr6 - 56897774 56897829 0.000150 0.005847 
3' ASS Ehbp1 chr11 - 22146462 22146700 0.000151 0.008219 
5' ASS Fam229b chr10 - 39133811 39133900 0.000153 0.004142 
RI Brd9 chr13 + 73941943 73942806 0.000157 0.001208 
3' ASS Dnajb2 chr1 + 75239107 75239333 0.000158 0.008384 
RI Ppia chr11 + 6418100 6418314 0.000158 0.001217 




Table Appendix-2. List of genes significantly alternatively spliced between human alpha 
and beta cells.  
Splicing 
Event 
Gene Chr Strand Exon_Start Exon_End PValue FDR 
5' ASS POPDC3 chr6 - 105161424 105162160 0.000000 0.000000 
RI LLGL1 chr17 + 18235469 18236760 0.000000 0.000000 
MXE SLC7A2 chr8 + 17554559 17554699 0.000000 0.000030 
5' ASS CHD5 chr1 - 6130147 6130328 0.000000 0.000086 
SE CAST chr5 + 96740744 96740783 0.000000 0.001277 
SE ZNF35 chr3 + 44652556 44652701 0.000000 0.001633 
SE CCNT1 chr12 - 48695998 48696162 0.000000 0.001633 
RI NDRG2 chr14 - 21017986 21018814 0.000000 0.000925 
SE PEG3 chr19 - 56833289 56833420 0.000001 0.003701 
SE SPATS2L chr2 + 200308886 200309090 0.000001 0.003701 
3'ASS AHDC1 chr1 - 27553073 27553304 0.000001 0.005376 
SE RMDN2 chr2 + 37951232 37952201 0.000001 0.004591 
SE LMF1 chr16 - 855106 856055 0.000002 0.005153 
3'ASS AHDC1 chr1 - 27553073 27553290 0.000003 0.006867 
MXE SLC3A2 chr11 + 62882504 62882618 0.000005 0.004869 
RI LDHD chr16 - 75114826 75115339 0.000006 0.006732 
RI NT5C3B chr17 - 41835587 41835957 0.000007 0.006732 
SE DOCK8 chr9 + 365590 366552 0.000008 0.019597 
SE TRANK1 chr3 - 36850153 36851417 0.000009 0.019597 
RI AKR1C2 chr10 - 4999199 5000666 0.000009 0.007013 
3'ASS SYNGAP1 chr6 + 33440552 33440965 0.000010 0.014692 
5' ASS PYROXD2 chr10 - 98410612 98410958 0.000011 0.008634 
5' ASS ZNF598 chr16 - 2000390 2000481 0.000012 0.008634 
SE ARFGAP2 chr11 - 47172709 47172751 0.000014 0.026272 
SE PUF60 chr8 - 143820665 143820716 0.000014 0.026272 
SE TRIM36 chr5 - 115163517 115163752 0.000021 0.034494 
RI SYTL1 chr1 + 27349971 27350485 0.000025 0.016503 
SE INO80E chr16 + 30001211 30004657 0.000026 0.039020 
SE AHDC1 chr1 - 27558304 27558530 0.000027 0.039020 
SE ZNHIT1 chr7 + 101218318 101218485 0.000032 0.043454 
SE AC055758.2 chr3 + 145946403 145946621 0.000039 0.049608 
RI NUDT8 chr11 - 67628918 67629921 0.000042 0.021870 
RI SSR2 chr1 - 156011809 156012565 0.000045 0.021870 
SE FAAP20 chr1 - 2192646 2192975 0.000047 0.055057 
RI RABGGTB chr1 + 75789951 75790274 0.000064 0.027519 
5' ASS MPRIP chr17 + 17137915 17138429 0.000067 0.038387 
MXE PEG3 chr19 - 56829782 56829921 0.000079 0.047095 
SE ZNHIT1 chr7 + 101218318 101221796 0.000087 0.093334 
199 
SE LINC00963 chr9 + 129493477 129493595 0.000092 0.093334 
SE DDX55 chr12 + 123607431 123607523 0.000093 0.093334 
5' ASS MFF chr2 + 227328677 227328899 0.000100 0.047621 
RI HMG20B chr19 + 3573691 3574586 0.000102 0.039554 
SE DNAJB5 chr9 + 34990347 34990611 0.000135 0.129500 
5' ASS ALS2CR12 chr2 - 201348099 201348302 0.000137 0.055487 
RI MAP4K2 chr11 - 64791908 64792422 0.000137 0.045662 
3'ASS SRSF5 chr14 + 69769510 69770540 0.000143 0.152612 
RI DHRS1 chr14 - 24291138 24291625 0.000156 0.045662 
RI YDJC chr22 - 21629307 21629761 0.000167 0.045662 
RI QTRT1 chr19 + 10712160 10712628 0.000171 0.045662 
RI IL17RC chr3 + 9923880 9924291 0.000176 0.045662 
SE SYNRG chr17 - 37579131 37579434 0.000177 0.161429 
SE AMDHD2 chr16 + 2527572 2527615 0.000189 0.165546 
5' ASS PYROXD2 chr10 - 98390870 98391082 0.000200 0.071186 
RI KRI1 chr19 - 10557551 10557895 0.000225 0.049016 
SE AC132008.2 chr3 - 197624471 197624720 0.000229 0.192113 
RI PIGO chr9 - 35091239 35092767 0.000238 0.049016 
SE NDUFS8 chr11 + 68031532 68031710 0.000247 0.198424 
RI SPAG5 chr17 - 28578217 28578528 0.000250 0.049016 
RI HEXDC chr17 + 82436666 82437363 0.000258 0.049016 
RI SLC25A39 chr17 - 44321057 44321558 0.000264 0.049016 
RI HAX1 chr1 + 154273335 154273961 0.000264 0.049016 
SE FAAP20 chr1 - 2192844 2192975 0.000318 0.242233 
SE PAPSS2 chr10 + 87721755 87721770 0.000325 0.242233 
3'ASS RELA chr11 - 65662178 65662347 0.000354 0.260617 
RI CARD19 chr9 + 93110567 93112289 0.000361 0.062167 
3'ASS DACH2 chrX + 86827765 86832602 0.000366 0.260617 
RI TRIM69 chr15 + 44756367 44758854 0.000367 0.062167 
SE GNAS chr20 + 58891581 58891865 0.000380 0.268411 
SE CIDEB chr14 - 24310406 24310548 0.000387 0.268411 
RI PELP1 chr17 - 4675273 4675884 0.000453 0.073523 
3'ASS CDK18 chr1 + 205530185 205530349 0.000456 0.278455 
MXE NSMAF chr8 - 58637233 58637389 0.000464 0.208562 
5' ASS LCLAT1 chr2 + 30447235 30447404 0.000511 0.146769 
5' ASS DDX47 chr12 + 12823202 12824016 0.000516 0.146769 
RI LIN37 chr19 + 35753086 35754157 0.000520 0.078843 
SE SETD5 chr3 + 9433369 9433562 0.000534 0.339625 
SE NGLY1 chr3 - 25732318 25732483 0.000539 0.339625 
RI YBX3 chr12 - 10701959 10704148 0.000549 0.078843 
SE SDR42E1 chr16 - 82007640 82007868 0.000551 0.339625 
200 
3'ASS CLUH chr17 - 2696433 2696538 0.000556 0.297313 
RI SKIV2L chr6 + 31969279 31969751 0.000560 0.078843 
RI CRACR2B chr11 + 830865 831295 0.000567 0.078843 
SE WSB1 chr17 + 27301817 27301956 0.000569 0.339625 
SE AC006001.3 chr7 - 66576754 66576932 0.000574 0.339625 
SE EPS8L2 chr11 + 706595 706801 0.000625 0.359231 
5' ASS IRF3 chr19 - 49661449 49662328 0.000697 0.179348 
RI PGAP2 chr11 + 3823882 3824376 0.000706 0.094770 
SE COL9A2 chr1 - 40315237 40315465 0.000714 0.389801 
SE NAA16 chr13 + 41362730 41362873 0.000717 0.389801 
5' ASS HDAC9 chr7 + 18495745 18496023 0.000756 0.179348 
RI PNKP chr19 - 49864178 49864403 0.000781 0.099061 
SE SRSF2 chr17 - 76735771 76735875 0.000793 0.419324 
RI ZSWIM7 chr17 - 15977578 15977913 0.000812 0.099061 
RI ECEL1 chr2 - 232484980 232485267 0.000847 0.099061 
RI CPSF7 chr11 - 61420469 61421608 0.000849 0.099061 
SE DOCK8 chr9 + 369221 369447 0.000865 0.445805 
RI RENBP chrX - 153944079 153944418 0.000878 0.099061 
RI ABCA2 chr9 - 137011406 137011749 0.000890 0.099061 
SE ABHD18 chr4 + 127989720 127989821 0.000928 0.466416 
RI ITGA7 chr12 - 55694777 55695637 0.000969 0.100060 
RI APBA3 chr19 - 3751188 3751553 0.000982 0.100060 
RI DMKN chr19 - 35500377 35500580 0.000985 0.100060 
RI SAT2 chr17 - 7627362 7627802 0.001002 0.100060 
SE PIGQ chr16 + 581198 581341 0.001015 0.481191 
SE SUGP2 chr19 - 18993647 18993740 0.001017 0.481191 
SE FRS2 chr12 + 69480298 69480359 0.001029 0.481191 
MXE MROH7 chr1 + 54679890 54680045 0.001045 0.375727 
5' ASS PTPRZ1 chr7 + 122010333 122013889 0.001059 0.231807 
RI SRSF5 chr14 + 69769181 69770540 0.001091 0.102629 
RI MAP4K2 chr11 - 64792171 64792422 0.001095 0.102629 
RI CDK10 chr16 + 89693273 89694232 0.001107 0.102629 
SE SUGP2 chr19 - 18993637 18993740 0.001167 0.533168 
RI MVD chr16 - 88657435 88658029 0.001321 0.119284 
RI PNKP chr19 - 49861607 49861881 0.001348 0.119284 
SE POLDIP3 chr22 - 42601969 42602107 0.001376 0.614610 
MXE HAUS2 chr15 + 42558197 42558290 0.001399 0.418994 
5' ASS ABHD11 chr7 - 73737220 73737735 0.001441 0.285469 
5' ASS CENPX chr17 - 82019509 82019694 0.001505 0.285469 
RI SIRT6 chr19 - 4175027 4175937 0.001518 0.130615 
RI UNC119 chr17 - 28546707 28547849 0.001543 0.130615 
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RI MAU2 chr19 + 19344848 19345369 0.001704 0.141213 
RI DRG2 chr17 + 18099016 18100435 0.001801 0.146137 
SE ITGA9-AS1 chr3 - 37818679 37818930 0.001814 0.772581 
SE LIPC chr15 + 58430826 58431151 0.001831 0.772581 
SE ZNF595 chr4 + 60057 60153 0.001850 0.772581 
RI CARD8 chr19 - 48232452 48234543 0.001863 0.148072 
SE WSB1 chr17 + 27301880 27301956 0.001883 0.772581 
RI CSK chr15 + 74800680 74800922 0.002003 0.154155 
SE FBXO44 chr1 + 11658532 11658628 0.002031 0.813243 
SE EPB41L1 chr20 + 36195328 36195364 0.002063 0.813243 
RI ERBB3 chr12 + 56094098 56094556 0.002068 0.154155 
RI CYP4F3 chr19 + 15647051 15647324 0.002086 0.154155 
RI CDK18 chr1 + 205529520 205530349 0.002098 0.154155 
SE FAM86EP chr4 - 3947143 3948220 0.002210 0.849500 
SE LIAS chr4 + 39467517 39468427 0.002240 0.849500 
MXE SLC25A45 chr11 - 65379375 65379561 0.002303 0.591269 
RI THOP1 chr19 + 2807441 2808444 0.002335 0.168367 
RI RNH1 chr11 - 499014 499999 0.002405 0.170240 
SE NME4 chr16 + 398207 398394 0.002554 0.950720 
RI MGAT4B chr5 - 179801333 179801694 0.002555 0.176169 
SE RNF135 chr17 + 30987943 30988106 0.002608 0.953254 
RI SBF1 chr22 - 50467531 50467923 0.002622 0.176169 
RI CXXC1 chr18 - 50285748 50286257 0.002668 0.176169 
RI TPP1 chr11 - 6619195 6619413 0.002669 0.176169 
5' ASS KL chr13 + 33055046 33055365 0.002678 0.449524 
5' ASS HMGA1 chr6 + 34240736 34240915 0.002686 0.449524 
SE LINC00963 chr9 + 129493418 129493595 0.002698 0.962583 
SE ATG9A chr2 - 219229009 219229174 0.002730 0.962583 
RI NECAB3 chr20 - 33659884 33660395 0.002753 0.178652 
RI ARAP1 chr11 - 72712437 72713243 0.002845 0.181631 
SE APOPT1 chr14 + 103571622 103571820 0.002866 0.962583 
SE LINC00963 chr9 + 129493415 129493595 0.002895 0.962583 
3'ASS MGRN1 chr16 + 4686258 4690974 0.002906 1.000000 
SE ATP6V0A1 chr17 + 42510058 42510183 0.002920 0.962583 
SE RHOC chr1 - 112705099 112706252 0.002921 0.962583 
SE OSBPL9 chr1 + 51756319 51756358 0.003101 1.000000 
RI DOCK8 chr9 + 368017 370300 0.003153 0.198038 
5' ASS NAA16 chr13 + 41362030 41362873 0.003251 0.497012 
RI MZF1 chr19 - 58570343 58571429 0.003255 0.201189 
SE MEG8 chr14 + 100977604 100977722 0.003267 1.000000 
SE MRPL9 chr1 - 151761450 151761552 0.003273 1.000000 
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5' ASS VRK3 chr19 - 50025266 50025372 0.003319 0.497012 
3'ASS CACNA1C chr12 + 2651573 2651768 0.003354 1.000000 
RI SCARB1 chr12 - 124782682 124786503 0.003371 0.205081 
3'ASS CLK4 chr5 - 178619837 178620673 0.003424 1.000000 
SE PBRM1 chr3 - 52682091 52682233 0.003501 1.000000 
SE ZBTB37 chr1 + 173873466 173873566 0.003521 1.000000 
SE SENP7 chr3 - 101501069 101501119 0.003551 1.000000 
RI GPAA1 chr8 + 144083388 144083861 0.003616 0.216605 
5' ASS C7orf43 chr7 - 100157292 100157459 0.003636 0.517286 
3'ASS ZFP30 chr19 - 37643264 37643363 0.003644 1.000000 
SE PEX5 chr12 + 7190021 7190216 0.003759 1.000000 
MXE BORA chr13 + 72728925 72729093 0.003816 0.857257 
SE SYNRG chr17 - 37520178 37520214 0.003819 1.000000 
3'ASS ARL4A chr7 + 12688165 12689176 0.003831 1.000000 
5' ASS THAP5 chr7 - 108565829 108566022 0.003885 0.526323 
SE POLDIP3 chr22 - 42601969 42602056 0.003895 1.000000 
RI CNBP chr3 - 129171078 129171538 0.003950 0.233047 
SE CHD2 chr15 + 92901166 92901299 0.003999 1.000000 
SE TOPORS chr9 - 32550773 32550968 0.004095 1.000000 
SE MUC20 chr3 + 195722500 195722818 0.004119 1.000000 
5' ASS ALMS1 chr2 + 73489633 73491498 0.004188 0.541642 
RI SHISA5 chr3 - 48467875 48469573 0.004199 0.241789 
RI IDH3G chrX - 153785765 153786272 0.004222 0.241789 
MXE ISYNA1 chr19 - 18436683 18436877 0.004340 0.866467 
SE CEP164 chr11 + 117382795 117382942 0.004442 1.000000 
SE SMCHD1 chr18 + 2722518 2722663 0.004524 1.000000 
SE SRSF11 chr1 + 70231858 70231975 0.004551 1.000000 
SE PKM chr15 - 72221167 72221284 0.004644 1.000000 
3'ASS UBE2D3 chr4 - 102826484 102826844 0.004690 1.000000 
3'ASS SLC2A11 chr22 + 23877384 23877869 0.004740 1.000000 
SE MEIS2 chr15 - 36894716 36894812 0.004764 1.000000 
RI ZFPL1 chr11 + 65085114 65086608 0.004965 0.266038 
RI SPNS2 chr17 + 4536075 4536426 0.004991 0.266038 
RI SPAG4 chr20 + 35618449 35618720 0.005024 0.266038 
5' ASS PSTK chr10 + 122983271 122983514 0.005069 0.602466 
5' ASS SH3BP1 chr22 + 37642538 37642737 0.005082 0.602466 
RI SARM1 chr17 + 28388173 28388539 0.005168 0.266038 
RI RCHY1 chr4 - 75490580 75491782 0.005179 0.266038 
RI NEK9 chr14 - 75105949 75106702 0.005191 0.266038 
RI FDXR chr17 - 74863895 74864347 0.005205 0.266038 
RI TMEM176A chr7 + 150801535 150802325 0.005211 0.266038 
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RI WDR81 chr17 + 1735571 1736218 0.005261 0.266038 
5' ASS MAPK8IP3 chr16 + 1761223 1761305 0.005336 0.607272 
SE ZNF772 chr19 - 57475659 57475786 0.005431 1.000000 
MXE AC022784.1 chr8 + 9168110 9169177 0.005498 0.987942 
5' ASS ITGA7 chr12 - 55700565 55701154 0.005683 0.621820 
SE NDRG4 chr16 + 58500987 58501077 0.005782 1.000000 
RI PQBP1 chrX + 48902232 48902795 0.005892 0.292040 
SE FAM126A chr7 - 22946951 22947247 0.005897 1.000000 
RI RBM6 chr3 + 50061461 50062108 0.005994 0.292040 
RI LARGE2 chr11 + 45926038 45926347 0.006220 0.292040 
RI REX1BD chr19 + 18588994 18589683 0.006274 0.292040 
RI BTN3A2 chr6 + 26373275 26373413 0.006292 0.292040 
RI NBEAL2 chr3 + 47007240 47007697 0.006333 0.292040 
RI GTF2H4 chr6 + 30911683 30912146 0.006344 0.292040 
RI GPAT2 chr2 - 96024772 96025603 0.006375 0.292040 
SE EHBP1 chr2 + 62949093 62949162 0.006439 1.000000 
SE FAM208B chr10 + 5709529 5709663 0.006455 1.000000 
SE SYNGR3 chr16 + 1990498 1990672 0.006477 1.000000 
SE TDRD9 chr14 + 104049864 104049937 0.006847 1.000000 
SE ETFA chr15 - 76295590 76295737 0.006861 1.000000 
5' ASS LZTR1 chr22 + 20990385 20990969 0.006867 0.723582 
SE MXD4 chr4 - 2255154 2255351 0.007124 1.000000 
SE REPIN1 chr7 + 150370713 150370884 0.007254 1.000000 
MXE SGSH chr17 - 80214614 80214765 0.007397 1.000000 
SE DCP1A chr3 - 53304176 53304290 0.007496 1.000000 
MXE CRTC3 chr15 + 90614452 90614488 0.007633 1.000000 
SE RFC5 chr12 + 118017689 118017815 0.008004 1.000000 
SE AC156455.1 chr12 + 122064138 122064433 0.008004 1.000000 
SE PPIP5K2 chr5 + 103135992 103136114 0.008051 1.000000 
3'ASS WDR63 chr1 + 85093773 85094555 0.008156 1.000000 
RI HNF1A chr12 + 120999267 120999627 0.008207 0.363403 
RI C1orf35 chr1 - 228102309 228102560 0.008215 0.363403 
RI RNF123 chr3 + 49712478 49713587 0.008278 0.363403 
RI GRM4 chr6 - 34058973 34062028 0.008306 0.363403 
RI DMKN chr19 - 35510183 35510510 0.008519 0.364278 
RI HPN chr19 + 35041721 35042522 0.008609 0.364278 
RI LRRC75A-AS1 chr17 + 16439326 16439703 0.008644 0.364278 
RI UNC93B1 chr11 - 68003021 68003798 0.008700 0.364278 
RI INO80E chr16 + 30001211 30004657 0.008844 0.366348 
5' ASS ELMOD3 chr2 + 85371085 85371562 0.008911 0.905428 
SE FAM131A chr3 + 184338386 184338529 0.008912 1.000000 
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RI CTSA chr20 + 45891568 45892027 0.009008 0.368363 
SE CAPNS1 chr19 + 36140357 36140511 0.009054 1.000000 
RI YDJC chr22 - 21629307 21629761 0.009081 0.368363 
SE RBM5 chr3 + 50110378 50110463 0.009128 1.000000 
SE DZIP1L chr3 - 138071642 138071835 0.009174 1.000000 
RI SH3BP2 chr4 + 2831922 2832412 0.009237 0.370797 
MXE KLHDC8A chr1 - 205344133 205344458 0.009267 1.000000 
3'ASS MVD chr16 - 88656104 88656561 0.009291 1.000000 
SE MPHOSPH9 chr12 - 123203249 123203375 0.009407 1.000000 
5' ASS MAP3K3 chr17 + 63685516 63685590 0.009426 0.924722 
RI TMEM175 chr4 + 947708 948154 0.009463 0.371655 
RI TRPM4 chr19 + 49188640 49189091 0.009477 0.371655 
SE MZF1 chr19 - 58572549 58572719 0.009490 1.000000 
SE FAM86EP chr4 - 3948089 3948220 0.009572 1.000000 
SE ABHD11 chr7 - 73737220 73737360 0.009589 1.000000 
RI PTK7 chr6 + 43142171 43143620 0.009637 0.371655 
RI INTS3 chr1 + 153772339 153772711 0.009640 0.371655 
SE BAZ2A chr12 - 56630775 56630865 0.009663 1.000000 
3'ASS CCDC74A chr2 + 131530578 131530827 0.009736 1.000000 
RI CFAP70 chr10 - 73293262 73297173 0.009895 0.375043 
RI POMT1 chr9 + 131509902 131510415 0.009920 0.375043 
5' ASS FUZ chr19 - 49812446 49812736 0.009989 0.941493 
3'ASS INTS11 chr1 - 1313731 1314105 0.010171 1.000000 
SE CTDP1 chr18 + 79728906 79729069 0.010172 1.000000 
SE ZNF708 chr19 - 21327959 21328141 0.010189 1.000000 
3'ASS ZNF711 chrX + 85246929 85247651 0.010209 1.000000 
SE GNE chr9 - 36236831 36236984 0.010220 1.000000 
5' ASS BUD23 chr7 + 73683766 73684000 0.010259 0.941493 
SE SUOX chr12 + 55997614 55997723 0.010273 1.000000 
RI HDAC10 chr22 - 50246297 50246735 0.010476 0.392245 
RI KANK1 chr9 + 732377 734835 0.010684 0.393799 
RI REX1BD chr19 + 18588994 18589683 0.010720 0.393799 
3'ASS STRADA chr17 - 63704483 63704908 0.010723 1.000000 
SE MYH14 chr19 + 50224153 50224177 0.010834 1.000000 
RI NELFCD chr20 + 58993623 58994239 0.010848 0.394783 
5' ASS NT5C2 chr10 - 103100662 103100943 0.011011 0.961719 
RI MMS19 chr10 - 97461495 97461896 0.011076 0.396757 
MXE MFSD8 chr4 - 127939852 127939997 0.011084 1.000000 
RI RAB26 chr16 + 2152819 2153222 0.011106 0.396757 
3'ASS TGFBR3 chr1 - 91719892 91720230 0.011145 1.000000 
SE UBE2D4 chr7 + 43942953 43943031 0.011220 1.000000 
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5' ASS WDR91 chr7 - 135197043 135198151 0.011280 0.961719 
SE C19orf48 chr19 - 50802453 50802614 0.011404 1.000000 
RI ELMOD3 chr2 + 85355075 85357252 0.011477 0.404187 
5' ASS CCDC7 chr10 + 32446139 32446631 0.011493 0.961719 
MXE DNM2 chr19 + 10796060 10796199 0.011501 1.000000 
SE INO80E chr16 + 30001211 30001530 0.011502 1.000000 
SE AMPD2 chr1 + 109620913 109621266 0.011524 1.000000 
SE ZNF415 chr19 - 53123500 53123655 0.011574 1.000000 
RI C1orf159 chr1 - 1084352 1084506 0.011636 0.404187 
RI TPCN1 chr12 + 113288162 113288847 0.011784 0.404187 
RI TRABD chr22 + 50197822 50198186 0.011815 0.404187 
SE FAM126A chr7 - 22947032 22947247 0.011826 1.000000 
RI NKTR chr3 + 42619663 42621516 0.011894 0.404187 
RI RUSC1 chr1 + 155325863 155327132 0.011937 0.404187 
SE PEG3 chr19 - 56833289 56833420 0.012089 1.000000 
RI TANC1 chr2 + 159219237 159219867 0.012440 0.414513 
SE BPHL chr6 + 3119284 3119512 0.012557 1.000000 
RI MRPL4 chr19 + 10252396 10252701 0.012561 0.414513 
RI RNF213 chr17 + 80381546 80383070 0.012683 0.414513 
RI ANKRD13D chr11 + 67291475 67291746 0.012690 0.414513 
MXE ZNF415 chr19 - 53115209 53115307 0.012746 1.000000 
SE MTMR14 chr3 + 9697710 9697866 0.012757 1.000000 
RI ARSA chr22 - 50627555 50628170 0.012824 0.414513 
RI ZNF662 chr3 + 42908021 42908909 0.012880 0.414513 
RI DDX51 chr12 - 132141497 132141956 0.013109 0.418039 
SE APOPT1 chr14 + 103563214 103563379 0.013152 1.000000 
RI NCKIPSD chr3 - 48678876 48679183 0.013240 0.418039 
SE RRNAD1 chr1 + 156734008 156734493 0.013249 1.000000 
RI REG3A chr2 - 79159329 79159753 0.013312 0.418039 
RI DXO chr6 - 31970605 31971147 0.013448 0.418944 
RI KLHDC4 chr16 - 87755193 87756477 0.013725 0.423430 
RI AL096870.2 chr14 - 24215551 24215797 0.013876 0.423430 
RI KLHL35 chr11 - 75425392 75426638 0.013919 0.423430 
3'ASS PLD3 chr19 + 40365552 40365930 0.013933 1.000000 
3'ASS INO80E chr16 + 30001211 30001530 0.013943 1.000000 
5' ASS PLEKHH3 chr17 - 42670993 42671130 0.013948 1.000000 
3'ASS KRT40 chr17 - 40980989 40981324 0.014072 1.000000 
3'ASS ACSL4 chrX - 109683135 109683666 0.014079 1.000000 
5' ASS MVD chr16 - 88657734 88658029 0.014115 1.000000 
5' ASS RASGRF1 chr15 - 79006176 79006434 0.014324 1.000000 
RI SFI1 chr22 + 31618114 31618547 0.014333 0.429386 
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RI NOL3 chr16 + 67174161 67174944 0.014335 0.429386 
SE NAB1 chr2 + 190655976 190656153 0.014410 1.000000 
SE CPNE1 chr20 - 35658929 35658982 0.014450 1.000000 
SE GGCX chr2 - 85560814 85560985 0.014555 1.000000 
RI WDR73 chr15 - 84645470 84646348 0.014631 0.434903 
SE SEC31A chr4 - 82830936 82830975 0.014653 1.000000 
3'ASS APBB1 chr11 - 6401573 6401982 0.014917 1.000000 
RI KDM2B chr12 - 121439856 121440977 0.014925 0.440289 
SE ARL13B chr3 + 93996547 93996684 0.014937 1.000000 
SE ZNRD1ASP chr6 - 30057090 30057717 0.014990 1.000000 
SE GULP1 chr2 + 188582340 188582565 0.015223 1.000000 
RI BEST1 chr11 + 61958145 61959578 0.015229 0.445868 
RI DDIT3 chr12 - 57517268 57517753 0.015654 0.454898 
MXE CTDP1 chr18 + 79728906 79729069 0.015655 1.000000 
SE EPHA10 chr1 - 37722005 37722296 0.015685 1.000000 
SE TEAD1 chr11 + 12675408 12675561 0.015719 1.000000 
SE BTBD3 chr20 + 11919085 11919176 0.015783 1.000000 
SE CTPS1 chr1 + 40980885 40981043 0.015872 1.000000 
5' ASS EPOR chr19 - 11382846 11383232 0.015875 1.000000 
SE APCDD1L-DT chr20 + 58519503 58519625 0.015886 1.000000 
SE MPHOSPH9 chr12 - 123227462 123227572 0.016277 1.000000 
5' ASS MTO1 chr6 + 73479935 73480367 0.016539 1.000000 
SE FAHD2A chr2 + 95405276 95405402 0.016542 1.000000 
RI CC2D1B chr1 - 52357780 52358461 0.016822 0.485213 
RI AAAS chr12 - 53314297 53314849 0.017051 0.485961 
RI AC104452.1 chr3 - 49419709 49420342 0.017166 0.485961 
RI RPL10A chr6 + 35468946 35469529 0.017222 0.485961 
SE ZNF860 chr3 + 31986247 31986409 0.017277 1.000000 
RI PMM1 chr22 - 41583958 41584372 0.017443 0.488658 
SE NR4A1 chr12 + 52052473 52052645 0.017493 1.000000 
MXE BTN2A2 chr6 + 26385014 26385362 0.017716 1.000000 
RI STAT2 chr12 - 56354777 56355351 0.017794 0.494625 
SE EBPL chr13 - 49669776 49669846 0.017803 1.000000 
RI SGSM3 chr22 + 40408932 40409372 0.017973 0.494625 
RI CCDC153 chr11 - 119193150 119193885 0.018037 0.494625 
SE SUOX chr12 + 55999332 55999458 0.018041 1.000000 
SE SGCE chr7 - 94644605 94644667 0.018170 1.000000 
RI CFB chr6 + 31947944 31948512 0.018287 0.494938 
RI ASL chr7 + 66089090 66089335 0.018377 0.494938 
3'ASS C1orf159 chr1 - 1090352 1091374 0.018429 1.000000 
RI CFAP410 chr21 - 44330462 44332014 0.018430 0.494938 
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RI NUBP2 chr16 + 1786536 1787831 0.018614 0.496470 
SE KIF21A chr12 - 39318072 39318201 0.018671 1.000000 
SE LUCAT1 chr5 - 91311645 91312413 0.018810 1.000000 
RI FNDC4 chr2 - 27493929 27494466 0.018812 0.498327 
SE FAM228B chr2 + 24167626 24167683 0.018829 1.000000 
3'ASS DAZAP1 chr19 + 1434736 1435687 0.019041 1.000000 
SE TRIM33 chr1 - 114397939 114397990 0.019171 1.000000 
RI AC104452.1 chr3 - 49419259 49420342 0.019215 0.505567 
3'ASS ARL13B chr3 + 93996547 93996684 0.019396 1.000000 
RI TPRN chr9 - 137191616 137192365 0.019445 0.507663 
RI KIF22 chr16 + 29799263 29799781 0.019556 0.507663 
3'ASS BTN2A1 chr6 + 26467718 26469637 0.019752 1.000000 
RI PPP4R1L chr20 - 58245782 58247506 0.020185 0.520527 
SE CLIP2 chr7 + 74372931 74373036 0.020194 1.000000 
MXE MROH7 chr1 + 54682655 54682794 0.020226 1.000000 
3'ASS KHDC4 chr1 - 155916624 155916737 0.020291 1.000000 
3'ASS ZC3H12A chr1 + 37482349 37482540 0.020432 1.000000 
RI SLC2A6 chr9 - 133478253 133479096 0.020473 0.520593 
5' ASS KIF12 chr9 - 114097518 114097741 0.020484 1.000000 
RI RELA chr11 - 65661936 65662205 0.020534 0.520593 
RI TNFAIP2 chr14 + 103129739 103130124 0.020682 0.520593 
RI ARHGEF40 chr14 + 21080872 21082119 0.020722 0.520593 
SE PHF20L1 chr8 + 132825034 132825157 0.020857 1.000000 
RI SELENBP1 chr1 - 151365767 151366453 0.020943 0.522759 
5' ASS TMEM134 chr11 - 67468016 67468092 0.021150 1.000000 
3'ASS UBL4A chrX - 154485770 154486083 0.021245 1.000000 
RI PITPNM1 chr11 - 67496177 67497436 0.021254 0.527165 
SE TOP3B chr22 - 21975980 21976187 0.021306 1.000000 
RI NPAS2 chr2 + 100982230 100988276 0.021456 0.528793 
RI TTC31 chr2 + 74490243 74491184 0.021696 0.530537 
RI HDAC6 chrX + 48814674 48814893 0.021802 0.530537 
3'ASS RAP1GAP chr1 - 21597960 21598095 0.021807 1.000000 
3'ASS CENPV chr17 - 16348615 16349333 0.021831 1.000000 
RI CROCCP3 chr1 - 16476929 16478437 0.021994 0.530537 
RI MTA1 chr14 + 105450057 105450324 0.022072 0.530537 
SE FOXP2 chr7 + 114570806 114570881 0.022214 1.000000 
RI ABCA2 chr9 - 137022701 137023052 0.022333 0.533528 
SE TARBP2 chr12 + 53502014 53502184 0.022526 1.000000 
3'ASS FAM122B chrX - 134769566 134772283 0.022549 1.000000 
RI RAD54L2 chr3 + 51630271 51630931 0.022577 0.534902 
3'ASS ZMYND8 chr20 - 47298728 47298947 0.022629 1.000000 
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5' ASS MCMBP chr10 - 119843247 119843426 0.022644 1.000000 
RI PDXDC1 chr16 + 15031734 15032979 0.022665 0.534902 
SE HAUS4 chr14 - 22951554 22951689 0.023068 1.000000 
5' ASS CLMN chr14 - 95194214 95194596 0.023254 1.000000 
3'ASS SLC25A29 chr14 - 100295625 100295993 0.023272 1.000000 
SE ZNF655 chr7 + 99571687 99571792 0.023278 1.000000 
RI YIF1A chr11 - 66284579 66284966 0.023376 0.545320 
SE GRB10 chr7 - 50732271 50732368 0.023497 1.000000 
RI C21orf58 chr21 - 46314870 46315547 0.023501 0.545320 
RI ADCY6 chr12 - 48770765 48771973 0.023527 0.545320 
5' ASS CFAP410 chr21 - 44334060 44335804 0.023635 1.000000 
3'ASS VEZF1 chr17 - 57980602 57980804 0.023734 1.000000 
SE SSBP4 chr19 + 18431352 18431418 0.023790 1.000000 
5' ASS MRPL55 chr1 - 228108436 228109021 0.023808 1.000000 
RI WDR90 chr16 + 653745 655147 0.023829 0.549048 
RI TNS1 chr2 - 217880897 217882411 0.024133 0.552789 
RI BAZ2A chr12 - 56604584 56605327 0.024381 0.553077 
RI MED25 chr19 + 49836225 49836979 0.024478 0.553077 
SE SYNE2 chr14 + 64215285 64215354 0.024515 1.000000 
RI P2RX2 chr12 + 132621474 132621972 0.024641 0.553077 
RI TMEM25 chr11 + 118531191 118531871 0.024714 0.553077 
RI B4GALNT3 chr12 + 552466 553983 0.024952 0.555226 
5' ASS THOC5 chr22 - 29543414 29543542 0.025010 1.000000 
SE ACIN1 chr14 - 23067313 23068671 0.025177 1.000000 
3'ASS GATD1 chr11 - 770992 771212 0.025443 1.000000 
SE RICTOR chr5 - 38949355 38949427 0.025843 1.000000 
RI TAF1C chr16 - 84183075 84183328 0.025878 0.572545 
RI TMEM184A chr7 - 1548518 1549945 0.026070 0.573536 
SE NMI chr2 - 151288890 151289077 0.026295 1.000000 
5' ASS TSC1 chr9 - 132925586 132927304 0.026315 1.000000 
RI PPOX chr1 + 161167099 161167486 0.026565 0.581145 
SE DGUOK chr2 + 73938909 73939022 0.026584 1.000000 
SE CPEB4 chr5 + 173932449 173932500 0.026647 1.000000 
5' ASS PACRGL chr4 + 20700457 20700747 0.026689 1.000000 
3'ASS NDUFA3 chr19 + 54106763 54106961 0.026749 1.000000 
RI THOC6 chr16 + 3026062 3026288 0.026754 0.582016 
RI GRIA2 chr4 + 157334009 157335877 0.026992 0.583923 
5' ASS CUL2 chr10 - 35090178 35090642 0.027032 1.000000 
3'ASS LETMD1 chr12 + 51053777 51053860 0.027171 1.000000 
RI SH3TC1 chr4 + 8235432 8237670 0.027427 0.586660 
RI MAPKBP1 chr15 + 41812515 41813781 0.027516 0.586660 
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SE DIS3L2 chr2 + 232198526 232198776 0.027538 1.000000 
5' ASS ARHGAP26 chr5 + 143014079 143014293 0.027713 1.000000 
RI AKNA chr9 - 114343707 114346009 0.027743 0.586660 
RI PER1 chr17 - 8146896 8147381 0.027760 0.586660 
RI DPP7 chr9 - 137114242 137114576 0.027872 0.586660 
SE HNRNPAB chr5 + 178210131 178210272 0.027909 1.000000 
SE EMC10 chr19 + 50481860 50481947 0.027914 1.000000 
3'ASS FBXW9 chr19 - 12689961 12690200 0.027923 1.000000 
3'ASS SUPT20H chr13 - 37022010 37023044 0.028066 1.000000 
SE RGS14 chr5 + 177371474 177371589 0.028226 1.000000 
SE BTD chr3 + 15632590 15632866 0.028489 1.000000 
3'ASS LSR chr19 + 35266835 35266967 0.028729 1.000000 
SE REPIN1 chr7 + 150370759 150370884 0.028827 1.000000 
RI ABCF3 chr3 + 184187396 184187761 0.028935 0.605772 
SE TLDC1 chr16 - 84502720 84502862 0.029025 1.000000 
3'ASS STARD3 chr17 + 39656909 39657085 0.029261 1.000000 
SE TCF12 chr15 + 57252420 57252492 0.029352 1.000000 
SE DPP9 chr19 - 4715528 4715726 0.029399 1.000000 
SE KCTD21 chr11 - 78177738 78177985 0.029497 1.000000 
SE MFF chr2 + 227328677 227330846 0.029535 1.000000 
RI VPS28 chr8 - 144424214 144424819 0.029679 0.615342 
RI COQ8B chr19 - 40705095 40705447 0.029708 0.615342 
SE LLGL2 chr17 + 75538530 75538636 0.029738 1.000000 
5' ASS ODF2 chr9 + 128460941 128461067 0.029794 1.000000 
SE ZNF711 chrX + 85246929 85247183 0.030199 1.000000 
5' ASS MYO15B chr17 + 75624542 75624688 0.030275 1.000000 
SE ARHGAP12 chr10 - 31839636 31839711 0.030292 1.000000 
RI PDE1B chr12 + 54570240 54572741 0.031380 0.643698 
RI SPATA20 chr17 + 50549984 50550312 0.031408 0.643698 
MXE MFSD8 chr4 - 127939852 127939997 0.031503 1.000000 
SE APCDD1L-DT chr20 + 58519503 58519599 0.031725 1.000000 
MXE GIT2 chr12 - 109947255 109947504 0.031748 1.000000 
RI MICALL2 chr7 - 1436741 1437608 0.031985 0.652101 
SE AFTPH chr2 + 64579485 64581273 0.032386 1.000000 
SE BANF1 chr11 + 66002843 66003070 0.032652 1.000000 
5' ASS RNF123 chr3 + 49712478 49712892 0.032702 1.000000 
SE RAB40B chr17 - 82696388 82696853 0.032767 1.000000 
RI CPNE2 chr16 + 57146084 57147964 0.032820 0.658808 
5' ASS ZFPL1 chr11 + 65085114 65085314 0.032907 1.000000 
RI RNF123 chr3 + 49704649 49705186 0.032963 0.658808 
RI PTPN21 chr14 - 88469498 88470050 0.032969 0.658808 
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RI TOP3B chr22 - 21957026 21958693 0.032991 0.658808 
RI VPS13D chr1 + 12348822 12349374 0.033402 0.661686 
RI CLN3 chr16 - 28491481 28491835 0.033475 0.661686 
SE TRMO chr9 - 97916163 97916338 0.033841 1.000000 
SE FOXK2 chr17 + 82595781 82596191 0.034324 1.000000 
SE GTF3C5 chr9 + 133054943 133054964 0.034393 1.000000 
3'ASS GGA2 chr16 - 23493359 23493587 0.034436 1.000000 
RI LPCAT4 chr15 - 34359588 34360209 0.034477 0.678048 
SE ATP2C1 chr3 + 130894730 130894775 0.034502 1.000000 
RI MPDZ chr9 - 13133823 13136182 0.034893 0.682783 
RI FBXL6 chr8 - 144356989 144357502 0.035277 0.684394 
5' ASS SMG9 chr19 - 43739672 43740218 0.035317 1.000000 
RI NSUN5P1 chr7 + 75412788 75415023 0.035327 0.684394 
SE MTO1 chr6 + 73480292 73480367 0.035330 1.000000 
SE SLC2A11 chr22 + 23877384 23877869 0.035698 1.000000 
RI MPDU1 chr17 + 7586898 7587271 0.035768 0.689251 
3'ASS SH3TC1 chr4 + 8236277 8237670 0.035854 1.000000 
5' ASS TIA1 chr2 - 70216752 70216994 0.035909 1.000000 
RI CDK5RAP3 chr17 + 47974399 47975337 0.035932 0.689251 
5' ASS PTPN4 chr2 + 119915178 119916690 0.036109 1.000000 
SE ZNF415 chr19 - 53115209 53115307 0.036256 1.000000 
3'ASS ANKRD18A chr9 - 38571357 38573129 0.036516 1.000000 
SE SEC23B chr20 + 18508090 18508297 0.036567 1.000000 
RI SLC5A6 chr2 - 27202812 27203345 0.036816 0.694557 
RI L3MBTL2 chr22 + 41227088 41227869 0.036825 0.694557 
RI GTF2H4 chr6 + 30913109 30913387 0.036936 0.694557 
RI ACADVL chr17 + 7222666 7223237 0.036991 0.694557 
RI DGKA chr12 + 55939414 55940433 0.037100 0.694557 
RI NELFE chr6 - 31954554 31955096 0.037677 0.701985 
SE RAB11FIP3 chr16 + 491133 491268 0.037935 1.000000 
3'ASS LRRC29 chr16 - 67210047 67211024 0.037939 1.000000 
3'ASS USP19 chr3 - 49115723 49115944 0.037970 1.000000 
3'ASS LRRC29 chr16 - 67210047 67211073 0.037972 1.000000 
5' ASS UMPS chr3 + 124737567 124738443 0.038104 1.000000 
RI TMEM94 chr17 + 75492928 75493593 0.038281 0.709833 
SE NOP58 chr2 + 202295673 202295837 0.038498 1.000000 
RI RPS6KB2 chr11 + 67433125 67433447 0.038814 0.714509 
RI PAF1 chr19 - 39390068 39390289 0.038963 0.714509 
RI SFI1 chr22 + 31604868 31606430 0.039271 0.714509 
RI LRCH4 chr7 - 100577085 100577389 0.039422 0.714509 
RI ABHD17A chr19 - 1877507 1880115 0.039450 0.714509 
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RI GPS1 chr17 + 82056839 82057470 0.039695 0.715604 
3'ASS FOXP4 chr6 + 41589962 41590170 0.039990 1.000000 
SE CEP164 chr11 + 117335604 117335680 0.039996 1.000000 
SE C12orf65 chr12 + 123233739 123233924 0.040469 1.000000 
RI DDX11 chr12 + 31103576 31104791 0.040514 0.727004 
SE RPH3AL chr17 - 333758 333934 0.040571 1.000000 
RI MRPL52 chr14 + 22829886 22830110 0.040963 0.728616 
RI LY6H chr8 - 143158802 143159709 0.040978 0.728616 
SE TMEM263 chr12 + 106957081 106957149 0.041237 1.000000 
RI PISD chr22 - 31620995 31621472 0.041350 0.731889 
RI METTL17 chr14 + 20995900 20996292 0.041563 0.732332 
3'ASS ENOSF1 chr18 - 690548 690745 0.041870 1.000000 
RI POFUT2 chr21 - 45263927 45267713 0.041992 0.734270 
RI ZNF34 chr8 - 144778037 144778525 0.042050 0.734270 
SE DDX47 chr12 + 12821207 12821396 0.042286 1.000000 
RI PFAS chr17 + 8256266 8256648 0.042436 0.737708 
SE ATG16L2 chr11 + 72823543 72823797 0.042461 1.000000 
SE TMCC1 chr3 - 129860939 129861012 0.042632 1.000000 
3'ASS SIRT2 chr19 - 38893818 38893971 0.042687 1.000000 
MXE MFSD8 chr4 - 127938782 127938838 0.042732 1.000000 
5' ASS ANXA4 chr2 + 69810593 69811456 0.042794 1.000000 
RI TRPT1 chr11 - 64224284 64224717 0.042839 0.741405 
SE MRPL55 chr1 - 228108436 228109021 0.043216 1.000000 
3'ASS TMEM268 chr9 + 114624135 114624459 0.043365 1.000000 
RI 
RTEL1-
TNFRSF6B chr20 + 63688527 63689132 0.043825 0.755109 
SE MCTP2 chr15 + 94278153 94278263 0.044021 1.000000 
5' ASS MADD chr11 + 47295495 47295579 0.044054 1.000000 
RI GPATCH4 chr1 - 156596080 156596478 0.044548 0.764189 
SE DDR1 chr6 + 30885624 30885680 0.044973 1.000000 
RI LUC7L chr16 - 227241 228402 0.045340 0.774367 
5' ASS IKBKB chr8 + 42293442 42293568 0.045534 1.000000 
SE TBC1D17 chr19 + 49879322 49879504 0.045648 1.000000 
RI NAT9 chr17 - 74771959 74772277 0.045785 0.775691 
5' ASS NFKBIL1 chr6 + 31557627 31557849 0.045794 1.000000 
RI MPP2 chr17 - 43882902 43883355 0.045816 0.775691 
SE MRPL55 chr1 - 228108436 228109021 0.046045 1.000000 
SE PRKDC chr8 - 47782161 47782254 0.046673 1.000000 
SE ZNRD1 chr6 + 30061916 30062017 0.046681 1.000000 
RI RPS16 chr19 - 39433521 39433761 0.046748 0.788031 
RI BBS1 chr11 + 66515539 66515731 0.047312 0.794109 
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SE MPHOSPH9 chr12 - 123227462 123227616 0.047850 1.000000 
MXE MEG3 chr14 + 100832511 100832641 0.047995 1.000000 
5' ASS ITFG2 chr12 + 2818105 2818353 0.048003 1.000000 
MXE FRMD8 chr11 + 65389360 65389528 0.048164 1.000000 
SE MAPK9 chr5 - 180279795 180280036 0.048175 1.000000 
3'ASS SLC25A10 chr17 + 81716680 81716855 0.048270 1.000000 
RI ZWINT chr10 - 56360017 56360383 0.048350 0.804746 
RI PHGDH chr1 + 119741766 119743044 0.048359 0.804746 
3'ASS TMEM175 chr4 + 951645 951717 0.048453 1.000000 
SE SDHAP1 chr3 - 195984593 195984737 0.048883 1.000000 
RI PKD1 chr16 - 2105321 2106024 0.049098 0.811410 
SE ALDOA chr16 + 30065875 30065927 0.049107 1.000000 
RI PPIL2 chr22 + 21694936 21695496 0.049176 0.811410 
SE ABHD11 chr7 - 73737220 73737391 0.049476 1.000000 
SE ZNF655 chr7 + 99561887 99561973 0.049560 1.000000 
SE YPEL5 chr2 + 30148244 30148541 0.049587 1.000000 
SE SYNRG chr17 - 37577379 37577613 0.049855 1.000000 
3'ASS SCRN2 chr17 - 47839443 47839858 0.049966 1.000000 
 
 
 
 
 
